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Pseudomonas aeruginosa is an important opportunistic pathogen that belongs to superbug 
microorganisms and shows an increased number of multi-drug resistant (MDR) clinical 
isolates. P. aeruginosa has three hierarchically organised quorum sensing (QS) or cell to cell 
communication systems named las, rhl and pqs. The las and rhl are classic QS systems that 
use an N‐(3‐oxododecanoyl) ‐L‐homoserine lactone as autoinducers. The las system is the 
major QS system of the cell and controls the other two and there is partial redundancy with the 
rhl system regarding the genes and functions controlled by the system. The pqs quorum sensing 
system of P. aeruginosa is a major regulatory network that controls the expression of genes 
involved in virulence, biofilms, oxidative stress and iron acquisition, especially in chronic 
conditions. The transcriptional regulator of the pqs system is PqsR which becomes functional 
upon direct binding to the main autoinducer of the receptor, PQS and its precursor HHQ. The 
inhibition of QS and in particular the pqs system is an approach to decrease the virulence of P. 
aeruginosa in vivo, improve the outcome of antibiotic treatments and decrease the P. 
aeruginosa associated morbidity. This work aims to develop PqsR antagonists that attenuating 
the pathogenicity and resistance of one of the most critical pathogens by designing and 
developing a range of novel QS inhibitors targeting the transcriptional regulator (PqsR) of the 
pqs system which is distinct to P. aeruginosa. Different chemical approaches are employed to 
synthesise a range of compounds, and the selected candidates are validated through different 
biological evaluations and molecular structure analysis. Chapter 2 focuses mainly on a SAR 
study for the selected hit, founded by in silico screening, with a quinazolin-4(3H)-one scaffold 
which is similar to the natural substrate of the receptor. In Chapter 3, the work aimed to expand 
the SAR further by replacing the quinazolin-4(3H)-one moiety with different heterocyclic ring 
systems; it was concluded that the optimal replacement is the 1-methyl-1H-benzo[d]imidazol-
2-amine ring. Many attempts were established to identify the optimal conditions to synthesise 
this series by employing different strategies, and the selected pathway was successful in 
synthesising a range of analogues with good yield. Cell based reporter gene assay with PAO1-
L CTX::PpqsA-lux strain of P. aeruginosa was employed to evaluate the activity of the 
compounds. Furthermore, the active compounds with sub-micromolar potency were analysed 
in pyocyanin quantification assay. 3.20 was analysed further in alkyl quinoline quantification 
assay against different genomic classes of P. aeruginosa. The crystal structures of PqsRCBD 
complexed with key compounds presented in chapter 2 and 3 were attained. These biological 
evaluations are presented in this work in an attempt to prove the concept and validate PqsR as 
a relevant therapeutic target. Furthermore, a cytotoxicity study of the most active compounds 
in the series was conducted to investigate the therapeutic-toxicity index of these compounds 
before proceeding to the in vivo study. Overall, this project has led to the successful 
development of hit to lead optimization study starting with previously identified compound 2-
(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile, 1.6 (IC50 
= 3.2 µM in PAO1-L) leading to a new series of potent benzimidazole containing compounds. 
2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile 3.20 (PAO1-L IC50 0.13 ± 0.04 µM, PA14 IC50 0.09 ± 0.01 µM) is one of 
the most potent PqsR antagonists in this series with high potency inhibition of pqs system 
signalling. In addition, 3.20 showed wide spectrum efficacy against different genomic classes 
of P. aeruginosa with significant inhibition of P. aeruginosa pyocyanin and AQ production. 
The co-crystal structure of 3.20 and some analogues with PqsRLBD were determined which 
revealed specific binding interactions of this new class of inhibitors. In addition, cytotoxicity 
studies revealed that 3.20 had a good safety margin against a human cell line which support 
3.20 progression to a murine in vivo study. However, it is critical to establish further 
pharmacokinetics in vitro and in vivo assays as well as a biofilm formation model to evaluate 
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1.1.1 The history of antibiotic resistance  
 
Figure 1-1: The timeline of antibiotic development over the last century. No new class of antibiotic has been 
identified since 1987.  
 
Over the past decades, the number of multi-drug resistant (MDR) bacterial clinical isolates, 
specifically gram-negative pathogens, has rapidly increased. At the same time, since 1987, no 
new class of antibiotic has been developed for gram-negative bacteria (Figure 1-1), and all new 
recently approved antibiotics have been based on modifications of existing antibiotic classes. 
This latter fact is surprising not only because industrial and academic research was heavily 
supported during this period but also because of the revolution in novel technologies, such as 
genomic and high-throughput screening, which were introduced and applied to improve the 
productivity of drug discovery programmes. The combination of increasing emergence of 
MDR strains and the lack of discovery of new classes of antibiotics represents a serious threat 
to human health, as it could lead to the disarming of healthcare providers in the battle against 
bacterial pathogens at some point. MDR strains are the primary threat to hospitalised patients 
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and have been associated with mortality rates of 30–70 %.1 As a result of this increasing 
morbidity, mortality rates could reach the levels seen prior to the antibiotic era. However, the 
emergence of MDR clinical isolates is not recent; it has been a persistent threat from the 
beginning of the antibiotic period. For example, penicillin was discovered by Alexander 
Fleming in 1928, and in 1940, several years before it was used to treat infections in patients, a 
bacterial penicillinase was identified by two members of the penicillin discovery team.2 In 
addition, penicillin-resistant strains of Staphylococcus aureus were isolated in 1944, only two 
years after the introduction of this antibiotic into the market.3  
The spread of resistance before the introduction of antibiotics into clinical practice was limited 
because of the absence of selective pressure from antibiotics. This pressure is a result of 
external influences, such as antibiotics, which lead to natural selection and differential survival 
of one group of organisms over another. In this case, antibiotics cause selective pressure by 
killing susceptible bacteria which allows antibiotic-resistant bacteria to survive and proliferate, 
thereby considerably accelerating the emergence of MDR strains. A similar trend has been 
observed for all antibiotics developed to date, with resistance observed before or shortly after 
first clinical use and a gradual increase in the proportion of resistant isolates over time. 
Typically, resistance usually affected a single antibiotic or antibiotic class. However, this has 
changed with the phenomenon of multi-drug resistance, which was first observed in 
enterobacteria during the late 1950s and has been spreading ever since.4 The situation has now 
become highly critical with the increase in the number of MDR microorganisms, popularly 
known as 'superbugs'. This term refers to any type of bacterium highly resistant, due to multiple 
mutations, to most antibacterial agents currently available causing severe therapeutic 
challenge. The gram-negative Pseudomonas aeruginosa is a superbug which usually causes 
different types of acute and chronic infections associated with high morbidity and mortality 
rates.4 In 2017, the World Health Organization (WHO) called for urgent development of new 
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antibiotics against a list of antibiotic-resistant strains which pose the greatest threat to human 
health. One of the top-priority pathogens in the list which needs immediate intervention is the 
carbapenem-resistant strain of P. aeruginosa;5 therefore, P. aeruginosa is the scope of this 
work. 
1.1.2 The opportunistic pathogen Pseudomonas aeruginosa  
P. aeruginosa is a ubiquitous aerobic monotrichous rod with a polar flagellum conferring 
motility to this organism. It also has protein structures on the surface known as pili which are 
responsible for adherence to the infected epithelium. As a gram-negative bacterium, its cell 
wall is made of a single layer of peptidoglycan surrounded by a membranous structure called 
the outer membrane (Figure 1-2). It produces several fluorescent siderophores, including 
pyoverdine and pyochelin, as well as a blue-green pigment called pyocyanin which gives P. 
aeruginosa a characteristic appearance in culture media.6 
 
Figure 1-2: The basic structure of Pseudomonas aeruginosa. The enlarged section shows the common structure 
of the gram-negative cell wall, including that of P. aeruginosa. 
 
The adaptability of P. aeruginosa allows it to grow in a wide range of environments and 
conditions with temperatures ranging from 5.5 to 45 °C and pH from 4 to 9.6  This adaptability 
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to different environments is due to the genetic flexibility provided by its large and complex 
genome, as will be discussed later (section 1.1.4). The pathogen can be found in different 
locations in the hospital environment and on medical equipment; as a result, it can be 
transmitted from patient to patient by healthcare providers.7 P. aeruginosa is an opportunistic 
pathogen which means that it rarely affects healthy individuals, and the infection can be 
initiated by different triggers that cause a break in first-line defences of eukaryotic host cells. 
These triggers engender breaks in normal cutaneous or mucosal barriers can result from trauma, 
surgery, serious burns, or catheter devices or disruption of normal protective mucosal flora by 
broad-spectrum antibiotics. Another possible factor is alteration of immunological defence 
mechanisms in cases such as chemotherapy-induced neutropenia, mucosal clearance defects in 
cystic fibrosis (CF), AIDS, and diabetes mellitus.8 
1.1.3 Clinical manifestations  
P. aeruginosa is an uncommon cause of pneumonia in healthy individuals or of community-
acquired pneumonia. Pseudomonas pneumonia mostly occurs in an immune-compromised host 
with haemorrhagic and necrotising lung pathology.9 Hospital-acquired pseudomonas 
pneumonia is most likely to occur in patients with HIV or chronic obstructive pulmonary 
disease (COPD), or in patients who have undergone surgery or tracheostomy.10 P. aeruginosa 
is the most frequent and important pathogen responsible for chronic infection in patients with 
CF, with a reported rate of colonisation up to 80%.11 The major determinant of morbidity and 
mortality due to this infection is recurrent endobronchial infection and exaggerated neutrophilic 
inflammation.12 
CF is a genetic condition caused by autosomal recessive inheritance of mutations, or in other 
words, both parents carry one copy of the mutated gene, cystic fibrosis transmembrane 
conductance regulator (CFTR) gene. 12 This mutation causes dysfunction of the CFTR protein 
which is an ion channel in epithelial tissue and controls the flow of water and chloride ions into 
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and out of cells. This protein is present inside the cells that produce mucus, sweat, saliva, tears, 
and digestive enzymes, and its malfunction leads to the disruption of the balance of ions and 
fluid and production of mucus that is abnormally thick and sticky. The abnormal mucus 
obstructs the airways and limits pathogen clearance from the lung, which is the main cause of 
CF symptoms.13 Deficiency in the physical clearance defence mechanism of the respiratory 
system leads to early recruitment of inflammatory defence mechanisms involving 
polymorphonuclear leukocytes (PMN) and antibodies.14 Therefore, from early childhood, CF 
patients have recurrent and chronic respiratory tract infections characterised by PMN 
inflammation.15 Despite the inflammatory response and intensive antibiotic therapy, biofilm 
formation is initiated by Staphylococcus aureus (S. aureus) at an early stage, and as infection 
progresses, P. aeruginosa eventually becomes the predominant pathogenic resident and 
persists for decades as a chronic infection leading to treatment failure and sometimes the need 
for lung transplantation.16  
Furthermore, P. aeruginosa is associated with bacteraemia, and it currently accounts for 15% 
of gram-negative bacteraemia cases.17 Interestingly, CF patients are rarely diagnosed with P. 
aeruginosa bacteraemia, which may be due to the high levels of circulating P. aeruginosa 
antibodies and the main infection of CF patients being localised pneumonia.18 The hospital 
mortality associated with P. aeruginosa bloodstream infections is reported to be greater than 
20% in most cases and is higher among patients who have been under inappropriate initial 
antimicrobial regimens.17 Some local infections, such as eye or ear infections, remain at the 
infection site while others, such as wound or burn infections, result in bacteraemia. The 
difference in response may be due to host defences and initial treatment.19 Furthermore, P. 
aeruginosa causes urinary tract infections associated with the use of catheters as a major factor; 
no specific characteristic distinguishes the infection caused by this organism from other types 
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of urinary tract infections. This type of infection is usually treated with a variety of 
antipseudomonal drugs with good results.9  
1.1.4 Genomic structure and diversity 
The large genome size (5.5–7 million base pairs [Mbp]) and genetic complexity of P. 
aeruginosa, compared to the other 25 sequenced bacterial genomes, reflect the evolutionary 
adaptations which permit this pathogen to thrive in diverse ecological niches.20 Analysis of its 
genome sequence has shown that this pathogen has a core genome found in all P. aeruginosa 
strains which is highly conserved among clonal complexes with sequence diversities between 
0.5–0.7%. In addition, P. aeruginosa has an accessory genome which consists of 
extrachromosomal elements like prophages, transposons, insertion sequences (IS), genomic 
islands (GI) and plasmids which are inserted into the chromosome at various loci.21 The 
transferable genetic elements of the accessory genome can be present in subgroups of the P. 
aeruginosa population, but may also occur only in single strains in variable proportions up to 
20% of the whole genome. The composition of the accessory genome accounts for most intra- 
and inter-clonal genomic diversity and rapid antibiotic resistance in P. aeruginosa which is 
apparently acquired by horizontal gene transfer from different sources as will be discussed in 
Section 1.3.2.20 It is important to consider these variations in drug discovery projects and 
identify targets conserved in all strains of this bacterium by focusing on core genes and 
avoiding targeting the accessory genome. Indeed, the fast increase in available P. aeruginosa 
genome sequences, due to the revolution in sequencing technologies, is expected to provide 
the field with an unbiased overview of the genetic repertoire of P. aeruginosa populations 
which can guide target selection.  
The first complete genome sequence analysis was performed for the PAO1 strain of P. 
aeruginosa which was isolated from the infected wound of an Australian patient. 22 This strain 
is regarded as the major reference for genetic and functional studies in most laboratories. PAO1 
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consists of a 6.264-Mbp circular chromosome encoding 5,570 predicted protein-coding 
sequences. The second most studied P. aeruginosa strain is PA14, a clinical isolate which is 
considered more virulent than PAO1. According to open reading frame (ORF) analysis, PA14 
contains 58 regions that are absent in PAO1, including the PA14 pathogenicity islands PAPI-
1 and PAPI-2.23 Both PAPI islands encode a cluster of discrete virulence genes which may 
confer additional pathogenic functions to this strain. Another clinical isolate (PA7) of 
Argentinian origin shows an unusual antimicrobial resistance pattern and is considered a 
taxonomic outlier of P. aeruginosa. In addition, LESB58 (Liverpool epidemic strain) is a strain 
isolated in 1988 from a CF patient from Liverpool. It is characterised by early overexpression 
of the cell-density-dependent quorum sensing (QS) regulon (for more details see Section 1.5), 
including virulence-related secreted factors such as elastase and pyocyanin. Furthermore, 
LESB58 is known to be a biofilm hyperproducer and has the potential to cause severe infections 
even in non-CF patients.24  
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1.2 Current therapy for Pseudomonas aeruginosa infections  
 
1.2.1 ‘Traditional’ approaches 
Antimicrobial chemotherapy is still the cornerstone of treatment for P. aeruginosa infections 
in the clinic. Generally, P. aeruginosa strains are susceptible to broad-spectrum penicillins, 
cephalosporins, monobactams, and carbapenems which all share the same β-lactam core ring 
with variable substitutions and extensions. Aminoglycosides and fluoroquinolones have also 
been introduced to clinical practice since the 1980s.10 The most common combination used for 
P. aeruginosa infections is intravenous therapy with piperacillin or ceftazidime (β-lactam 
antibiotic) with an aminoglycoside which has been effective for the last two decades.10 
However, the emergence of resistance against this treatment, particularly in intensive care and 
patients with chronic disease, has called for alternatives.25 β-lactam is a class of antibiotic 
targeting penicillin-binding proteins which are enzymes that contribute to the synthesis of 
peptidoglycan, the vital constituent of bacterial cells, which leads to autolytic processes within 
the cell.26 In response to this selective pressure, the pathogen releases a β-lactamase enzyme 
that hydrolyses the β-lactam ring and deactivates the antibiotic. Recently, two new 
cephalosporins – ceftazidime-avibactam and ceftolozane-tazobactam – combined with β-
lactamase inhibitor have been introduced to the clinic; this combination has been effective 
against this type of resistance.25 On the other hand, the bacterium employs a different resistance 
strategy against aminoglycosides which have a bactericidal effect by inhibiting protein 
synthesis essential for survival. These strategies are exemplified by the production of 
aminoglycoside-modifying enzymes (AMEs) and modification of the target of 
aminoglycosides with different mutational strategies.27 Another strategy to combat MDR 
strains is the revival of old polypeptide drugs, colistin and polymyxin B, whose use was 
abandoned for many years because of their neurotoxic and nephrotoxic side effects. 
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Nevertheless, the vital need for more active therapy has led to their relaunch in clinical practice. 
These cationic polypeptide antibiotics work by disrupting the outer cell membrane by 
interacting with anionic lipopolysaccharide (LPS) molecules leading to the displacement of 
calcium (Ca2+) and magnesium (Mg2+) and neutralisation of the lipopolysaccharide, thereby 
increasing the permeability of the bacterial membrane and leakage of cell contents.28 Despite 
the novelty of the mechanism of action of these antibiotics, a P. aeruginosa isolate from a high-
risk clone has shown new resistant isoforms to these antibiotics which emphasises the urgency 
of finding alternatives.29 
1.2.2 The ‘modifications of current classes’ approach 
 
Figure 1-3: The ‘modification of current classes of antimicrobial drugs’ approach. The design of cefiderocol, 
a new member of the cephalosporin family, by employing cephalosporin core with side chains similar to 
ceftazidime and cefepime. The aminothiazole ring and carboxy propyl-oxyimino group (highlight in yellow) block 
recognition and inhibit hydrolysis by β-lactamases. A catechol 2-chloro-3,4-dihydroxybenzamide moiety 
(highlight in red) functions as the siderophore mimic. a pyrridoline ring (highlight in green) confers zwitterionic 





All the recent improvements in the field are associated with modifications of analogues of 
current classes of antimicrobial drugs that share the basic chemical structures and mode of 
action. For example, cefiderocol is a new member of the cephalosporin family and shares its 
side chains with ceftazidime and cefepime which block recognition and inhibit hydrolysis by 
β-lactamases. Its novelty is due to the extension of one side chain by a catechol 2-chloro-3,4-
dihydroxybenzamide moiety which enables ferric ion binding to create a cefiderocol–iron ion 
complex. Active iron transport systems then facilitate the transport of the complex across the 
outer membrane to the periplasmic space where dissociation occurs releasing the cefiderocol 
moiety to bind to penicillin-binding proteins. This strategy reduces the resistance associated 
with cell membrane permeability in addition to the ability to overcome resistance to β-
lactamase in the first place. In in vitro assays, cefiderocol is more potent than ceftazidime-
avibactam and ceftolozane-tazobactam against different MDR strains, including the strain 
highly resistant to carbapenem. In clinical studies, this antibiotic seems to address the problem 
of the highest priority strain (carbapenem-resistant strain) at least at present. A completed phase 
II clinical trial (ClinicalTrials.gov identifier: NCT02321800) has shown clinical efficacy and 
safety of intravenous cefiderocol in patients with complicated urinary tract infections. Further 
phase III clinical trials provided evidence of cefiderocol efficacy in the treatment of serious 
infections caused by carbapenem-resistant strains (ClinicalTrials.gov identifier: 
NCT02714595) and the efficacy and safety of intravenous cefiderocol compared 
to meropenem and linezolid, a synthetic antibiotic in the oxazolidinone class, in patients with 
hospital pneumonia (ClinicalTrials.gov identifier: NCT03032380). Both studies have resulted 
in cefiderocol being approved for use in the clinic. 
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1.2.3 The ‘novel mechanism of action’ approach 
 
Figure 1-4: The ‘novel mechanism of action’ approach. Structure of antibiotics with their novel mechanisms of 
action.31,32,28,33,34 
 
Murepavadin is another example of the recent progress in this area with a novel mechanism of 
action (Figure 1-4). This antibiotic is a highly active and selective weapon against P. 
aeruginosa as a 14–amino acid synthetic peptidomimetic. It is the first antibiotic targeting the 
outer membrane protein transporter LptD which is responsible for transport of 
lipopolysaccharides from the periplasmic side of the outer membrane to its final location on 
the cell surface.31 Inhibition of this transporter causes alterations to lipopolysaccharide in the 
outer membrane and ultimately bacterial cell death. 31 Although the clinical studies of this 
antibiotic progressed to phase III with two clinical trials targeting 2 and 41 participants 
(ClinicalTrials.gov identifiers: NCT03582007 and NCT03409679, respectively), both studies 
were terminated due to an unexpectedly high frequency of renal failure in participants who had 
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received murepavadin. Due to the high efficacy of this antibiotic against a range of P. 
aeruginosa strains, including carbapenem-resistant, ceftolozane/tazobactam-resistant and 
colistin-resistant strains, further development of an aerosolised formulation of murepavadin for 
topical application is ongoing. Recently, preclinical studies on mice demonstrated the efficacy 
of this formulation for treating P. aeruginosa infection in neutropenic lung infection models.35   
It is clear from the discussion above that all the current treatments used in clinical settings aim 
to inhibit cellular viability which has been highly effective over the past decades. However, 
this type of mechanism imposes selective pressure that fosters the growth of MDR strains of 
P. aeruginosa which are associated with high morbidity and mortality rates. Different strategies 
have been employed to modulate the permeability, signalling or virulence of P. aeruginosa 
instead of targeting bacterial growth. Vaara and Vaara (1983) introduced the concept of the 
outer membrane disorganising sensitiser which makes the membrane more permeable to 
amphiphilic and lipophilic compounds.36 To date, there are three sensitisers (approved anti-
protozoal drug pentamidine and the polymyxin B analogues SPR206 and SPR741, (Figure 1-4) 
in preclinical and clinical studies which employ this concept to work as adjuvant therapy and 
increase the permeability of fluoroquinolones.25 
Furthermore, the use of efflux pump inhibitors has emerged as a potential therapeutic strategy 
for treatment of P. aeruginosa infections. A good example of this strategy is phenylalanine 
arginyl β-naphthylamide (PAβN) which is a well-studied efflux pump inhibitor (Figure 1-4) 
that not only impairs antibiotic efflux through competitive inhibition of efflux pumps but also 
increases the permeability of bacterial outer membranes.33 This compound has been shown to 
reduce virulence and increase antibiotic susceptibility of P. aeruginosa.33  
The well-known macrolide antibiotic, azithromycin (Figure 1-4), is normally not included in 
P. aeruginosa treatment regimens because of the absence of bactericidal or bacteriostatic 
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activity against this pathogen. However, several studies have highlighted the benefit of long-
term administration of this medication in CF patients.32 It has been administered in a small 
number of people at concentrations below those needed for growth inhibition but enough to 
inhibit QS-induced gene expression.37 Only one clinical trial has been established to 
demonstrate the concept of employing azithromycin as a QS inhibitor in patients and assess its 
clinical efficacy in preventing or delaying the occurrence of pneumonia in ventilated patients 
colonised with P. aeruginosa. Unfortunately, the study was terminated due to financial issues 
(ClinicalTrials.gov identifier: NCT00610623).   
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1.3 Pseudomonas aeruginosa resistance and tolerance  
 
P. aeruginosa displays all types of known resistance and tolerance strategies which can be 
categorised as intrinsic, acquired and adaptive mechanisms. A resistance mechanism is any 
type of mutation that eliminates the molecular target of the antibiotic or effluxes the drug 
outside the bacterial cell. In contrast, tolerance is usually derived through physical mechanisms 
that adapt bacterial populations to environmental stress by employing different strategies such 
as biofilm formation. This adaptive strategy supports bacterial cells to survive high antibiotic 
concentrations only if embedded in biofilms. However, when the biofilm is dispersed, 
planktonic cells will regain their susceptibility to the minimum inhibitory concentration (MIC) 
dose of the antibiotic which indicates that tolerance is driven by physical barriers rather than 
mutations in bacterial cells.  
 
1.3.1 Intrinsic resistance  
Intrinsic resistance of P. aeruginosa comprises all its inherent properties, including low outer 
membrane permeability, expression of efflux pumps and the production of antibiotic 






Figure 1-5: The differences between gram positive and gram negative bacterial membranes. The cross 
section illustrating the presence of porins and efflux systems across the membrane.  
 
Decreased permeability. Being a gram-negative bacterium, P. aeruginosa is less susceptible 
to antibiotics than gram-positive bacteria. This is because the structure of a gram-negative 
bacterium consists of, in addition to an inner lipid membrane and peptidoglycan layer, an outer 
lipid membrane layer that serves as an impermeable barrier to many small molecules (Figure 
1-5).38 Furthermore, the outer membrane of the gram-negative bacterium contains water-filled 
pores that extend across the membrane and facilitate the uptake of hydrophilic compounds up 
to a certain size limit. The proteins that form these channels are called porins; generally, there 
are four classes of porins. 39 OprF, the predominant type which is responsible for non-specific 
uptake of ions and saccharides, has low efficiency for antibiotic permeation. Only 5% of this 
protein population is open channel which explains the low permeability of this pathogen in 
comparison to other bacteria. In addition, some porins allow penetration of specific types of 
molecule, for example, OprB for carbohydrates and OprD for basic amino acids. One of the 
known resistance mechanisms that could be used by P. aeruginosa is reduction of the 
expression of specific porins, such as OprD which represents the second major porin protein 
and the gate through which carbapenems enter the bacteriun.40 The expression of this porin is 
reduced in the carbapenem-resistant strain which, as mentioned earlier (1.1.1), is categorised 
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as one of the most critical resistant strains.5 The third class of porins is constituted by the ion-
regulated gated porins which are responsible for uptake of ion complexes, and the fourth class 
consists of efflux porins (OprM) which are important components of the efflux pump system.39 
Expression of efflux systems. Efflux pumps, when coupled with a low-permeability cell 
membrane, represent a greater threat of antibiotic resistance in P. aeruginosa due to the 
synergistic effect between these two resistance strategies. Active efflux pumps are used to 
prevent intracellular accumulation of toxic compounds, including antibiotics. There are 
different families of efflux pumps, such as resistance-nodulation-division (RND), small 
multidrug resistance (SMR), multidrug and toxic compound extrusion (MATE) and major 
facilitator superfamily (MFS), in P. aeruginosa.41 However, the most investigated family is 
RND due to its key role in antibiotic resistance. P. aeruginosa expresses twelve RND efflux 
pumps, four of which can expel a range of antibiotics and contribute to antibiotic resistance. 
The MexAB–OprM efflux pump, for example, can expel β-lactams and quinolones, while 
MexCD–OprJ targets β-lactams only. Quinolones are the substrate for MexEF–OprN and 
aminoglycosides are expelled by MexXY–OprM. Overexpression of multiple efflux pumps in 
some clinical isolates of P. aeruginosa is the main factor contributing to the development of 
multidrug resistance in these strains, without affecting the ability of the pathogen to cause 
severe infections.42  
Antibiotic inactivating enzymes. Chemical modification of antibiotics catalysed by P. 
aeruginosa enzymes is one of the major intrinsic mechanisms of drug resistance. A good 
example of this type of resistance is the β -lactamase enzyme which mediates resistance against 
different types of β-lactam antibiotics such as penicillin, extended-spectrum cephalosporins, 
monobactams, and carbapenems. This enzyme is able to break the amide bond of the β-lactam 
ring, leading to inactivation of β-lactam antibiotics. One successful strategy for combating this 
type of resistance is combination therapy involving a β-lactam antibiotic with a β-lactamase 
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inhibitor, such as clavulanate, sulbactam, and tazobactam, which has been developed and 
applied in clinical practice.43 
1.3.2 Acquired resistance 
Acquired resistance refers to a susceptible strain becoming resistant through either horizontal 
transfer of resistance genes to the next generation or mutational changes.44 Horizontal transfer 
of DNA may occur via three main mechanisms involving conjugation, transduction and 
transformation (Figure 1-6).45  
 
Figure 1-6: Different mechanisms of horizontal gene transfer. The horizontal transfer mechanisms include 
conjugation, transduction and transformation. a) Conjugation is a process that transfers DNA through direct 
physical contact between donor and recipient cells. b) Transduction is the transfer of DNA from one bacterium to 
another by bacteriophages. c) Transformation, bacteria take up free fragments of DNA released into the 
environment and incorporate it into their own genome. Source: Pang Z et al.42 
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Conjugation processes occur through physical contact between the donor cell and the recipient 
cell, while transduction is transfer of DNA from one bacterium to another by bacteriophages. 
Transformation is bacterial uptake and incorporation into their own genome of free fragments 
of DNA of dead cells released into the environment.45 
The second strategy to acquire resistance in P. aeruginosa is by mutational changes which lead 
to reduced antibiotic uptake, modifications of the antibiotic target, overexpression of efflux 
pumps and production of antibiotic-inactivating enzymes.42 The significance of using the 
appropriate treatment regimen at sufficient dose is all too apparent as incomplete eradication 
of the pathogen leads to the acquisition of resistance through one or more of these mechanisms.  
1.3.3 Adaptive resistance 
In P. aeruginosa, the best characterised mechanisms of adaptive resistance are formation of 
biofilm and generation of persister cells which result in persistent infection and poor prognosis 
in CF patients.46  
Biofilm is a highly structured community of bacterial cells enclosed within an extracellular 
matrix that adheres to abiotic or biological systems. The matrix of extracellular polymeric 
substance (EPS) that holds the microbial cells together contains mainly polysaccharides, 
proteins, extracellular DNA (eDNA), and lipids, while 10% of the biofilm is represented by 
bacterial cells. Biofilm formation depends mainly on the genomic structure of the strain and 
the environmental conditions which lead to the development of different phenotypes. Biofilm 
development is regulated by QS systems (for more details see Section 1.5) and an intracellular 
second messenger molecule known as 3′,5′-cyclic diguanylic acid (c-di-GMP). In fact, c-di-
GMP has been implicated in numerous cellular functions, including regulation of the cell cycle, 
differentiation, and coordination of the ‘lifestyle transition’ from planktonic cells to biofilm 
and vice versa. In general, increases in the level of c-di-GMP in experimental biofilm model 
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systems promote biofilm formation, whereas decreased levels promote dispersion of the 
biofilm. The concentration of c-di-GMP is high in biofilm cells (75–110 pmol per mg of total 
cell extract), whereas planktonic cells contain less than 30 pmol per mg.47 Small, non-coding 
regulatory sRNAs have also been shown to be involved in the regulatory network that 
determines the switch from the planktonic to the sessile form of growth in various bacterial 
species.48 In vitro studies have also shown that iron serves as a signalling molecule for biofilm 
development and that subinhibitory concentrations of the iron chelator lactoferrin block the 
ability of P. aeruginosa biofilms to mature from thin layers of cells attached to a surface into 
large multicellular structures. Respiratory secretions and sputum of CF patients contain micro-
molar concentrations of free iron, making this micronutrient more readily available to inhaled 
pathogens and creating an appropriate atmosphere to build biofilm.49 
Biofilm formation is described as a multi-stage process: initially, free floating bacteria adhere 
to an inert or living surface; these bacteria proliferate and form microcolonies; and mature 
biofilms emerge from these colonies. In the mature biofilm stage, subpopulations of the 
bacterial community start to appear with a wide range of metabolic activity, including the 
periphery subpopulation which is characterised by high physiological activity, whereas the 
inner part consists of a physiologically less active subpopulation (called dormant cells).50 This 
heterogeneity of the bacterial community leads to different degrees of efficacy of bactericidal 
antibiotics which depends mainly on the metabolic rate of the cells. For example, β-lactam and 
aminoglycosides have no activity against non-dividing cells inside the biofilm, while anaerobic 
conditions impair the activity of quinolones.51 Current treatment of these types of infections 
usually decreases the number of bacteria in biofilm but does not completely eradicate them 
which leads to relapse of biofilm infection.52 Several studies have shown the significance of 
early intervention in treating biofilm infections. However, the tolerance of mature biofilm 
infections to antibiotics has led to treatment at high concentrations, in some cases up to 1000 
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times higher than for planktonic cells. These doses cannot be achieved without toxicity in vivo 
by systemic administration.53 This demonstrates the significance of topical administration, such 
as inhalation therapy, which provides the required concentration to the location of infection. In 
addition, combination therapy using different classes of antibacterial drugs, as well as the use 
of adjuvant medication that targets the biofilm formation process, increases the susceptibility 
of bacterial cells to the antibiotic. 
Another reason for relapsed P. aeruginosa infections is the occurrence of persister cells. These 
small subpopulations of dormant cells possess high tolerance to antibiotics due to their reduced 
metabolism and entry into a dormant state without undergoing genetic changes. Consequently, 
when antibiotic treatment is terminated, these cells can resume their growth and increase the 
size of the population which is genetically identical to the original population and equally 
susceptible to antibiotics.54 The fraction of persister cells in biofilms is usually low (1%); 
however, it is believed that they are responsible for the recalcitrance of chronic infections 
highly resistant to antibiotics. Many factors and transcriptional regulators stimulate the 
formation and proliferation of persister cells; these include, but are not limited to, 
environmental stress and nutritional deficiency as well as the QS signalling molecule N‐(3‐
oxododecanoyl)‐L‐homoserine lactone (3-OC12-HSL) and pyocyanin (see Section 1.5).54   
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1.4 Establishment of Pseudomonas aeruginosa infection  
Another characteristic of P. aeruginosa is the expression and secretion of various virulence 
factors during the course of an infection as illustrated in Figure 1-7.55  
 
Figure 1-7: Schematic representation of P. aeruginosa infection establishment process and virulence factors 
secretion. HCN is hydrogen cyanide, PCN is pyocyanin, RhlA and RhlB , rhamnolipids, LasB is elastase and 
LasA is protease.   
Pili and flagella promote adhesion to the initial infection site as well as the motility of the 
pathogen for dissemination of the infection.56 The adherence process is further supported by 
lectin A and B which bind to specific carbohydrates on the surface of host cells.57  
The production of bacterial surfactants, especially rhamnolipids (RhlA and RhlB), increases 
the permeability of host epithelia, thereby facilitating bacterial invasion.58 Rhamnolipid is a 
surface-active amphipathic biosurfactant molecule. In P. aeruginosa, it is employed to 
modulate swarming motility and affect biofilm architecture. On the other hand, under iron-




Secretion systems are another strategy employed by P. aeruginosa to release enzymes that 
hydrolyse complex carbon sources into usable compounds, or to release proteins that capture 
essential ions such as Fe3+. In P. aeruginosa, five of the six secretion systems (T1SS–T6SS, 
except T4SS which is not found in this species) are dedicated to specific secretion of 
exoproteins and enzymes. These systems are critical for pathogenicity and environmental 
adaptation of the pathogen.60  
Furthermore, secretion of different cytotoxic extracellular products like hydrogen cyanide 
(HCN) and the redox-active blue pigment pyocyanin (PCN) induces damage to host cells and 
impairs the growth of competing pathogens.61,62 PCN is one of the major virulence factors in 
this pathogen that contributes to both acute and chronic infections. It is readily recovered in 
large quantities from the sputum of CF patients who have P. aeruginosa infection.61 It increases 
cellular oxidative stress by elevating the intracellular levels of reactive oxygen species, 
especially superoxide and hydrogen peroxide, leading to subsequent cell lysis and damage.63 
In addition, pyocyanin contributes to biofilm formation by promoting eDNA binding (a critical 
element in biofilm formation) to P. aeruginosa cells, and consequently influences cell surface 
properties, physicochemical interaction between cells and aggregation.63 
P. aeruginosa secretes various enzymes like elastase (LasB) which is responsible for degrading 
host proteins,64 proteases (LasA) for staphylolytic activity, phospholipases that damage cell 
membranes,65 and exotoxin A that impairs protein biosynthesis in eukaryotic cells.66 In 
addition, the pathogen employs high-affinity uptake systems or siderophores – pyoverdine and 
pyochelin – which bind to Fe3+ and deliver iron to the bacterial cell. However, the absence of 
freely available iron in the human body causes P. aeruginosa to use the iron transport proteins 
transferrin and lactoferrin as iron source. Therefore, these siderophores need extracellular 
elastase (LasB) which is responsible for the transferrin-hydrolysing activity of small peptides. 
This allows the pathogen to overcome iron limitation and facilitate iron acquisition from host 
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proteins.67 Overall, all these virulence determinates contribute to the establishment and 
maintenance of the infection process. 
The release of virulence factors and biofilm establishment and maturation would remain 
ineffective if they were carried out by a single organism. Hence, these activities need to be 
coordinated on a population-wide scale, and regulation behaviours mostly involve bacterial 
cell-to-cell communication systems which are discussed in the following section.68   
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1.5 Quorum sensing networks of Pseudomonas aeruginosa 
 
During the last decades, our understanding of bacterial lifestyle has changed drastically. 
Previously, bacteria were considered unicellular planktonic organisms, while nowadays it is 
more appreciated that bacterial cells are, in fact, highly communicative and can build organised 
communities. The generic term QS or cell-to-cell communication is the ability of bacterial cells 
to produce and secrete (or freely diffuse) small chemical signals called autoinducers into the 
surrounding environment. 69 Thus, at high population density, the accumulated signals interact 
with cognate receptors to set up autoinduction of autoinducer biosynthesis as well as induce 
transcriptional expression of various target genes, including those encoding the production of 
virulence factors.70 This can modify the nature and dynamics of the pathogen, and bacterial 
cells act as a community to accomplish tasks that would be impossible to achieve by individual 
cells.70 The first described quorum-sensing system is the lux system, responsible for the cell-
density dependent control of bioluminescence genes by the marine bacteria Vibrio fischeri, and 
it is considered the paradigm for quorum sensing in most gram negative bacteria.68 These 
bacteria did not synthesise luciferase and therefore did not produce light in the freshly 
inoculated culture. However, at high cell population densities, the organism produced an 
extracellular substance that could induce bioluminescence which was subsequently purified, 
and the structure was confirmed as belonging to that of the N-acyl-homoserine lactones (AHL) 




Figure 1-8: Schematic representation of the interconnected quorum sensing systems in Pseudomonas 
aeruginosa (las, rhl and pqs). Solid green arrows and dashed red lines indicate upregulation and downregulation, 
respectively. Oval shapes represent various proteins, chemical structures of quorum sensing signal molecules 
(QSSMs) are shown, and large coloured arrows represent genes. large grey arrows represent protein expression, 
and yellow arrows indicate QSSM biosynthesis. Source: Soukarieh et al.72 
The QS systems in P. aeruginosa may be considered as a hierarchical QS network which 
contains sets of connected systems including las, rhl and pqs (Figure 1-8). This network has 
highly adaptive mechanisms for responding to external cues of biological stress, which 
provides the pathogen flexibility in controlling virulence gene expression.73 QS in P. 
aeruginosa may be categorised into two classes according to the chemical structure of the 
autoinducer: N-acyl-L-homoserine lactone (HSL) and alkyl quinoline (AQ) which activate las, 
rhl and pqs respectively.73 
 
1.5.1 N-acyl-L-homoserine lactone-dependent quorum sensing 
Two QS systems, las and rhl, belong to this class as they employ two different N-acyl-L-
homoserine lactone (AHL) signal molecules, N-(3-Oxododecanoyl) ‐L‐homoserine lactone (3-
oxo-C12-HSL)74 and N‐butanoyl‐L‐homoserine lactone (C4-HSL)75, respectively. In general, 
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these two systems employ LuxI-type enzymes (LasI and RhlI) which generate the 
corresponding autoinducer (AHL). These signal molecules are accumulated in the medium, 
and at threshold population density, the autoinducer molecules bind to corresponding 
transcriptional regulator cytoplasmic LuxR-type proteins (LasR and RhlR) which function as 
AHL receptors. This type of protein is insoluble and its binding to the corresponding AHL 
stabilises the receptors, enabling dimerisation, DNA binding, and transcription of QS target 
genes.73 It is worth mentioning that the las and rhl systems play their more significant roles 
during the early stages of exponential growth of P. aeruginosa, when the cells are more 
metabolically active.76 In addition, these systems are intimately connected, and they regulate 
the production of multiple virulence factors, including several proteases, exotoxin A, 





1.5.2 Alkyl quinoline-dependant quorum sensing 
Another QS system in P. aeruginosa is pqs which is a distinct system that produces more than 
55 different AQs, including PQS (2-heptyl-3-hydroxy-4(1H)-quinolone), its immediate 
precursor HHQ (2-heptyl-4-hydroxyquinoline) and NHQ (2-nonyl-4-hydroxyquinoline).69 
PQS and HHQ are regarded as the most prominent autoinducer molecules among AQs.69 
 
 
Figure 1-9: Schematic representation of the pqs quorum sensing (QS) system in Pseudomonas aeruginosa. 
The core of the pqs QS system is composed of the pqsABCDE-phnAB operon and the pqsR gene. Proteins coded 
by the pqsABCDE-phnAB operon synthesise HHQ; the conversion of the latter to PQS is controlled by the pqsH 
gene. Both molecules bind to PqsR, and the complex PqsR–HHQ or PqsR–PQS then activate the PpqsA promoter, 
leading to the transcription of the pqsABCDE-phnAB operon which in turn produces the enzymes required for the 
biosynthesis of HHQ which upon modification by PqsH results in the generation of PQS. The pqsL gene is 
required for biosynthesis of HQNO which does not act as a signal molecule and has no effect on its own 
biosynthesis. Dashed grey arrows indicate gene expression; solid green arrows represent biosynthesis; the solid 
black arrow indicates PqsR-dependent activation (+); dashed black arrows indicate PqsR-independent activation 
(+); and solid red arrows indicate negative regulation (-). Oval shapes represent various proteins and the large 
coloured arrows represent genes. Source: Rampioni et al.79  
 
These signal molecules (PQS and HHQ) are the autoinducers that activate PqsR, the key 
regulatory receptor protein in this system. Hence, HHQ or PQS interacts with PqsR to form the 
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PqsR–AQ complex which in turn binds to the promoter region of the pqsABCDE operon, 
known as PpqsA, and triggers the transcription of the genes required for AQ biosynthesis. 
These genes produce a range of enzymes, which contribute to the biosynthesis of  HHQ as well 
as a range of different AQ and virulence factors.79 The monooxygenase PqsH then catalyses 
the oxidization of HHQ to PQS under aerobic conditions.80,81 PqsL in an additional 
monooxygenase which together with PqsABCD synthesise 2-heptyl-4-hydroxyquinoline N-
oxide (HQNO) and other AQ N-oxides (Section 1.5.3). 
AQs produced by activation of this system have a variety of functions, including cell signalling, 
redox activity and antimicrobial activity.80 It is worth mentioning that mutations in the 
biosynthetic genes pqsA, pqsB, pqsC, or pqsD or in the regulatory gene pqsR prevent AQ 
production. However, the mutation in pqsH or pqsL leads to accumulation of HHQ and HQNO 
or HHQ and PQS, respectively.80,81,82 On the other hand, the mutation in pqsE does not affect 
AQ biosynthesis, which may be due to an alternative thioesterase that replaces the functionality 
of PqsE thioesterase.79 
 
 
Figure 1-10: Schematic representation of alkyl quinolone biosynthesis. The biosynthesis starts from chorismic 
acid, the product of the shikimate pathway, converting to anthranilic acid which is activated by PqsA. Different 
steps mediated via PqsBC, PqsD, and PqsE generate HHQ which is converted to PQS via PqsH. Oval shapes 




The biosynthesis of HHQ (Figure 1-10) starts with the cellular metabolite, anthranilic acid, 
which is activated by coenzyme A ligase PqsA to anthraniloyl-CoA. This is followed by PqsD 
catalysing a Claisen-type condensation reaction using anthraniloyl-CoA and malonyl-CoA to 
yield 2-aminobenzoylacetyl-CoA (2-ABA-CoA). The thioester of 2-ABA-CoA is cleaved by 
PqsE thioestrase to obtain the free carboxylic acid 2-aminobenzoylacetate (2-ABA). Then, the 
heterodimer PqsBC, a β-keto acyl synthase III enzyme, catalyses the condensation of 2-ABA 
and octanoyl-CoA to form HHQ, which is subsequently oxidised to PQS.80 
1.5.3 Key effectors of the pqs QS system in virulence 
 
PqsE enzyme. Although PqsE seems superfluous for AQ biosynthesis, it emerges as a major 
effector of the pqs QS system as it controls the full expression of virulence biosynthetic genes 
like pyocyanin, hydrogen cyanide and rhamnolipids, in addition to the transcription of genes 
involved in biofilm development and resistance-nodulation-cell division (RND) efflux pump 
coding which are involved in antibiotic resistance.83 Knock-out complementation studies have 
clearly demonstrated that PqsE can activate PQS-controlled genes in the absence of a functional 
pqs system.84,85 Similar experiments have confirmed these findings in different in vivo infection 
models.83 The regulatory function of PqsE is at least partially mediated via RhlR.84,85 
Furthermore, PqsE downregulates the expression of its own operon leading to a negative 
regulatory loop. 83,85 Microarray analysis showed that 12.2% of the genes upregulated by PqsE 
could be classified as secreted factors (toxins, enzymes, and alginate), while 7.3% belonged to 
adaptation and protection functional classes, highlighting the importance of PqsE in the 
adaptive behaviour and virulence of P. aeruginosa.79 However, 29.3% of the PqsE upregulated 
genes are still unclassified or unknown which limits the understanding of its physiological 
role.79 On the other hand, the crystal structure of PqsE has been determined and key active site 
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residues have been identified; however, neither the substrate nor the product of PqsE catalysis 
has been identified, making this target less exploited.86  
PQS molecule. It is more active than HHQ as a PqsR agonist, with EC50 values of 16.4 ± 2.6 
μM and 3.8 ± 1.6 μM for HHQ and PQS, respectively. These values were determined in a 
chromosomal reporter PpqsA::lux fusion in a P. aeruginosa pqsAH mutant strain.87 This strain 
can neither synthesise endogenous HHQ nor convert exogenously supplied HHQ to PQS which 
is necessary to provide the absolute measurement of agonistic activity. Although both HHQ 
and PQS can function as pqs system signal molecules, PQS is a multifunctional molecule via 
several PqsR-dependent and PqsR-independent pathways. It regulates the expression of 182 
genes; 103 genes are upregulated and 79 genes downregulated in response to exogenous PQS. 
79 The majority (75%) of genes upregulated by PQS are also induced by iron starvation and 
contribute to iron acquisition, cytotoxicity, modulation of host immune response and 
biogenesis of outer-membrane vesicles (OMV).88 Biogenesis of OMV has many implications 
for P. aeruginosa virulence, one of which relates to overcoming the problem of PQS associated 
with high lipophilicity and low solubility (1 mg/L) and enhancing PQS bioavailability in 
biological systems. These vesicles package PQS, which remains biologically active and can 
reinstate biosynthesis of virulence factors in PQS-deficient mutant strains.89 In addition, the 
hydroxyl group in PQS is essential for iron binding and PQS–iron complex formation. 
However, this complex is not transported back into the cell and, therefore, does not function as 
a siderophore. Instead, PQS is found at high concentrations in the outer cell membrane of P. 
aeruginosa within membrane vesicles. The PQS–iron complex in the membrane seems to 
contribute to accumulation of iron close to the cell which facilitates the work of actual 
siderophores (pyoverdine and pyochelin).90 The benefit of this mechanism is allowing the 





HQNO molecule. The N-oxide of HHQ does not act as a signal molecule and has no effect in 
promoting its own biosynthesis. However, it has a role mainly during polymicrobial infections 
by contributing to environmental competition.79 An in vitro coculture model of polymicrobial 
infection showed that HQNO and the siderophore of P. aeruginosa protect S. aureus from 
antibiotics with mechanism of action targeting cell wall synthesis or protein synthesis.91 The 
proposed mechanism is that P. aeruginosa causes S. aureus to shift from respiration to 
fermentation growth, leading to a reduction in the latter’s growth 92 and decreased susceptibility 
to antibiotics.91 In addition, HQNO induce the formation of Small Colony Variants (SCV)  in 
S. aureus. This SCVs constitute a slow-growing subpopulation of bacteria with distinctive 
phenotypic and pathogenic traits. Phenotypically, SCVs have a slow growth rate, atypical 
colony morphology and unusual biochemical characteristics, making them a challenge for 
clinical microbiologists to identify. Clinically, SCVs are better able to persist in mammalian 
cells and are less susceptible to antibiotics than their wild type strain and can cause latent or 
recurrent infections.93 On the other hand, HQNO possesses innate antimicrobial activity against 
S. aureus due to its ability to bind and inhibit the activity of cytochrome b.94,95 Currently, the 
role played by HQNO in P. aeruginosa physiology and the mechanism by which HQNO self-
poisoning is avoided have not been determined.79  
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1.6 Targeting quorum sensing as a novel strategy for treatment of Pseudomonas 
aeruginosa infections 
 
The current treatment for P. aeruginosa infection targets bacterial viability (it is bactericidal) 
or bacterial replication (it is bacteriostatic); this promotes the spread of resistant bacterial 
strains.96 On the other hand, the development of anti-virulence drugs which prevent the 
expression of highly virulent phenotypes without affecting bacterial viability is an attractive 
and innovative strategy to control bacterial resistance. In contrast to conventional antibiotics, 
this strategy does not exert selective pressure on bacterial populations and, therefore, it is 
assumed to be less susceptible to rapid development and spread of resistance.97 However, this 
claim is still controversial in the scientific community and has to be proved or contradicted in 
future studies.98 
Most anti-virulence strategies for P. aeruginosa target either virulence traits (protein secretion 
and biofilm formation) or master virulence regulators (c-di-GMP and QS). T3SS secretion 
system in P. aeruginosa is critical for delivery of toxins into host cells. This system is well 
conserved among pathogens, broadening the application of T3SS inhibitors to multiple 
pathogens and polymicrobial infections. Another strategy employing biofilm inhibitors, which 
target carbohydrate-binding lectins, has shown good potency in vitro and in vivo, but might 
disrupt host lectins. On the other hand, targeting P. aeruginosa pili is an unsuitable strategy 
because they are not well conserved in all isolates. Global biofilm regulators, such as 
intracellular cyclic-di-GMP and intercellular QS signalling systems, are appealing as attractive 
anti-virulence targets. 60 
QS systems in P. aeruginosa contribute to the production of virulence factors, such as 
proteases, lectins, toxins, and biofilm polymers. This has spurred interest in the design of QS 
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inhibitors as anti-virulence drugs. Several QS inhibitors have been shown to reduce virulence 
and to aid the clearance of pathogens in both animal and plant infection models.88 In addition, 
different mutagenesis studies of QS in P. aeruginosa have shown attenuated pathogenicity and 
restoration of the susceptibility of conventional antibiotics,88 supporting the employment of 
this strategy to interfere with the production of virulence factors and attenuate bacterial 
pathogenicity. Several studies that successfully designed QS inhibitors proceeded to in vivo 
studies targeting different regulatory systems in P. aeruginosa; these are summarised in 
Sections 1.6.1, 1.6.2 and 1.6.3. 
 
 
Figure 1-11: The structures of current successful candidates targeting quorum sensing systems in 
Pseudomonas aeruginosa. All these candidates have proceeded to in vivo studies (except 1.4).72,99 
 
1.6.1 Targeting the las system 
According to Soukarieh (2018), despite the extensive efforts to target the las system, only one 
candidate, 1.1 (Figure 1-11), has proceeded to preclinical development,72 with covalent binding 
between Cys79 and the isothiocyanate electrophile, leading to inhibition of LasR activity with 
IC50 of 69 and 154 µM in two different strains of P. aeruginosa.
100 
Although, the las system does not regulate pyocyanin production directly, its position in the 
hierarchy of QS systems affects pyocyanin production in indirect ways; therefore, production 
of pyocyanin in the presence of las inhibitors has been investigated. Pyocyanin production in 
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the P. aeruginosa PA14 wild-type strain in the presence of 100 µM of 1.1 was reduced by 
almost 40% relative to the control. In addition, swarming motility is another important 
phenotype that is regulated by QS, and it was inhibited by 44% using 20 µM of 1.1. Moreover, 
the inhibitory effect was examined in two different disease models: burn wounds in ex vivo 
grown human skin samples and in vivo study of Caenorhabditis elegans. Results showed that 
1.1 increased the survival rate of C. elegans over the course of four days and reduced PA14 
infections in the burn wound model.100 However, 1.1 has a lactone group considered a labile 
functional group and isothiocyanate as a reactive species which could be associated with 
metabolic issues in biological systems. Nevertheless, the knowledge gained, along with the 
availability of crystal structures for LasR and LasI, should facilitate future discovery and 
evaluation of more drug-like molecules.72 
1.6.2 Targeting the rhl system 
The absence of structural information for RhlR and RhlI and the lack of validation of the rhl 
system as a therapeutic target makes the design of RhlR and RhlI inhibitors more difficult, and 
efforts to exploit this QS system have been limited.72 A study targeting this system reported 
that the RhlR modulator 1.2 (Figure 1-11) could act as an antagonist in the presence of C4-
HSL and an agonist in its absence. However, pyocyanin production was reduced, with IC50 = 
8 μM, biofilm formation was inhibited, and C. elegans survival was increased during P. 
aeruginosa PA14 infection at 50 μM ligand concentration.101 A subsequent study explained the 
effect of 1.2 as an RhlR agonist – it inhibits pyocyanin production through the downregulation 
of the pqs system.102 However, further investigation of this system is needed as it is not yet 
clear whether antagonising this system alone would yield a therapeutic benefit. 
1.6.3 Targeting the pqs system 
The pqs system could be targeted in different ways through: (i) inhibition of AQ biosynthesis 
by targeting PqsA, PqsD, and PqsBC enzymes; (ii) inhibition of signal reception by targeting 
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the PqsR regulatory protein; and (iii) inhibition of the virulence factor effector by targeting 
PqsE. 
However, the validity of PqsBC and PqsE as anti-virulence targets remain to be validated, and 
only PqsA, PqsD and PqsR have been exploited in different drug discovery programmes.72 
Despite the attempts to target PqsA and PqsD enzymes, most inhibitors suffer from weak 
potency or the lack of ability to reduce AQ and pyocyanin production, and as a result, no further 
progress has been made with these inhibitors.72 On the other hand, only two candidates targeted 
the PqsR receptor are proceeded to preclinical development. 
An in vivo effect of the first candidate, 1.3, or as reported in literature M64, (Figure 1-11), was 
investigated by Starkey et al. 1.3 binds to the PqsR co-inducer binding domain with KD = 5.4 
nM 103 and antagonises the receptor in two different strains, PAO1-L and PA14, with IC50 of 
0.32 and 1.22 μM, respectively.99 The substantial reduction of virulence factor production at 
concentrations of 0.20–0.35 μM and the impact on PA14 biofilm eradication along with 
tobramycin were other factors that progressed this antagonist to in vivo study in two burn and 
lung infection models. 1.3 was successful in potentiating the effect of ciprofloxacin and 
reduced persistence and increased post-infection survival rates in burn and lung infection 
models in mice.103 
A recent study introduced 1.4, which was the result of further optimisation of 1.3.99 This 
compound showed similar activity in PAO1-L, with IC50 of 0.25 ± 0.12 µM, but better activity 
in PA14, with IC50 of 0.34 ± 0.03 µM. This candidate is one of the most potent PqsR 
antagonists reported and shows significant inhibition of P. aeruginosa pyocyanin production 
and pqs system signalling in both planktonic cultures and biofilms. However, no in vivo study 
has been established for this candidate. 
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An extensive structure activity relationship (SAR) study by Spero Therapeutics to optimise 1.3 
led to the publication of the most potent candidate, 1.5 in the aryloxyacetoindole series, as a 
PqsR inhibitor. The patented compound is highly potent in inhibiting pyocyanin production, 
with a stated IC50 in the range of 50–250 nM. In addition, in a murine thigh infection model 
using PA14, 1.5 was able to reduce PQS and HHQ levels to 50% and 40%, respectively, 12 
hours after infection. To date, no further optimisation or development of these compounds has 
been reported. The available biological data for both candidates provide robust proof of concept 





1.7 PqsR receptor as a transcriptional regulator in Pseudomonas aeruginosa QS 
1.7.1 Validation of PqsR receptor as a therapeutic target in Pseudomonas aeruginosa 
infections 
Most studies have focused on the las system because of its hierarchical position and ability to 
control both rhl and pqs systems. However, spontaneous lasR mutants of this pathogen are 
frequently found in chronic infections in humans questioning its validity as a therapeutic 
target.104 In parallel, some studies have shifted the focus towards the rhl system which shows 
a contrasting virulence modulatory effect as mentioned above (Section 1.6.2). The agonist of 
this system reduces pyocyanin but induces rhamnolipid production, while antagonists have the 
opposite effect.105 These findings have made LasR and RhlR less attractive as anti-virulence 
targets than originally anticipated. 
The fact that AQs have been found in sputum, plasma and urine of chronic CF patients infected 
with P. aeruginosa and that their levels correlated with negative prognosis suggest a key role 
of the pqs system in infection. Furthermore, it suggests that AQs could be used as a potential 
biomarker for the severity of infection,106 These findings make exploitation of the pqs system 
as an anti-virulence target promising.  The PqsABSDE enzymes and the PqsR regulator are 
key for the biosynthesis of AQ, and hence most of them have been considered as drug targets. 
The question is which of these drug targets are crucial for attenuating the virulence of P. 
aeruginosa in a wide range of strains.  
Among the various anti-virulence strategies, targeting key transcriptional regulator of genes 
involved in the production of virulence traits appears to hold great promise for future discovery 
and development of anti-virulence treatments.107  
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According to current knowledge, PqsR is a target that controls an array of virulence 
mechanisms at once, and focusing on this receptor instead of addressing just single factors 
seems an efficient strategy to reduce pathogenicity.108  
A study established by Xiao et al. analysed the survival rate of four groups of thermally injured 
mice infected with wild-type PA14, pqsR, pqsA or pqsH mutant strains. The result shows that 
the pqsH strain displays wild-type virulence in mice, which indicates fully functional PqsR. In 
contrast, both pqsR and pqsA exhibit attenuated virulence strains and a high survival rate of the 
mouse groups infected with these strains due to reduced AQ production in the in vivo model.109  
 
Figure 1-12: Thermally injured mouse model.109 Mice were infected with PA14, (mvfR¯) pqsR, pqsA¯ or pqsH¯ 
mutant strains. The mutant strains are isogenic with PA14. Fifteen mice were used for each experiment. Each 
experiment was performed twice. Source: Xiao et al 109  
 
Other studies have also shown that this reduction is not only because of the deficiency in AQ 
production but also due to the loss of pqsE108 and phnAB expression, 81,110 providing further 
evidence for the significance of this receptor as a therapeutic target for P. aeruginosa 
infections.  
Furthermore, the targeting of this receptor with an antagonist in different in vivo disease models 
103,111 has provided robust proof of the significance of focusing on PqsR as a therapeutic target. 
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Starkey et al. demonstrate two in vivo murine models of acute infection; thermal injury and 
lung infection. 1.3 exhibits significant in vivo therapeutic efficacy against both mammalian 
infections with an increase in survival rate as shown in Figure 1-13. 
 
 
Figure 1-13: Thermal injured and lung infection mice models. a) Survival rate of burn and infection mice 
model following PA14 infection, minus (black, n= 30), and plus (blue, n= 36), 1.3 (M64) (4 mg/kg). 1.3 was 
administered by intravenous injection 6 h post-burn and infection, and then twice a day for 6 days post-infection. 
b) Survival rate of lung infection mice model following PA14 infection, minus (solid black line, n≥10), and plus 
(solid blue line, n≥10) 1.3 (4 mg/kg); and infection with PqsR¯ (MvfR¯), minus (dot black line, n≥10), and plus 
(dot blue line, n≥10) 1.3 (12 mg/kg). 1.3 was administered by intravenous injection at 2, 4, 8, and 12 h post 
infection, and then twice a day up to day 4. Differences between PA14 and PA14 + 1.3 (p,0.05) or between MvfR¯ 
and + 1.3 (p,0.05) are statistically significant, while differences between MvfR¯ and MvfR¯ + 1.3 (p.0.05) or 
between PA14 + 1.3 and MvfR¯ + 1.3 (p.0.05) are not statistically significant (Kaplan-Meier method). PqsR¯ or 
MvfR¯referred to PqsR mutant strain of PA14. Source: Starkey et al.103 
The evidence mentioned above, provide the basis for selecting PqsR as a promising therapeutic 
target that decreases the pathogenicity of P. aeruginosa and improves the efficiency of current 









Figure 1-14: Schematic representation of the PqsR ligand-binding domain. a) Representative diagram of PqsR 
domains.112 b) crystal structure of PqsRCBD complexed with PqsR agonist (NHQ; PDB code 4JVD).87   
 
PqsR (also known as MvfR) belongs to the LysR-type transcriptional regulator (LTTR) 
receptor family, which consists of an N-terminal helix-turn-helix (HTH), DNA-binding domain 
(PqsRDBD). Additionally, LTTR contains a C-terminal that encodes a ligand-binding domain 
(LBD) known as the co-inducer binding domain (CBD) (PqsRCBD) (Figure 1-14a). PqsRCBD 
recognises and responds to their cognate autoinducer to mediate their respective regulatory 
activity.113 Generally, LTTRs, which are approximately 300 amino acids in length, form 





dimers form a tetrameric complex that leads to the bending of the DNA strand. The binding of 
autoinducer molecules results in an alteration to this bending that facilitates the interaction of 
RNA polymerase with the promoter region, thereby leading to enhanced transcription of the 
target genes.114 It is worth to mention, this working model has been proven for similar LTTRs 
but not specifically for PqsR. However, PqsR exhibits several characteristic features indicating 
that it works in a similar fashion; for example, specific DNA binding110, enhanced expression 
of pqsABCDE and phnAB operons in the presence of autoinducer molecules 115,109, and its CBD 
crystallising as a homodimeric complex.87 
To our knowledge, no existing work has described the crystal structure for the full length of 
the PqsR protein. However, the CBD of PqsR (PqsRCBD) has previously been described. 
Ilangovan et al. reported the first crystal structure of PqsRCBD (Figure 1-14b), which showed 
that the domain is generally hydrophobic and consists of two subdomains (pockets A and B) 
connected by an antiparallel β-sheet hinge region that provides flexibility to the protein and 
enables the two domains to rotate relative to each other.87 The analysis of the natural substrate 
(NHQ; PDB code 4JVD) orientation and binding interactions to the binding domain was 
obtained via a crystal soaking experiment. The results of this experiment showed that the 
quinolone ring accommodates pocket A, whilst pocket B is accommodated by an aliphatic 
chain supported by hydrophobic interactions with Tyr258, Leu189, Ile186, and Val170. 87,116 One 
special feature about this binding is that all interactions are hydrophobic, with no hydrogen 





1.8 The design of an anti-virulence development project 
 
Drug discovery is the process through which potential new therapeutic entities are identified 
by using a combination of computational, experimental, and clinical models. Despite advances 
in biotechnology and the understanding of biological systems, drug discovery is still a lengthy, 
costly, and difficult process with a high attrition rate of novel therapeutic discoveries. Drug 
design is the inventive process of finding new medications based on the knowledge of a 
biological target and involves the design of molecules that are complementary in shape and 
charge to the molecular target. In general, drug discovery projects can be initiated by two 
approaches to identify a novel molecule; a structure-based which relies on the knowledge of 
the three-dimensional structure of the biomolecular target and a ligand-based which is relies 
on knowledge of other molecules that bind to the biological target of interest. A previous work 
by Fadi Soukarieh had undertaken a virtual screen of University of Nottingham Managed 
Chemical Compound Collection (MCCC), with the PqsR ligand binding domain (LBD) crystal 
structure (PDB: 4JVI) reported by Ilangovan et al 87 and had identified the following hits with 





Figure 1-15: The result of in silico virtual screening of MCCC library to identify PqsR inhibitors.  Chemical 
structures of the five hits that showed inhibition of PqsR activity employing PAO1-L CTX::PpqsA-lux strain. 
Source: Fadi Soukarieh et al.99  
 
Grossman et al. and Soukarieh et al. employed 1.7 and 1.10, respectively, as hit in two 
independent studies which provide the field with potent candidates in the sub-micromolar range 




Compound 1.6 was selected as a hit in this work, as it shows reasonable balance between good 
activity and low lipophilicity. In addition, the chemical structure of 1.6 is simple and novel 
with scope for a rapid med chem exploration. 
 
 
Figure 1-16: The analysis of the biological activity of 1.6 enantiomers in PAO1-L CTX::PpqsA-lux strain. Source: 
Fadi Soukarieh et al, in press. 
Further analysis of both enantiomers of 1.6 was established by Soukarieh demonstrating that, 
the R isomer, 1.13 is the more active isomer, (IC50 = 1.1 ± 0.4 µM), while the S isomer, 1.14 
was 7-fold less active (IC50 of 7.3 ± 1.4 μM) (Figure 1-16). 
A SAR study was established for quinazolin-4(3H)-one series (chapter 2) which were affected 
to some extent by the structural features discussed in Section 1.8.1. A hit to lead stage was 
presented in (Chapter 3) and several candidates were identified with good potency and 
physicochemical proprieties. In the lead optimization stage, different secondary 
pharmacological assays as well as cytotoxicity studies were performed to evaluate the selected 
candidate before proceeding to in vivo study. The type of biological assay employed in the 
literature are discussed below (Section 1.8.2) to provide a general view of the design of the 
biological work presented in this thesis. 
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1.8.1 Physicochemical properties of antibacterial compounds 
 
 
Figure 1-17: Two-dimensional representation of physicochemical properties (clogD7.4 and MW) of a 
comprehensive medicinal chemistry (CMC) dataset (grey) and major classes of antibacterial drugs (colour). 
Abbreviations: FQs = fluoroquinolones; Gram-neg BL = gram negative β-lactams; AGs = aminoglycosides; 
Gram-pos BL = gram positive β-lactams. Source: O’Shea and Moser. 118 Structure examples of each class of 




Consideration of the molecular properties of the hit from the early stages of the drug discovery 
project is more likely to yield a successful candidate with a good pharmacokinetic profile.119 
Over the past two decades, the number of failures of small-molecule drug candidates due to 
poor pharmacokinetic profiles seems to have diminished significantly due to the guidance for 
the design of new compounds offered by different analyses and rules, such as the Lipinski 
rules, which direct hit selection to the right property space with molecular weight (MW) less 
than 500 and cLogP less than 5.120,121 However, antibacterial compounds have always been 
considered exceptions to these rules mainly because they are required to penetrate the pathogen 
membrane and frequently the human cell membrane (Figure 1-17) .118  
In general, natural antibacterial compounds tend to shift the property space towards higher 
polarity and MW. The best example are aminoglycosides. However, this type of antibiotic is 
not orally bioavailable, and its penetration of the bacterium is due to an active electron transport 
mechanism that facilitates the drug entry into the cytoplasm via a slow, energy dependent, 
electron transport mediated process 122; therefore, no conclusions can be drawn from this type 
of compound. On the other hand, the physicochemical proprieties of the synthetic 
fluoroquinolone antibiotics, are the best example of the desirable unique property space of 
antibacterial medication. They fulfil the requirements to: (1) achieve gram-negative activity by 
obtaining high polarity to penetrate bacterial porins and (2) be bioavailable orally by 
maintaining a reasonable level of lipophilicity to penetrate the lipid membrane.  
 
Figure 1-18: The fluoroquinolone antibiotics pharmacophore. The substitution at R7 is the most influential 
point on the molecule. The five- or six-membered nitrogen heterocycle at this position has improved antibiotic 
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activity and pharmacokinetic profile. The most popular heterocycle employed at position 7 is piperazine, which 
is found in Ciprofloxacin.123   
The nature of most fluoroquinolones as zwitterionic compounds leads to a lower cLogD7.4 
value with a mean of -0.8 in general and cLogP of 1.3. In addition, the pKa value is required 
to be close to neutral pH 7.4 in order for charged and noncharged species to coexist in the 
biological environment.118 The experimental pKa values of ciprofloxacin for example are 6.15 
for carboxylic acid and 8.66 for piperazine ring which restricts the types of functionality 
allowed in this type of antibiotic (Figure 1-18).124  
Consideration of the possible routes of administration of novel candidates is another factor that 
contributes to the determination of the appropriate property space which affects to some extent 
the design of the structure–activity relationship study. Systemic oral dosing remains the 
preferred delivery method for most drug therapies and the ideal route of administration for 
chronic patients. However, oral bioavailability is a major hurdle in drug development as it 
requires properties of the compound that allow dissolution and stability in the gastrointestinal 
tract as well as stability against the first-pass metabolism in the liver. Therefore, it is important 
to consider the required properties proprieties of alternative routes of administration in the early 
stage of the study design. The pulmonary route is an ideal alternative for chronic P. aeruginosa 
lung infections in patients with CF or non-CF bronchiectasis. This route provides a high local 
concentration of the drug with low systemic exposure which reduces the risk of unwanted 
systemic adverse effects. The ideal characteristics of a compound for this type of administration 
are a long residence time in the lungs to increase local efficacy and rapid clearance after 
systemic absorption. From the perspective of medicinal chemistry, consideration of the 
molecular properties that contribute to increasing retention time in the lungs is important to 
guide the design of the study. A previous study suggests that increasing lipophilicity and MW 
leads to increased retention time in the lungs.125 In addition, a review summarised different 
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efforts to determine the factors required for lung accumulation of different pharmacological 
classes. Although the investigated drugs, species and experimental models varied, lung 
accumulation was particularly significant for basic amines with pKa values greater than 8. Most 
basic amines are amphiophilic, with a large lipophilic group and a hydrophilic group that is 
ionised at physiological pH 7.4.126 P. aeruginosa infections start usually in the smaller airways, 
the bronchioles, and move into the larger airways. Therefore, the optimal deposition for inhaled 
antimicrobial therapy would be a uniform distribution on the conducting airways.127 However, 
many factors, such as particle size, pharmaceutical formulation, the severity of the disease and 




1.8.2 Biological evaluation of novel quorum sensing inhibitors 
An overview of current biological assays employed in the literature to evaluate a new candidate 
as quorum sensing (QS) inhibitors in P. aeruginosa is presented here (Figure 1-19). 
 
 
Figure 1-19: The biological assays employed in evaluation of quorum sensing (QS) inhibitors, according to 
the literature.99,103,117,128,129  
Cell-based reporter gene assays. According to the literature, cell-based reporter gene assays 
are routinely used to assess the activities of putative QS inhibitors in P. aeruginosa. In these 
experiments, a receptor (regulatory protein) of interest is typically expressed in a heterologous 
species, such as Escherichia coli (E. coli), that does not produce the corresponding QS signal 
molecule and carries a plasmid construct encoding a transcriptional fusion of a receptor-
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regulated promoter coupled to a reporter gene. Different reporter genes, such as green 
fluorescent protein (GFP), β-galactosidase or luciferase could be employed in these assays in 
which the intensity of fluorescence emission is proportional to the level of transcriptional 
activation by the receptor of interest. However, the limitation of this approach is that these 
heterologous reporter systems may not accurately represent the cellular environment of the 
native host. The IC50 values of QS inhibitors are substantially higher in the native P. aeruginosa 
background than in E. coli reporters.130 There are several reasons for this discrepancy, 
including lower membrane permeability and higher active efflux in P. aeruginosa than in E. 
coli, competition with native ligands (autoinducers) for receptor binding in P. aeruginosa, and 
differences in the levels of receptor expression between P. aeruginosa and E. coli. Therefore, 
two strains of P. aeruginosa were employed in this study to overcome these problems and 
exclude compounds with permeability issues.131  
 
Figure 1-20: Schematic representation of the PAO1-L or PA14 bioreporter strains. The chromosomal 
transcriptional fusion of PpqsA-lux was introduced to report on PqsR activation by HHQ and PQS (AQ). These 
strains produce AQ signal molecules that activate PpqsA::luxCDABE transcription, which results in light emission 
in the biosensor strain. Compounds antagonising PqsR are expected to reduce bioluminescence relative to 
untreated samples.131 Oval shapes represent various proteins and the large orange arrows represent genes. Red 




These strains, which are PAO1 or PA14 wild-type strains carrying CTX-lux vector fused in the 
pqsA promoter region, were used in a transcriptional fusion assay to evaluate the antagonistic 
activity of compounds presented in this work.  
Since P. aeruginosa is not naturally bioluminescent, these strains were designed to emit 
bioluminescence when the PqsR transcriptionally regulated target is activated by natural 
ligands, especially PQS and HHQ. However, PqsR is no longer able to activate the PpqsA 
promoter upon interaction with antagonists leading to a reduced bioluminescence output for 
active compounds. This assay was used as a primary screening assay to determine the inhibitory 
potency of the highest-scoring compounds in virtual screening (Section 1.8) and the 
synthesised compounds demonstrated in Chapters 2 and 3. Any compound with a threshold of 
10 μM concentration that led to ≤ 50% bioluminescence density suppression relative to DMSO 
(0.1%) control values would be classified as a hit. Concentration-response experiments were 
then conducted to determine the IC50 values for the active compound. The initial IC50 screen 
employed the PAO1-L strain, and any candidate with good activity was further analysed using 
the PA14 strain. This assay provides a rapid and sensitive evaluation based on the detection of 
bioluminescence to identify an appropriate candidate that can proceed to further biological 
evaluations.  
Protein binding assay. A more direct approach known as electrophoretic mobility shift assay 
(EMSA) is employed to measure the effect of the putative QS inhibitors on the binding ability 
of the receptor of interest to the target DNA. In this assay, the purified protein is incubated with 
the test compound and a short segment of DNA containing a promoter sequence which is 
recognised by the receptor. The binding of the receptor to DNA is indicated by a shift in the 
protein band in gel electrophoresis. The advantage of this assay is that it provides a direct 
measurement of the activity of the compound on the protein regardless of permeability and 
efflux pump effects. Unfortunately, most QS receptors in P. aeruginosa, including PqsR, have 
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low solubility when isolated in vitro and complexed to non-native ligands, making the 
establishment of this type of assay challenging. On the other hand, Ilangovan et al. reported a 
purification process for the PqsR ligand binding domain (LBD) complexed to native (NHQ) 
and non-native ligands.87 This process could be employed to perform another technique called 
isothermal calorimetry (ITC) to test whether the putative QS inhibitors directly bind to the 
domain and measure their affinity. ITC is a quantitative method used to directly detect the heat 
either released or absorbed during the receptor–ligand binding interaction. Measurement of 
heat transfer during binding enables accurate determination of binding constants (KD), 
stoichiometry, entropy, and enthalpy of the binding reaction in solution, without the need to 
use reporter genes. This deeper understanding of molecular binding enables more confident 
decision-making in hit selection and the lead optimisation process. This technique was used to 
measure the affinity of 1.3 and confirm its binding to PqsR.103 Another technique to confirm 
the bond interaction with the receptor is determination of the crystal structure which provides 
qualitive data about the molecular interaction rather than the strength of the bond.  
Secondary phenotypic assays. Inhibition of QS systems and the pathoblocker concept are 
strategies with no clinical proof of concept for their translation as a therapeutic approach. 
Therefore, secondary phenotypic assays are needed as well as analysis of biofilm formation to 
prove the concept before the selected candidate proceeds to in vivo study. The most common 
secondary phenotypic assay employed in the literature to evaluate PqsR antagonists is LC 
MS/MS detection of AQ and pyocyanin production which are robust outputs of pqs system 
activation.84,99,100,117  
Biofilm formation analysis. The biofilm formation process is another important virulence trait 
that needs to be evaluated in PqsR antagonist discovery projects. The in vitro biofilm assay 
consists of two stages: biofilm formation and biofilm analysis. The type of platform selected 
for biofilm formation affects to some extent the type of data that can be extracted. A Commonly 
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used assays in this regard are static microtiter plate assays or the Calgary biofilm device. These 
techniques are suitable for high throughput screening without the need for advanced equipment. 
However, in microtiter plate assays, a part of the biomass may be of cells sedimented at the 
bottom of the wells and subsequently embedded by extracellular polymeric substances 
(EPS).132 On the other hand, the Calgary biofilm device overcomes this limitation by assaying 
at the coverlid composed of pegs that fit into the wells of the microtiter plate containing the 
growth medium and bacteria. The biofilm formed on the pegs does not result from cell 
sedimentation but only from sessile development. However, the sonicated biomass does not 
represent the whole sessile community and the physiological properties of the detached 
population may not reflect the physiology of sessile cells, as different populations inside the 
biofilm community could exhibit different adhesive and detachment properties on the 
material.133 Currently, biofilms grown on glass coverslips under flow conditions and light 
microscopy are used to evaluate established biofilms.117, 134  
Based on the literature, reliable methods of establishing biofilm include continuous flow-cell 
systems, colony biofilms, drip flow reactors and rotating disc reactors.135 The analysis of 
established biofilm could be achieved by microscopy or the calculation of colony-forming units 
(CFUs). However, the throughput of these methods is low and they typically require an abiotic 
surface that produces biofilm, which is structurally very different from those seen in vivo.132  
 
Biofilm assays in literature. A previous study by Rahme et al., examined the biofilm treatment 
with 1.3 which showed that 1.3 can interfere with further biofilm development but does not 
disrupt a preformed PA14 biofilm.136 The formation of biofilm involved the use of a Calgary 
Biofilm Device in which biofilms were grown on peg lids in microtiter plates. Crystal violet 
staining and CFU counts were used to quantify biofilm biomass (Figure 1-21a) and viable cells 





Figure 1-21: Biofilm formation analysis in the presence or absence of 1.3 candidate. (a) Biofilm biomass and 
(b) biofilm viable cells were measured by crystal violet staining or CFU counts, respectively, in the presence or 
absence of 0.1, 1 or 10 µM 1.3. c) Biofilm CFUs were quantified before (24 h or 48 h) or after (72 h) treatment 
with 10 µM 1.3. Data show the average +/- standard error of the mean (SEM) of at least six replicates. Statistical 
significance was assessed using the unpaired t-test. Source: Maura and Rahme.136 
 
1.3 was added at different concentrations (0.1, 1 and 10 µM) and different time points (24, 48 
and 72 h). Treatment with 1.3 reduced the increase in biofilm CFUs that occurred between 48 
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and 72 h by 50% relative to the control. However, 1.3 did not reduce biofilm CFUs to below 
the pre-treatment level, indicating that 1.3 alone can interfere with further biofilm development 






































Figure 1-22: Biofilm formation analysis in the presence or absence of 1.12 (40) candidate. a) Quantification 
of AQ concentrations in PAO1-L biofilm cultures treated with 1.12 (10µM). Biofilms were grown in M9 minimal 
medium for 18 h in 24-well glass-bottom plates and supernatants were extracted for AQ analysis. b) PAO1-L 
biofilm viability quantified after treatment with different conditions for 6 (blue) or 24 h (orange). The 




Another study that examined the effect of PqsR antagonist on biofilm formation was conducted 
by Soukarieh et al, 2020. This study analysed the inhibitory effect of 1.12 on AQ production 
in biofilm cultures. The biofilm was grown on round glass coverslips under flow conditions. It 
was established for 48 h and incubated for a further 6 or 24 h before treatment (1.12 10 μM 
or/and ciprofloxacin 60 μg/mL). However, the results obtained from this experiment 
contradicted the hypothesis since they indicated a slight increase in the viability of samples 
treated with the PqsR antagonist 1.12 in comparison to the control (Figure 1-22). 
The reasons of these conflicting results were not investigated; however, this raises the question 
of whether biofilm experiments performed in the laboratory are useful for understanding how 
the novel candidates can inhibit QS and interfere with biofilm formation. Therefore, there is a 
need to investigate this area in depth and provide the field with experiments reflecting the 
pathological situation in an in vivo system. 
From a pharmacokinetic perspective, the ability of a candidate to show metabolic stability and 
safety in the corresponding in vitro assays, such as cytochrome P450 (CYP) inhibition assay, 
using human liver microsomes and cytotoxicity assays with cultured cells, is critical at this 





1.9 Project overview and objectives   
The work performed in this thesis mainly focuses on attenuating the pathogenicity and 
resistance of one of the most critical pathogens by designing and developing a range of novel 
QS inhibitors targeting the transcriptional regulator (PqsR) of the pqs system which is distinct 
to P. aeruginosa. Different chemical approaches are employed to synthesise a range of 
compounds, and the selected candidates are validated through different biological evaluations 
and molecular structure analysis. 
Chapter 2 focuses mainly on an SAR study for the selected hit with a quinazolin-4(3H)-one 
scaffold which is similar to the natural substrate of the receptor. The chemistry to synthesise 
different analogues is discussed in this chapter as well as the approaches employed to enhance 
the physicochemical properties of the series. 
In chapter 3, the work aimed to expand the SAR further by replacing the quinazolin-4(3H)-one 
moiety with different heterocyclic ring systems; it was concluded that the optimal replacement 
is the 1-methyl-1H-benzo[d]imidazol-2-amine ring. Many attempts were established to identify 
the optimal conditions to synthesise this series by employing different strategies, and the 
selected pathway was successful in synthesising a range of analogues with different 
substitutions. 
Biological evaluations of the active compounds are presented in the final chapter (4) in an 
attempt to prove the concept and validate the target as a relevant therapeutic target. 
Furthermore, a cytotoxicity study of the most active compounds in the work was conducted to 
investigate the therapeutic-toxicity index of these compounds before proceeding to the in vivo 
study. However, it is critical to establish further pharmacokinetics in vitro and in vivo assays 




2 Design, Synthesis and Evaluation of Novel quinazolin-4(3H)-one-
based PqsR antagonists as Adjuvant Therapies to Treat 
Pseudomonas aeruginosa Infection 
 
2.1 Background of the project 
The first step of any drug discovery program aiming to develop a new drug candidate is finding 
a hit with which to establish a structure–activity relationship (SAR) study. Two previous 
studies employed a ligand-based design approach using the structures of PqsR agonists.87,111 
The findings offer insights into the ligand–receptor interaction of PqsR and provide a promising 
starting point for further drug design.  
 
Figure 2-1: Summary of the first SAR study designed to identify a PqsR antagonist 2.5 by employing a 
ligand-based approach. The inhibition of PqsR activity was measured using β-galactosidase reporter gene assays 
based on E. coli a or P. aeruginosa b.  
The Hartmann laboratory have been a pioneer in the design of PqsR antagonists.137 In a pivotal 
study using a ligand-based drug design approach, Hartmann and co-workers outlined a general 
SAR for PqsR antagonism by developing structural analogues of PQS.111 Notably, they found 
that an alkyl chain of at least six carbons was required for biological activity, and introducing 
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electron-withdrawing groups (EWGs) at the 6- position of the quinolone core resulted in strong 
inhibition of PqsR activity. The antagonistic effect was not only attributable to the nature of 
the substituents, it was also affected by the substituent position, as substitution of the 7- and 8- 
positions of the quinolone did not show inhibition. These trends allowed the identification of 
the first competitive inhibitors of PqsR, with compound 2.3 emerging as the lead compound 
(Figure 2.1). Compound 2.3 bound to PqsR with KD = 7 nM and IC50 = 51 nM in an E. coli 
reporter assay. However, a subsequent study showed that 2.3 behaved as a mild agonist of PqsR 
in a reporter gene assay based on P. aeruginosa.138 Hartmann and co-workers proposed that 
2.3 may be a substrate for the PqsH enzyme, which hydroxylates the 3- position in the final 
step of PQS synthesis. A small library of compounds was prepared with different functional 
groups substituting the hydrogen atom in the 3- position to block the reaction site of the PqsH 
enzyme. Compound 2.5 with a carboxamide functional group was selected as the best candidate 
from that series, showing good activity in the P. aeruginosa reporter gene assay. This 
compound provided the first proof of concept that PqsR antagonists reduce the mortality caused 
by P. aeruginosa in two in vivo models (Caenorhabditis elegans and Galleria mellonella). 138 
 
Figure 2-2: Summary of SAR study employing ligand-based approach and novel 2-alkyl-4(3H)-
quinazolinone scaffold. The inhibition of PqsR activity was measured by a reporter gene assay based on P. 





A study conducted by Williams and co-workers analysed a series of AQs and 2-alkyl-4(3H)-
quinazolinone (QZN) analogues with either 7 or 9 carbon atoms in the aliphatic side chain.87 
The SAR study revealed that the QZN core in 2.6 and 2.7 was devoid of both agonist and 
antagonist activity, while hydroxylation at R1 of both analogues led to weaker agonist activity 
compared to PQS (2.8 and 2.9). Interestingly, halogenation at the R2 position with chlorine or 
fluorine improved the agonistic activity (2.10 and 2.11). Replacing the OH at R1 with its 
isostere NH2 resulted in good antagonistic activity, with IC50 values of 5 and 3.9 µM for 7- Cl 
2.12 and 7- F 2.13 analogues, respectively.  
According to these two previous studies, the most important structural features for achieving 
antagonistic activity was the introduction of strong EWGs at the 6- position of the quinolin-
4(1H)-one core or at the 7- position of the quinazolin-4(3H)-one core. In addition, these studies 
revealed that substitution of the 3- position has a role beyond blocking the metabolic hotspot, 
as it appears that converting the hydroxyl to an amino group in 2.12 and 2.13 results in 
antagonistic activity. These findings affect, to some extent, the design of the SAR study 
presented in this chapter. 
2.2 Hit characterization  
As discussed in Section 1.8, a virtual screening experiment was established by Soukarieh 
employing the crystal structure of PqsRLBD followed by biological analysis of the top scoring 
compounds to evaluate their activity through measuring the IC50s. Compound 1.6 was selected 
as a hit for this project and further analysis of both enantiomers demonstrated that, the R- 
isomer, 1.13 is more active enantiomer.  
Subsequently, a work presented by Sou et al. analysed the pharmacokinetic properties of 1.13 
and 2.12 using intratracheal pulmonary administration in rats model to predict their therapeutic 




Figure 2-3: Pharmacokinetic analysis in in vivo model.   2.12 (SEN001) and 1.13 (SEN019) were administered 
into rats via intratracheal administration. Blood, lung, and (bronchoalveolar lavage (BAL) for 2.12 only) samples 
were collected at determined time points, and the concentration of both compounds were analysed by LC-MS. 
Source: Sou et al.139   
The compounds were given via intratracheal administration to the lungs at doses of 0.07 mg/kg 
and 0.12 mg/kg of body weight, respectively. The selection of doses was restricted by the 
aqueous solubility and availability of the tested compounds. Samples were collected from 
blood, lung, and (bronchoalveolar lavage for 2.12 only) at determined time points, and the 
samples were analysed by LC-MS. The results showed that, both compounds (1.13 and 2.12) 
were rapidly cleared from the lung to the plasma, as demonstrated by the rapid appearance of 
the compounds in plasma shortly after administration (Figure 2-3). However, the plasma 
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concentration of 2.12 declined steadily over the sampling period while the plasma 
concentration of 1.13 declined more rapidly and was below 1 µg/mL after 3 h.139  
Furthermore, the solubility determination showed that 1.13 and 2.12 were poorly water-
soluble, 20 µg/mL and ˂ 1 µg/mL, respectively. However, the addition of PP2% formulation 
improved the solubility of the compounds significantly and increased the amount of solubilized 
compounds to more than 180 μg/mL. This formulation is a mixture of polyethylene 
glycol400 (PEG400) 2% + polysorbate 80 (PS80) 2% w/w in water. Another advantage of 
PP2% formulation that it does not cause any detectable acute toxicity to the lungs of the 
animals, as shown by histological examination of the terminal lung samples. Therefore, PP2% 
was used to deliver solubilized drugs for IT administration in the PK studies. 139 
 These results highlight the importance of designing novel PqsR antagonists with enhanced 
water solubility and an increased residence time in the lung to enable local efficacy in 
combination with rapid clearance after systemic absorption to reduce the risk of adverse 




2.3 Rationale of the design 
 
This study aimed to analyse the effect of slight modifications of the original structure (1.6) on 
the pharmacological activity and to explore the essential pharmacophore for antagonistic 
activity (Figure 2-4). 
 
Figure 2-4: a) Chemical structures of the previously identified antagonists 1.3, 2.5 and 2.12. b) Chemical structure 
of hit compound 1.6, the SAR study design and the investigated functional groups in this study.  
The main core of 1.6 is the quinazolinone ring, which is a class of fused heterocycles that are 
of considerable interest owing to their diverse biological properties.140 This privileged structure 
in drug development and discovery can be found in more than 200 naturally occurring alkaloids 
with a wide range of pharmacological applications including antibacterial, anti-inflammatory, 
antifungal and antimalarial activities.140 The quinazolinone ring is stable towards oxidation, 
reduction and hydrolysis inspiring medicinal chemists to explore this scaffold in the search for 
new potential medicinal agents.140 In addition, the similarity of 1.6 to the natural ligands of 
PqsR (quinolin-4(1H)-one) and to the structure of the previously identified antagonists 2.5 and 
2.12 (with a quinolin-4(1H)-one or quinazolin-4(3H)-one core) together support the selection 
of 1.6 as an ideal hit to initiate a SAR study in an attempt to improve the potency and the 
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physiochemical properties of this compound. Previous studies demonstrated that the R isomer 
of  1.6 (1.13) was poorly water-soluble and had a short retention time in the lung,139 which 
guided our study design to focus on enhancing the hydrophilicity of the compound by 
introducing weakly basic functional groups in order for charged and noncharged species to 
coexist in the biological environment, as previously discussed (1.8.1).126 Furthermore, it was 
shown that substitution with electron withdrawing groups (EWGs) on the phenyl ring of the 
quinazolin-4(3H)-one core are important to improve antagonistic activity; however, the 
position of the substitution should be carefully considered. Therefore, it is important to probe 
the effect of substituting different positions of the phenyl ring with different EWGs to identify 
the optimal substituent and position. In addition, the linker was investigated by replacing the 
secondary alcohol with different substituents to determine the type of interaction provided by 
this functional group. Importantly, the position of the nitrile functional group on the phenyl 
ring were also probed. Furthermore, different types of nitrile bioisosteres, as well as 
heterocycles, were employed to increase the overall polarity or ionization of the compound to 
enhance its water solubility and probe biological activity. Finally, as an inspiration from the 
literature, the published compound 1.3 containing a diphenyl ether functional group showed π-
π stacking interactions with the side chain of Tyr258.112,103 Therefore, an attempt was made to 
modify the acetonitrile functional group by replacing this functional group with a phenoxy 
substitution at the para position.  
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2.4 Results and discussion  
2.4.1 Synthesis of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) 
phenyl) acetonitrile, 1.6 and its analogues 
The route used to prepare 1.6 and its analogues (2.34-2.37) is shown in Scheme 2-1, which 
employed two building blocks: 4-(3H)-quinazolinone 2.20 and epoxides 2.29-2.33. 
Scheme 2-1: Synthesis of compounds 1.6 and its analogues (2.34-2.37).  
 
Reagents and conditions: a) Formamide, 150°C, 16 h, 99%. b) BBr3, DCM, rt, 16 h, 80%. c) (±) epichlorohydrin, 
Cs2CO3, CH3CN, reflux, 16 h, 28%. d) Cs2CO3, TBAI, CH3CN, reflux, 16 h 46%.  
 
The 4-(3H)-quinazolinone 2.20 was prepared according to the method described by Vi 
Niementowski in 1895.141 The reaction was carried out by condensing different substituted 2-
aminobenzoic acids with formamide to form the substituted quinazolinone cores. The yield of 
this reaction was very high, leading to a clean product with water as a side product.142  
The second building block required to synthesise 1.6 and 2.34-2.37 was 2-(phenoxymethyl) 
oxirane 2.29-2.33, which was synthesised by employing either a two-step synthesis for some 
analogues or a one-step for others. The phenol as a starting material for analogues 2.25-2.27 
was either commercially unavailable or very expensive and therefore anisoles 2.21-2.23 were 
used in the first step. The ether demethylation is synthetically challenging, as it is a stable group 
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and can be activated only if it is an aryl-alkyl ether by using an acid with a nucleophilic counter 
ion, such as HBr or HI. However, using strong acids in this specific case could hydrolyse the 
nitrile functional group present in the starting material, converting it to carboxylic acid, An 
alternative approach is to use a strong Lewis acid, such as BBr3.
143 The oxygen atom in 2.21-
2.23 will attack the empty p orbital of the boron, and the methyl attached to the resulting 
oxonium ion can be attacked by Br– in an SN2 reaction. The workup with water led to the 
phenols 2.25-2.27.143   
Epoxide preparation. The epoxides were prepared by reacting a range of phenols with (±)-
epichlorohydrin in basic conditions through an expected SN2 reaction to produce racemic 
epoxides.  
4-(3H)-quinazolinone alkylation. The reaction to synthesise 1.6 and 2.34-2.37 consisted of two 
steps and proceeded via an in situ epoxide ring-opening at the less substituted carbon atom by 
adding a catalytic amount of tetrabutylammonium iodide (TBAI). The second step was a 
substitution reaction in which the nitrogen atom at position 3 of the QZN attacked the 
electrophilic alkyl iodide to furnish the final product (Figure 2-5). 
 
 
Figure 2-5: Alkylation of 4 (3H)-quinazolinone ring. The reaction uses a catalytic amount of 
tetrabutylammonium iodide (TBAI). 
In an unsymmetrical epoxide, two ring-opening products can be formed corresponding to the 
reaction of the nucleophile at the two different carbons of the ring. However, in basic 
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conditions, the nucleophile typically reacts at the carbon atom bearing the greater number of 
free hydrogen atoms.144 This carbon is highly reactive and is considered to be a hard 
electrophile because epoxides possess significant angle strain, and the bonds of an epoxide are 
weaker than those of cyclic ethers with larger rings or open-chain ethers. However, employing 
TBAI led to epoxide ring opening and provided the corresponding alkyl halide which is 
considered as a soft electrophile. This decreased the reactivity of the electrophile and enhanced 
the selectivity ratio to produce the desired regioisomer. Most literature reports two sites of 
possible alkylation: N3, O or a mixture of both products, which depends on the electronic and 
steric nature of the C2 substituents and the reaction conditions.
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The selectivity of OH-alkylation can be directed by using specific conditions, such as the 
Mitsunobu reaction, 146 or specific reagents, such as BOP 147, POCl3 or HCCP.
148 Otherwise, 
the regioselectivity mainly depends on the alkylating agent, substrate, reaction solvent and 
other reaction conditions.149 
The 13C NMR spectra (Figure 2-6) showed that the same chemical shift of the carbonyl group 
in the 4 (3H)-quinazolinone ring of 2.20 as in the product 2-(4-(3-(6-chloro-4-oxoquinazolin-
3(4H)-yl)-2-hydroxypropoxy)phenyl)acetonitrile 1.6, with shifts of 160.28 ppm and 159.99 
ppm, respectively. This evidence proves that the OH-alkylation did not take place in this 






Figure 2-6: The 13C NMR spectra of 4 (3H)-quinazolinone ring of 2.20 (above) and 2-(4-(3-(6-chloro-4-
oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy)phenyl)acetonitrile 1.6 (below) with an enlarged section of the 
aromatic region, in DMSO-d6 solvent at 100.66 MHz.    
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A heteronuclear single quantum correlation (HSQC) experiment was used with the resulting 
two-dimensional (2D) spectrum showing one axis for proton (1H) and the other for a hetero-
nucleus (an atomic nucleus other than a proton), which is in this case 13C. The spectrum implies 
that carbon 13, which is attached to nitrogen appears at 50 ppm and couples to two protons 
appearing in different regions, 4.35 ppm and 3.87 ppm. Further analysis was established 
employing a heteronuclear multiple-bond correlation (HMBC) experiment to determine the site 
of alkylation. This experiment detects heteronuclear correlations over longer ranges of 
approximately 2–4 bonds. The characteristic peak of the carbonyl group (160 ppm) was 
coupled with proton appear at 4.35 ppm, indicating that N3 rather than N1 was the site of 





Figure 2-7: 2D NMR analysis of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl) -2-hydroxypropoxy) phenyl) 
acetonitrile, 1.6.  The heteronuclear single quantum correlation (HSQC) spectrum (above) and the heteronuclear 
multiple-bond correlation (HMBC) spectrum (below), in DMSO-d6 solvent.    
 
2.4.2 Oxidizing the hydroxyl functional group in 2-(4-(3-(6-chloro-4-oxoquinazolin-
3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile, 1.6 
Scheme 2-2: Oxidation of a secondary alcohol to a ketone functional group. 
 




There are a variety of oxidizing methods and reagents that can be used for secondary alcohol 
oxidation, such as chromates, Swern oxidation, or Dess–Martin periodinane (DMP) reagent. 
DMP oxidation is preferable in comparison to other oxidation reagents due to its mild reaction 
conditions such as room temperature and a neutral pH.150 This reaction also avoids the use of 
toxic chromium reagents and does not require a large excess of oxidizing reagent or co-
oxidants. The reaction of the hypervalent iodine-containing reagent with secondary alcohol in 
1.6 was efficient to afford ketone 2.38 (Scheme 2-2), with acetic acid and the mono-
acetoxyiodinane as easily removed side products.150   
2.4.3 Synthesis of 2-(4-(2-amino-3- (6-chloro-4-oxoquinazolin-3(4H)-yl) propoxy) 
phenyl) acetonitrile 2.40 and its analogues 
Scheme 2-3:Synthesis of 2.40. 
 
Reagents and conditions: a) triphenylphosphine (Ph3P), di-isopropyl azodicarboxylate (DIAD), di-phenyl 
phosphoryl azide (DPPA), THF, 45°C, 16 h, 30%.151 b) Ph3P, NH4OH, THF: H2O, rt, 16 h, 25%. c) Tosyl chloride, 
NEt3, DMAP, DCE: 5% THF, rt, 16 h, 82%. d) NaN3, DMF, 60ºC, 16 h, 65%.  
Two different well-known reactions were employed to furnish 2.40. The Mitsunobu reaction 
was used to substitute the hydroxyl group with azide 2.39. The azide was subsequently reduced 
to the primary amine through the Staudinger reaction to give 2.40. This product 2.40 was 
employed in subsequent reactions to either alkylate or form amides.  
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Mitsunobu reaction 2.39. The Mitsunobu reaction was employed to furnish an SN2 product in 
a one-pot synthesis by activating the alcohol into a better leaving group, which then underwent 
nucleophilic substitution (SN2) by azide anion as the nucleophile.  
 
Figure 2-8: Mechanism of Mitsunobu reaction. The reaction employs 1.6, PPh3, DPPA and DIAD to furnish the 
azide moiety in 2.39. 
Two reagents (PPh3 and DIAD) were mixed for 30 minutes to form an active intermediate 2.42, 
as shown in Figure 2-8. Subsequently, 1.6 was added and the active intermediate 2.42 
deprotonated the alcohol, generating the alkoxide ion which immediately attacked the 
positively charged phosphorus atom, forming a strong bond. In the second step, DPPA was 
added, which was attacked by the second basic nitrogen anion, thereby liberating the azide as 
a nucleophilic anion. Finally, the azide attacked the electrophilic carbon in a normal SN2 
reaction, leading to the displacement of the phosphorus derivative of the alcohol by azide 
moiety 2.39. The whole process took place in one operation. The four reagents (DIAD, PPh3, 
DPPA and the substrate) were all added to one flask, generating two side products—phosphine 
oxide and the reduced azo diester with two NH bonds replacing the N=N double bond.  
An alternative approach was used by transforming the hydroxyl group in 1.6 into a good 
leaving group and subsequent substitution with the desired nucleophile. The alcohol was 
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treated with p-toluenesulfonyl chloride and base to form sulfonate ester 2.41, which was 
obtained in good yield. Subsequently, the product was reacted with NaN3 to produce 2.39 in 
good yield and purity. The advantage of this approach was to avoid the generation of phosphine 
oxide (a side product from the Mitsunobu reaction), which interferes with the desired product 
in the chromatographic separation process.  
Staudinger reaction 2.40. The azide moiety can be reduced to the primary amine by several 
methods such as catalytic hydrogenation, LiAlH4 reduction or the Staudinger reaction. 
However, the first two reduction methods are not chemo-selective, and they could affect 
different labile functional groups present within the compound. Catalytic hydrogenation using 
10 wt% palladium on carbon, for example, can hydrogenate the aryl chloride 152 in 2.39, while 
LiAlH4 
153
 can also reduce the nitrile functional group present in the starting material to an 
amine. Therefore, the Staudinger reaction provides the optimal condition to afford the desired 
primary amine moiety with high chemo-selectivity.  
  




Mechanistically, the first step of this reaction is nucleophilic addition of triphenylphosphine 
leading to the formation of the 4-membered ring intermediate 2.45, which is not stable due to 
angle strain and therefore is rapidly decomposed. The side product of this reaction is nitrogen 
gas, which means that this reaction will be thermodynamically favourable due to an increased 
reaction entropy. Following that, decomposition yields the corresponding iminophosphorane 
intermediate 2.46, similar to the Wittig ylide. A water molecule then attacks the phosphorus 
atom in 2.46, and a series of proton transfer steps take place to form the final primary amine 
2.39, with triphenylphosphine oxide as a by-product. 
Scheme 2-4: Amide bond formation in 2.47 and 2.48.  
 
Reagents and conditions: a) (CH3CO)2O, rt, 3 h, 95%. b) (CH3)2NCH2COOH, PyBrop, Et3N, DMF, rt, 4 h 59%. 
 
Amide bond formation is one of the most important reactions in organic chemistry, and the 
design and synthesis of innovative coupling reagents have been an area of intense 
investigation.154 In this work, amide bond formation was achieved by employing a robust and 
classical method using acid anhydrides. The desired anhydride was readily reactive with the 
secondary amine at room temperature. In theory, this reaction does not require a base, as the 
addition generates a carboxylate anion in situ and no coupling would be obtained. Another 
strategy used here is coupling the amine to the desired carboxylic acid. The leaving group, in 
this case, is the hydroxyl anion, which is a poor leaving group and therefore carboxylic acid 
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needs to be activated by a coupling reagent. A one-pot coupling condition was employed here 
using a phosphonium reagent called bromo tri-(pyrrolidino) phosphonium 
hexafluorophosphate (PyBrop), which is a more efficient peptide coupling reagent for 
secondary amine groups when compared to benzotriazol-1-yl-oxy- tris-(dimethylamino)-
phosphonium hexafluorophosphate (BOP) and benzotriazol-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate (PyBop).155 This may be because of the formation of in situ 
acyl bromide, which has less steric hindrance than the acyl benzotriazole generated by BOP or 
PyBop coupling reagents.155 
Amine alkylation 2.50. In general, the alkylation of amines can be obtained via nucleophilic 
addition to aldehydes or ketones, followed by reductive amination or SN2 reaction with an alkyl 
halide.  
Scheme 2-5: Synthesis of imine functional group in 2.49. 
 
Reagents and conditions: a) MeOH with 10% acetic acid, 40°C, 16 h. b) 2-picoline-borane complex or sodium 
borohydride NaBH4.  
The first attempt to synthesise 2.49 was to employ a reductive amination reaction by reacting 
2.38 with the primary amine N1, N1-dimethylethane-1,2-diamine or 2.40 with 2-
(dimethylamino) acetaldehyde in acidic conditions to form imine intermediate 2.49, which was 
planned to subsequently reduce by an appropriate reducing agent, such as 2-picoline-borane 
complex or sodium borohydride. However, the nucleophilic addition did not take place, and no 
product was detected from this reaction.  
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The formation of imines is reversible and generally takes place under acid or base catalysis or 
with heat.156 To drive the reaction to completion, different strategies were employed by adding 
the reducing reagent to produce the amine as the imine formed, removing the water from the 
reaction, and increasing the heat. Unfortunately, all of these strategies failed to produce the 
required product. The reduction of the starting material 2.38 to 1.6 (reduction of the ketone to 
alcohol) was the only reaction that occurred in this condition.  
Scheme 2-6: Synthesis of 2.50. 
 
Reagents and conditions: a) C2H5I, Cs2CO3, CH3CN, 60°C, 16 h, 65%. 
 
A further attempt to alkylate the amino functional group in 2.40 with alkyl iodide was 
employed to directly alkylate the amine and produce 2.50. This was the only successful strategy 
that provided a simple alkylation. However, the biological analysis of this compound did not 
show promising results; therefore, the synthesis effort was directed to different series of 
analogues.   
2.4.4 Nitrile hydrolysis in 1.6 to synthesis 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-
yl) -2-hydroxypropoxy) phenyl) acetamide 2.51 
Scheme 2-7: Synthesis of amide moiety in 2.51 
 
Reagents and conditions: a) Cs2CO3, DMSO:30% H2O2, rt, 30 min, 96%. 
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Preparation of the Amide 2.51. The hydrolysis of a nitrile group to an amide is one of the 
critical transformations in organic chemistry, as amides can undergo further hydrolysis to 
furnish carboxylic acids. Therefore, the selection of the proper reagent and conditions to 
hydrolyse the nitrile to an amide is important to obtain the desired product. One specific 
condition is to use a weakly basic condition of 30% hydrogen peroxide in DMSO.157 The 
mechanism and kinetics of the reaction were investigated by Wiberg (1953), demonstrating 
that this reaction involves the oxidation-reduction of hydrogen peroxide with simultaneous 
hydrolysis of the nitrile.157  
 
Figure 2-10: Mechanism of nitrile hydrolysis with alkaline hydrogen peroxide.  
The hydrogen peroxide first reacts with the carbonate to generate hydroperoxide anion, which 
attacks the electrophilic carbon of the nitrile and forms peroxycarboximidic acid intermediate, 
2.52. After a proton transfer, this intermediate, 2.52 undergoes oxidation-reduction with 
DMSO to afford the amide 2.51 and dimethyl sulfone (DMSO2) (Figure 2-10). Notably, adding 




2.4.5 Modification of the nitrile group to different heterocycles 
Scheme 2-8: Synthesis of 3-methyl-1H-1,2,4-triazole and 1H-tetrazole heterocycles. 
 
Reagents and conditions: a) Acetyl- hydrazide, sodium methoxide, CH3OH, 80°C, 16 h, 15%.158 b) NaN3, 
Et3N·HCl, DMF, 130°C, 16 h, 75%.159 
By considering the carbon of the nitrile as an electrophile functional group, two different 
nucleophiles were used, leading to internal cyclisation and producing two different 
heterocycles: 3-methyl-1H-1,2,4-triazole 2.53 and 1H-tetrazole 2.54. As the acetonitrile group 
was attached to an electron-withdrawing group (phenyl), the cycloaddition of acetyl hydrazide 
or NaN3 took place at a sufficient rate, followed by internal cyclisation to furnish the 




2.4.6 Different approaches for linker modifications 
Here, two different approaches were applied to modify the linker of 1.6: 1) replacing the 
oxygen with an amine functional group, 2) substituting the hydroxyl moiety with a methyl or 
hydrogen. 
Scheme 2-9: Synthetic route approaches for linker modifications. 
  
Reagents and conditions: a) (±) epichlorohydrin, Cs2CO3, TBAI, CH3CN, reflux, 16 h, 38%. b) 4-aminobenzyl 
nitrile, Cs2CO3, CH3CH2OH, microwave, 125°C, 30 min, 47%. c) 1-bromo-3-chloro-2-propane for 2.57 and 1-
bromo-3-chloro-2-methylpropane for 2.58, Cs2CO3, TBAI, CH3CN, reflux16 h, 70–72%. d) 4-
hydroxylphenylacetonitrile, Cs2CO3, TBAI, CH3CN, reflux 16 h, 40–49%. 
 
First, to replace the oxygen with nitrogen in 2.56, the synthesis pathway previously used for 
1.6 synthesis (Scheme 2-1) was slightly modified to a new route (Scheme 2-9).  The new route 
starts with chlorine displacement in (±) epichlorohydrin by deprotonated QZN. Subsequently, 
the epoxide was ring opened by 4-aminobenzyl nitrile under microwave irradiation to furnish 
the final product 2.56.  
Additionally, QZN reacted with 1-bromo-3-chloro-2-propane or 1-bromo-3-chloro-2-
methylpropane to produce two intermediates, 2.57 and 2.58, respectively, which were later 
reacted with 4-hydroxylphenylacetonitrile. The principle of the chemical behaviour of this 
reaction depends on many influencing factors. a) the strength of the covalent bond and b) the 
stability of the corresponding halide anions. Except for the C-F bond, all of the C-halogen 
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bonds are weaker than the C-C and C-H bonds, and the increase in electronegativity is in direct 
proportion to the strength of the covalent bond. This makes the C-Br bond more susceptible to 
breakage than the C-Cl bond. Another reason to direct the chemo-selectivity of this substitution 
toward the C-Br bond is the stability of the halide anions, which mainly depends on the charge 
distribution over the halide anion. The stability of the charge distribution is in direct proportion 
to the size of the halide, which makes the bromide anion more stable and the substitution with 
C-Br more favourable. Therefore, the substitution by activated QZN was expected to be at the 
C-Br bond. This was in agreement with the molecular weight of the intermediates detected by 
LC-MS. Subsequently, the chlorine was displaced by 4-hydroxylphenylacetonitrile in SN2 




2.5 Molecular analysis 
2.5.1 Isothermal calorimetry titration (ITC) of PqsRCBD with 1.13 
 
An important element of drug discovery projects is the confirmation of direct binding to the 
receptor and one approach of achieving this, is by determination the thermodynamic signature 
of a molecule. Notably, ITC is the gold standard for this purpose.160 ITC experiments measure 
the heat evolved (ΔH) when a drug interacts with its target. Additionally, it measures the Gibbs 
free energy (ΔG binding) associated with binding that is related to the affinity of this interaction. 
Gibbs energy (ΔG), enthalpy of reaction (ΔH), and entropy of reaction (ΔS) are related via the 
following equation: ΔG = ΔH – TΔS. A negative ΔG value will favour ligand-protein 
interaction, whilst a ΔG value of –10 kJ/mol is sufficient to complete a reaction. Therefore, to 
increase the binding affinity of the candidates, ideal contributions from both enthalpy and 
entropy are required.161 However, the simultaneous optimisation of these elements is 
challenging since enthalpic optimisation can often be offset by a loss in the entropic 
contribution. Entropy is generally based on the hydrophobic effect and increasing ligand 
lipophilicity will simply optimise this parameter. In contrast, optimising enthalpy is difficult 
due to its dependence on establishing productive electrostatic and van der Waals interactions. 
The critical point here is employing incorrectly positioned polar groups that not obtaining 
further interaction with the receptor. This can frequently be offset by the entropic penalty 
associated with the desolvation energy without gaining further improvement of the enthalpy 
element. The energy required to desolvate a polar group is ∼8 kcal/mol, which is 10 fold higher 





Figure 2-11: ITC binding data of 1.13. The experiment employed 100 μM of 1.13 and 10 μM PqsRCBD in two 
independent experiments. This work was carried out by William Richardson (work in press). 
 
ITC experiment was obtained successfully for 1.13 with PqsRCBD to determine the KD value 
and evaluate the binding affinity to the protein. This experiment confirmed that 1.13 binds to 














Figure 2-12: Schematic representation of the crystal structure of PqsRCBD complexed with PqsR antagonist; 
1.13 (above) and 2.34 (bellow). Hydrogen bonds are shown as dotted lines. The racemic mixture of 2.34 was 
soaked, and the R enantiomer was observed. This work was carried out by William Richardson (work in press). 
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To gain a detailed insight into the molecular interaction of the antagonists belonging to the 4-
(3H)-quinazolinone series with PqsRCBD, the mode of binding of 1.13 and 2.34 was determined 
by obtaining the co-crystal structure with the PqsRCBD domain employing crystal soaking 
experiments. As previously discussed (1.7.2), PqsRCBD compromises of a deep pocket (A 
pocket) which usually accommodates the quinolone part of the autoinducer, as shown with the 
NHQ crystal structure, while the superficial pocket (B pocket) contains the aliphatic side 
chain.87  
The ligand-bound complex revealed that the quinazolinone ring inserted deeply into the 
hydrophobic pocket A in a similar manner to NHQ, whilst the para-phenyl acetonitrile faced 
Tyr258 in pocket B. The quinazolinone moiety of 1.13 and 2.34 was surrounded by aliphatic 
residues (Ala102, Ala168, Ile207, Ile208) while the hydroxyl group establishes hydrogen bonding 
interactions with Glu194 and Arg209 or Gln194 and Leu208, respectively. Overall, both compounds 




2.6 Structure–activity relationship analysis  
2.6.1  Analysing the optimal position of electron-withdrawing substitution on the 
quinazolin-4(3H)-one core 
In all of the natural ligands and the PqsR antagonists presented in this chapter, the quinolin-
4(1H)-one or quinazolin-4(3H)-one core was conserved. Therefore, the attempt here was to 
explore the SAR by substituting the quinazolin-4(3H)-one core with EWGs at the R1-R4 
positions, as presented in Table 2-1. 
Table 2-1: SAR study of quinazolin-4(3H)-one core (2.61-2.68). The inhibition of PqsR activity was initially 
measured in the PAO1-L CTX::PpqsA-lux strain of P. aeruginosa at 10 µM. NA, not active at 10 µM. All 
compounds resulting in a greater than 50% inhibition of activity were further analysed by concentration-response 
curves measured in the PAO1-L CTX::PpqsA-lux strain. The asterisk (∗) indicates that this parameter was predicted 
using ChemDraw 19.0.1.28 (http://www.chemaxon.com). The sign ($) indicates that the synthesis and biological 
















Values reported as Mean ± SEM of n = 3.  
 
Compound R1 R2 R3 R4 
IC50 (µM) PAO1-L 
CTX::PpqsA-lux 
cLogP* 
$2.61 Cl H H H NA 1.9 
$2.62 H Cl Cl H NA 2.6  
$2.63 H H Cl H 6.7 ± 0.3 1.9  
$2.64 H H H Cl NA 1.9  
$2.65 H Cl H Cl NA 2.6  
$2.66 H NO2 H H 0.5 ± 0.1 1.0  
$2.67 H H NO2 H NA 1.0  
$2.68 H CF3 H H 0.6 ± 0.1 2.2  
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This analysis demonstrated that the introduction of a chlorine atom at the C5-R1 or C8-R4 
position (compounds 2.61 and 2.64, respectively) led to a loss of potency as well as the di-
substituted compounds 2.62 and 2.65. In addition, the C7-R3 chlorine analogue 2.63 had a 2-
fold loss of activity indicating that the substitution at the C6-R2 is the optimal position. It is 
noteworthy, that the 7-nitro substituted derivative 2.67, as opposed to 2.63, was completely 
inactive which is likely due to the size of the nitro group compared to the chlorine atom. 
Furthermore, R2 was substituted with a stronger EWG functional group such as CF3 (2.68) or 
NO2 (2.66), with Hammett constant 0.54 and 0.78, respectively in comparison to 0.23 for Cl 
substitution.163 The inhibitory potency of 2.68 and 2.66 was enhanced 6- or 7.5- fold, 
respectively, compared to 1.6, which confirmed the importance of the electron-withdrawing 
effect on that position.  
This finding suggests that the EWG creates localised electron-deficient sites, thereby forming 
a stronger interaction with electron-rich aromatic side chains of amino acids present in the 
recognition site of the receptor. However, the lack of an electron-donating groups (EDGs) 
substituent at the C6-R2 position in this study limited the ability to make a proper comparison 
or draw this conclusion. Another possible interpretation is that these moieties (Cl, NO2 and 
CF3) form H-bonds with the receptor, which is consistent with previously reported findings.
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Cl in position C6-R2 was maintained for all the future SAR analyses. The nitro group, in general, 
has been extensively associated with mutagenicity and genotoxicity issues,164 while the 




2.6.2 Amino propan-2-ol linker investigation 
Here, the SAR investigation efforts focused on determining the type of interactions formed by 
the linker by varying the substituents at the R position while the head and tail moieties were 
fixed corresponding to those of 1.6. The optimal length of the linker was also investigated, as 
shown:  
Table 2-2: SAR study of amino propan-2-ol linker. The inhibition of PqsR activity was initially measured in 
the PAO1-L CTX::PpqsA-lux strain of P. aeruginosa at 10 µM. NA, not active at 10 µM. All compounds resulting 
in a greater than 50% inhibition of activity were further analysed by concentration-response curves measured in 
PAO1-L CTX::PpqsA-lux. The asterisk (∗) indicates that this parameter was predicted using ChemDraw 19.0.1.28 
(http://www.chemaxon.com). Compounds 2.70 and 2.72 were not synthesised. The sign ($) indicates that the 
synthesis and biological evaluation was carried out by Fadi Soukarieh. The sign (£) indicates that the biological 














£1.6 OH O 1 3.2 ± 1.0  1.9  
£2.40 NH2 O 1 2.4 ± 0.2  2.0  
2.59 H O 1 NA 3.1  
2.60 CH3 O 1 NA 3.5  
$2.69 F O 1 NA 3.3  
£2.38 =O O 1 4.3 ± 1.3  2.3 
2.56 OH NH 1 NA 1.6  
2.70 NH2 NH 1 - 1.7 
$2.71 OH O 2 NA 2.3  
2.47 NH(CO)CH3 O 1 NA 2.0  
2.48 NH(CO)CH2N(CH3)2 O 1 NA 2.2  
2.50 NHCH2CH3 O 1 NA 2.9  
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2.72 NHCH2CH2N(CH3)2 O 1 - 2.9 
 
Values reported as Mean ± SEM of n = 3. 
 
All the lipophilic substituents (2.59, 2.60 and 2.69) lead to the loss of activity, while replacing 
the hydroxyl with the isosteric H-donor or/and acceptor group 2.40 slightly enhanced the 
inhibitory potency. Interestingly, oxidising the hydroxyl to the ketone 2.38 maintained similar 
activity to the original hit (IC50 = 4.3 ± 1.3 µM), which was likely due to the lone pairs of the 
carbonyl oxygen still acting as a H-bond acceptor. Additionally, the optimal linker length was 
investigated by introducing an additional carbon in 2.71, which led to the loss of activity. Taken 
together, these results confirmed that there is a H-bond interaction between the molecule at the 
R position and the binding domain, and the position of this substituent is critical for biological 
activity. The co-crystal structure of 1.13 and 2.34 with PqsR provided further evidence 
consistent with this finding. 
The design of a di-basic compound was applied here in order to find a compound with ionizable 
basic functional groups in neutral pH 7.4 which could lead to an increase in the retention time 
of the compound in the lung.  
 
Figure 2-13: analogues that contain acidic (in red) or basic (in blue) functional groups.  The parameters (pKa and 
LogD7) were predicted using ChemDraw 19.0.1.28 (http://www.chemaxon.com). 
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The strategy applied here is by replacing the hydroxyl in 1.6 with the amine in 2.40, this would 
convert the weak acid functional group in 1.6 to a base in 2.40 with pKa 8.4. this base can be 
ionized in neutral pH 7.4. Furthermore, the alkylation of the amino functional group in 2.50 
slightly enhanced the basicity. Similarly, replacing the O atom at the X position with nitrogen, 
then substituting the R position with amino group to produce 2.70 will enhance the basicity as 
well as provide other weak basic functional group in the molecule. In addition, link the amino 
group in compound 2.40 with acyl or alkyl chain containing a dimethyl amino group at the end 
of the side chain (2.48 or 2.72 respectively) will provide the desired basic functional group 
with other weak acidic, 2.48 or basic, 2.72 functional group in the molecule as shown in Figure 
2-13. 
The synthesis of 2.48 and 2.72 proved very challenging, and many attempts were made to 
synthesise these molecules. First, replacing the oxygen atom with nitrogen at the X position 
lead to inactive compound 2.56; therefore, no further chemical reaction was carried out for this 
molecule to convert the hydroxyl to an amino functional group (compound 2.70). Second, a 
simple alkyl chain (ethyl) was linked to the amine at the R position to test the activity of the 
compound before coupling with an alkyl chain containing a dimethyl amino group at the end 
of the side chain. Unfortunately, the biological activity was lost in the resulting compound 2.50, 
and compounds containing an amide linker 2.47 and 2.48, also proved inactive. These results 
are in agreement with the previous conclusion: H-bonding at the R position is critical for the 
inhibitory potency of the molecule. Regardless of the effect of the different linkers, this strategy 





2.6.3 Analysing the substituents on the 2-(4-hydroxyphenyl) acetonitrile ring 
As the manipulation of the substitution on the quinazolin-4(3H)-one core as well as in the linker 
group did not show any improvement in potency, a series of modifications were introduced to 
the aromatic phenyl ring in 1.6 to explore the SAR of this region (Table 2-3). 
 
Table 2-3: SAR study of 2-(4-hydroxyphenyl) acetonitrile ring of 1.6. The inhibition of PqsR activity was 
initially measured in the PAO1-L CTX::PpqsA-lux strain of P. aeruginosa at 10 µM. NA, not active at 10 µM. All 
compounds showing a 50% or greater inhibition of activity were further analysed by concentration-response 
curves in PAO1-L CTX::PpqsA-lux. The asterisk (∗) indicates that this parameter was predicted using ChemDraw 
19.0.1.28 (http://www.chemaxon.com). The sign ($) indicates that the synthesis and biological evaluation was 
carried out by Fadi Soukarieh. The sign (£) indicates that the biological evaluation was carried out by Fadi 
Soukarieh.  
 






$2.73 H H CN NA 2.3  
$2.74 H CN H NA 2.3  
$2.75 H CH2CN H NA 2.1  
$2.76 H H CH2CH2CN 2.9 ± 1.2 a 2.4  
£2.34 H H OCH2CN 4.5 ± 0.7 a 1.8  
£2.35 F H CH2CN 2.2 ± 0.2 a 2.3  
£2.36 H F CH2CN 6.4 ± 0.7 a 2.3  
$2.77 H H CH2(CO)OH NA 2.0  
2.51 H H CH2(CO)NH2 NA 1.1  
$2.78 H H (CO)CH2CH3 NA 2.8  
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$2.79 H H 
 
1.9 ± 0.0 a 
2.1  




2.54 H H 
 
NA 2.1  
2.37 H H      O(C6H5) NA 4.3  
 
Values reported as Mean ± SEM of n = 3a. 
 
The SAR exploration of 2-(4-hydroxyphenyl) acetonitrile was initiated by finding the optimal 
length and position of the nitrile functional group. The aromatic nitriles in 2.73 and 2.74 with 
para- and meta- benzonitrile respectively, exhibited loss of activity. In addition, the analogue 
with meta- acetonitrile substitution 2.75 lost biological activity which proved the importance 
of the acetonitrile group at para- position. Extending the chain length by an extra methylene 
group or introduction of an ether bond between the phenyl and acetonitrile group in 2.76 or 
2.34, respectively maintained the activity. A further attempt to enhance the potency was 
rationalised by the crystal structure of 1.13 with PqsR (2.5.2) and achieved by introducing a 
fluorine atom at the ortho- (2.35) or meta- position (2.36) in order to gain a hydrogen bond 
interaction with the Tyr258 side chain. Unfortunately, 2.35 did not gain further potency, while 
the activity of 2.36 was reduced 2-fold.  
Another approach focused on finding an appropriate bioisostere for the nitrile moiety that could 
maintain the activity and prevent the possibility of cyanide ions release during metabolism in 
biological systems.165 The unique structural characteristic of the nitrile group with linear shape 
enables the moiety to fit readily into binding site sub-pockets of the receptor.166 In addition, as 
a hydrogen bond acceptor, the lone pair of electrons on the nitrogen atom can form hydrogen 
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bond (HB) interactions with various protein residues.166 Thus, this moiety has traditionally 
been considered as a bioisostere of carbonyl, hydroxyl and carboxyl groups.166 In this study, 
the nitrile moiety was modified to a carboxylic acid 2.77, an amide 2.51 and a ketone 2.78, and 
all modifications led to the complete loss of inhibitory potency. These results indicate that the 
geometry and rigidity of the acetonitrile moiety, the length, and the lone pairs of the nitrogen 
are critical for activity.  
Subsequently, different heterocycles were substituted on the para- position to replace the 
acetonitrile moiety and to enhance the physicochemical properties of the compound. The 1,2,4-
oxadiazole ring in 2.79 was the best replacement for the acetonitrile moiety, with similar 
activity to the original hit 1.6, while the 1,2,4-triazole 2.53 and tetrazole 2.54 analogues showed 
a loss in the activity. In addition, extending the para-position of the phenyl ring with a bulky 
phenoxy group 2.37 led to a loss of the activity and therefore the acetonitrile moiety at the 





2.6.4 The analysis of 1.6 enantiomer activity. 
 
Figure 2-14: Biological evaluation of 1.6 (racemic), 1.13 (R) and 1.14 (S).The inhibition of PqsR activity was 
initially measured in the PAO1-L CTX::PpqsA-lux strain of P. aeruginosa at 10 µM. 1.6 and 1.13 showed greater 
than 50% inhibition of activity and therefore further analysis by concentration-response curves measured in the 
PAO1-L CTX::PpqsA-lux strain.  
Although the two enantiomers of any chiral drug are identical in their NMR, IR and physical 
properties, 50% of chiral marketed drugs are a single enantiomer. This is because living 
systems are also chiral, and the two enantiomers of a chiral drug can behave very differently in 
vivo.167 For example, one enantiomer may be responsible for the therapeutic effects of the drug 
whereas the other is inactive and/or contributes to side effects.167 Owing to the FDA regulations 
for the development of new stereoisomeric drugs, it is critical at this stage of the project to 
determine the activity of both enantiomers.168  As discussed before (Section 1.8), Soukarieh 
analysed the activity of the enantiomers of 1.6. The analysis demonstrated that, the R isomer, 
1.13 is the more active enantiomer, with slightly better potency (1.13, IC50 = 1.1 ± 0.4 µM), 





2.7 Conclusion and future work 
 
 
Figure 2-15: Pharmacophore of quinazolin-4(3H)-one series.  
The SAR analysis of the original hit 1.6 showed that the hydroxyl functional group in the linker 
interacts with the binding site as a hydrogen bond donor or acceptor which is critical for 
biological activity. The co-crystal structure of 1.13 with PqsR (Figure 2-12) demonstrates the 
pharmacophore that is essential for PqsR antagonistic potency (Figure 2-15). The chlorine 
atom, which has an electron-withdrawing effect on QZN is essential for activity. In addition, 
other EWGs such as nitro or trifluoromethyl enhanced the inhibitory potency 6- or 7.5- fold, 
respectively. Thus, the chlorine atom or QZN may act as a hydrogen bond acceptor for the 
protein residue in the receptor. On the other hand, the role of the acetonitrile group in binding 
to the receptor is not clearly defined. The lipophilic interaction provided by this moiety, as well 
as the hydrogen bonding with the lone pair of N, could be why this moiety is critical for the 
activity. In addition, the acetonitrile moiety is sp hybridised and it could act as an electron-
deficient pi system in π-π interaction with electron-rich aromatic ring (Tyr258) presents in the 
receptor.169 This interaction was not provided by the bioisosteres of the nitrile functional group 
(carbonyl, hydroxyl and carboxyl groups), however the 1,2,4-oxazole ring was able to maintain 
this type of interaction.  
Previous work indicated that any simple modification of the quinazolin-4(3H)-one series led 
to the loss, decrease or maintenance of biological activity similar to that of the original hit 1.6. 
For this reason, a limited SAR for this series was carried out. The only modifications that 
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maintained similar or better activity were: 1) replacing the chlorine atom with a stronger EWG, 
enhancing the inhibitory potency by 6-fold and 7.5-fold in 2.73 and 2.75, respectively; 2) 
introducing a hydrogen bond donor or acceptor at the hydroxyl position, which was critical for 
activity and; 3) introducing a 1,2,4-oxazole ring in 2.87, which was the only analogue that 
maintained activity similar to that of the nitrile moiety. Finally, the triazole analogue 2.53 and 
the tetrazole analogue 2.54 lost activity, which could have been due, in part to cell permeability 
issues.170 The focus of this project was to investigate scaffolds that probe the receptor to 
examine the molecular basis of PqsR receptor–ligand binding and inhibitor interactions. A 
deeper understanding of these interactions will support target-based antivirulence drug 




3 Hit to lead Optimisation of Novel 1H-benzo[d]imidazole based 
PqsR Inhibitors as Adjuvant Therapy to Treat Pseudomonas 
aeruginosa Infections 
3.1 Background and aim of the project 
In the previous chapter, a SAR study based on the quinazolin-4(3H)-one (QZN) scaffold as 
PqsR antagonists in P. aeruginosa was established. This study identified that introduction of 
an electron-withdrawing group to the 6- position of the quinazolin-4(3H)-one ring as well as 
the hydrogen bonding of the hydroxyl moiety within the linker group are is critical for 
inhibitory activity as well as hydrogen bonding with the linker. The SAR analysis of 1.6 as a 
hit was limited, as any small modification in the molecular structure led to a loss of activity. 
Therefore, another study was established to replace the quinazolin-4(3H)-one core with 
different heterocyclic ring systems (Table 3-1). An inspiration from the literature (compound 
1.3), replacing the quinazolin-4(3H)-one ring with the 1-methyl-1H-benzo[d]imidazol-2-amine 
ring 3.1 enhanced activity 15- fold in comparison to 1.6. While replacing the quinazolin-4(3H)-
one ring with benzo[d]oxazol-2-amine 3.2 and benzo[d]thiazol-2-amine 3.3 led to a loss of the 
inhibitory activity. This confirms that the benzimidazole chemotype may be interacting with 
the receptor in a unique fashion relative to other heterocycles. In fact, this is the only ring that 
has a methyl substitution (3.1, R1 = Me) which provides a key lipophilic interaction in the 
ligand binding site as eventually shown by X-ray crystallography. However, replacing the 
amine functional group in the linker with thiol moiety 3.4 lead to loss the activity. Compound 
3.1 was an ideal hit with lead-like properties to start a SAR study. However, the synthesis of 
the 1-alkyl-1H-benzo[d]imidazol-2-amine ring proved challenging, especially with bulky 
substitutions, and therefore this chapter aims to find an appropriate synthetic route that provides 
a range of 3.1 analogues with reasonable yield and high purity.  
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Table 3-1: The initial SAR study conducted by Soukarieh and it aimed to investigate different heterocycles 
replacing the QZN core in 1.6. The inhibition of PqsR activity was measured initially in the PAO1-L CTX::PpqsA-
lux strain of P. aeruginosa at 10 µM concentration. Compounds showing inhibition of activity by 50% or more 
were further analysed by concentration-response curve measured in PAO1-L CTX::PpqsA-lux and PA14 
CTX::PpqsA-lux strains. NA, not active at 10 µM concentration. NT, not tested in PA14 CTX::PpqsA-lux strains. The 
asterisk (∗) indicates that this parameter was predicted using ChemDraw 19.0.1.28 (http://www.chemaxon.com). 

















$3.1 N NH CH3 0.21 ± 0.04 a 0.20 ± 0.00 a 3.2 
$3.2 O NH - NA NT 3.0 
$3.3 S NH - NA NT 3.7 
$3.4 N S CH3 NA NT 3.5 
Values reported as Mean ± SEM of n = 6 a 
The most potent and efficacious PqsR inhibitor reported to date is 1.3, as identified by Rahme 
and colleagues (Figure 3-1).103 In fact, the discovery of this compound was through the use of 
phenotypic high-throughput screening (HTS) of a library with over 280,000 compounds, 
followed by SAR analysis and biological evaluation of HAQ and pyocyanin production in the 
presence of 10 and 1 µM of the compounds. Indeed, the result from HTS showed that from the 
17 successful compounds, eight shared a benzamide- benzimidazole scaffold which indicates 




Figure 3-1: Summery of SAR study conducted by by Rahme and colleagues.103 It started with 3.5 by adding 
an electron withdrawing group to give 3.6, the potency of HHQ and PQS inhibition was increased. Benzamide-
benzimidazole derivatives containing a phenoxy substituted benzamide ring (1.3) was the best candidate in that 
series. 103 The study did not report IC50 values to make clear comparison however, the IC50 of 1.3 was determined 
in our lab by Ruiling Liu and the results reported.99 
 
Consistent with previous findings, the key features for antagonistic activity, identified from 
this study, are a strong electron-withdrawing group (nitro) in the 6- position of the 
benzimidazole ring, and a hydrophobic extension in the 4- position of the benzamide with the 
phenoxy group as an ideal substitution. The thioether linker was preserved in all analogues 
without further investigation.103 
3.2 Rationale of the design 
The benzimidazole moiety is an important heterocycle which has a wide spectrum of 
physiological and pharmacological properties. It is the basic part of the vitamin B12 structure 
as well as being considered a structural isostere of naturally occurring nucleotides.171 In 
addition, this nucleus is present in several FDA-approved agents and serves as a central core 
in marketed proton pump inhibitors, anthelmintics, anticancer agents, and vasodilators.171 
According to PqsR inhibition, 1.3 with the benzamide-benzimidazole scaffold was the first 
compound that showed in vivo efficacy against acute and chronic infections in mice with 
nanomolar range activity against the PAO1-L strain.103 This study provides new insight into 
the interaction between PqsR and the benzimidazole scaffold at the molecular level.112  
Furthermore, the initial SAR exploration discussed above demonstrated that replacing the 
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quinazolin-4(3H)-one ring with benzo[d]oxazol-2-amine 3.1 or benzo[d]thiazol-2-amine 3.2 
led to a loss of the activity, while the 1-methyl-1H-benzo[d]imidazol-2-amine ring 3.1 
enhanced activity 15-fold in comparison to 1.6. This evidence supports the selection of 3.1 as 
an ideal hit to establish a SAR study aiming to enhance the potency and the physiochemical 
properties of the hit compound.  
 
Figure 3-2: The chemical structure of hit compound 3.1 and the design of the SAR study. The aim of this 
study is to explore groups R1 to R6.  
The design strategy focused on three aspects: i) exploration of receptor-ligand interactions to 
build SAR; ii) exploration of the steric and lipophilic requirement for the key R3 substituent; 
and iii) introduction of polar solubilising functional groups to enhance the drug-like properties 
of the series.  
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3.3 Results and discussion  
3.3.1 Synthesis overview 
Although the benzimidazole ring system is a privileged substructure among bioactive 
compounds,124 the synthesis of 2-aminobenzimidazole is still challenging. Different synthetic 
strategies have been accordingly optimised in this study to obtain products with varied 
substitutions, with high yield and high purity. 
  
Figure 3-3: The synthetic routes employed in this project to synthesise the 2-aminobenzimidazole scaffold. 
Three different synthetic routes were carried out in this chapter to furnish 3.1 or 3.20 employing 
different functional groups: 1-aminopropan-2-ol in 3.10, epoxide in 2.29, and isothiocyanate 




Preparation of benzene-1,2-diamine starting material.  
(Scheme 3-1): preparation of 4-chloro-N1-methylbenzene-1,2-diamine 3.9. 
 
Reagent and condition: a) methylamine, MeOH, reflux, 16 h, 93%. b) Zn, NH4Cl, 10% CH3COOH; MeOH, rt, 
1h, 90-95%. 
Practically, most syntheses of benzimidazoles start with benzene derivatives possessing 
nitrogen-containing functions ortho- to each other 3.9. 1-Fluoro-2-nitrobenzene is the 
immediate precursor to furnish 3.8 as an intermediate. The preparation of this scaffold was 
initiated by substituting the fluorine atom in 3.7 with methylamine in order to furnish 3.8.172 
The type of reaction shown here is the addition–elimination mechanism. The amine adds to the 
carbon atom attached to the fluorine atom and the negative charge is delocalised through the 
aromatic ring and stabilised by the nitro group presented on the ortho- position to the fluorine 
atom. Following this, the negative charge will move again toward the tetrahedral carbon 
intermediate and push the electrons to the fluorine atom as a leaving group. The presence of an 
electron-withdrawing group in ortho- or para- position to the leaving group is critical for this 
type of reaction. 
Subsequently, the nitro group was reduced to the alanine using a metal reducing reaction with 
Zn as an electron transfer reagent and proton source (AcOH, NH4Cl) in order to furnish the 
benzene-1,2-diamine moiety 3.9. The selection of these conditions over the more common 
method of nitro reduction (catalytic hydrogenation) was for a chemo-selectivity issue, as 
catalytic hydrogenation could remove the chlorine atom present in the scaffold in addition to 
reducing the nitro functional group.173 
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3.3.2 The first synthetic route employing amino functional group in 3.10 
(Scheme 3-2): preparation of 3.1 and 3.19, 3.20. (This scheme was conducted by Fadi 
Soukarieh).  
 
Reagent and condition: a) NH3/MeOH, rt, 16 h, 80%. b) CDI, DCM, 50°C, 3h. c) POCl3, neat, 90°C, 16h. d) 
MW, Et3N, EtOH, 180°C, 3h. 10-25%.  
The first approach to prepare 3.1 was by coupling two intermediates: 2,6-dichloro-1-alkyl-1H-
benzo[d]imidazole 3.16 and 1-amino-3-propan-2-ol 3.10. 
Preparation of 1H-benzo[d]imidazole series (3.1 and 3.19, 3.20). 2,6-Dichloro-1-methyl-1H-
benzo[d]imidazole 3.16 was reacted with 2-(4-(3-amino-2-hydroxypropoxy) phenyl) 
acetonitrile 3.10 to furnish the final product under microwave irradiation, as shown in Scheme 
3.2 to give 2-(4-(3-((6-chloro-1-methyl-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile, 3.1. In addition, the same strategy was applied to 
synthesise 3.19 and 3.20 analogues. However, this strategy was not efficient enough to 
synthesise a library of analogues for the SAR study, as the yield was poor (10-25% purified 







(Scheme 3-3): preparation of 3.1 employing 3.10 & 3.21, 3.22 and 3.24.  
 
Reagents and conditions: (a) CS2, Et3N, EtOH, rt, 16 h, 83%. (b) CH3I, NaOH, MeOH, (C2H5)2O, rt, 16 h, 56%. 
(c) oxone, MeOH, H2O, rt, 16 h, 42%. (d) Et3N, HgCl2, DCM 0º C, 30 min then rt for 16h. (e) MW, Et3N, MeCN, 
150°C, 4h.  
Preparation of thiourea 3.21, methyl thiol 3.22 & sulfonyl methane 3.24. By maintaining the 
1-aminopropan-2-ol moiety in 3.10 as a nucleophile, an alternative approach was adopted by 
changing the chlorine leaving group in 3.16 to a more stable conjugate base, such as the 
sulfonyl-methane moiety 3.24, which can stabilise the resulting negative charge by 
delocalisation over the two oxygen atoms.  
The synthesis started with substituted benzene-1,2-diamine moiety 3.9 reaction with carbon 
disulphide to furnish the thiourea 3.21. Compound 3.21 was then alkylated by methyl iodide in 
basic conditions to afford 3.22. It is noteworthy that the electrophilic carbon of methyl iodide 
is considered a soft electrophile because its orbitals are diffuse, and it is uncharged giving the 
chemo-selectivity toward thiol alkylation over the nitrogen. This is because, thiol is considered 
a soft nucleophile as it is a large atom with diffuse high-energy electrons. However, the 
nitrogen is considered a hard nucleophile and its reaction is dominated by charges and 
electrostatic effects. The interaction here is dominated by the polarisable orbital interaction 




Figure 3-4: The mechanism of sulfide oxidation. Sulfide in 3.22 was oxidized to sulfoxide 3.23 and subsequently 
to sulfone 3.24. 
 
The following step was to oxidise the sulphur atom with Oxone to furnish the sulfonyl-methane 
moiety 3.23. Oxone is a stable mixture of potassium peroxymonosulfate, potassium hydrogen 
sulfate, and potassium sulfate (KHSO5 . ½ KHSO4 . ½ K2SO4) which is considered an 
alternative to hydrogen peroxide with high selectivity to sulfides in the presence of other 
functional groups.174 It is the salt of peroxy-acid which has an extra oxygen atom between the 
carbonyl group and its acidic hydrogen; therefore, it is less acidic than carboxylic acids because 
its conjugate base is no longer stabilised by delocalisation into the carbonyl group. However, 
it is electrophilic at the extra oxygen, because the nucleophilic attack at the electrophilic oxygen 
generates carboxylate sulfonate, which is a good leaving group. The first step 
of sulfide oxidation to sulfoxide 3.23 is the sulfur atom attacking the terminal oxygen of the 
peroxide group followed by the breakage of the peroxide bond, resulting in the formation of an 
alkoxy anion and a protonated sulfoxide. Proton exchange yields the sulfoxide and the alcohol 
corresponding to the peroxide. This is faster and the rate-determining step of the reaction. 
Following that, the oxidation of sulfoxide to sulfone in neutral condition follows the same 
mechanism described in the first step, as described in Figure 3-4.175 
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Preparation of 1H-benzo[d]imidazole 3.1. The coupling of the amine functional group was 
investigated with the three moieties (thione, methyl thiol and sulfonyl-methane) in 3.21, 3.22 
and 3.24, respectively. According to the literature, a similar substrate was employed with a 
thiourea moiety to displace the thione with a primary amine using a basic condition in the 
presence of mercury (II) chloride, resulting in different asymmetrical N,N-disubstituted 
guanidine with a good yield. 176 The same condition was applied here to displace the thione 
moiety in 3.21 with the primary amine of 3.10. Unfortunately, the reaction did not work, and 
no product was obtained. Moving to displace the methyl thiol 3.22 or sulfonyl-methane 3.24 
with the primary amine in basic conditions, refluxing the two building blocks or using 
microwave irradiation did not enhance the efficiency of the coupling reaction.  
3.3.3 The second synthetic route employing epoxide moiety in 2.29  
(Scheme 3-4): synthesis of 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-amine. 
 
Reagents and conditions: (a) BrCN, MeOH, H2O, 60°C, 3 h, 85% (b) MW, EtOH, 150°C, 30 min. 
Preparation of 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-amine 3.25. The strategy of 
synthesis was modified further by preparing the 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-
amine 3.25 employing 1,2 diamino benzene 3.12 with cyanogen bromide.177  
The synthesis proved a straightforward process carried out in a protic solvent to stabilise the 
generated bromide ion and generate the 1H-benzo[d]imidazol-2-amine scaffold in good yield. 
Following this, 3.25 was refluxed with the epoxide moiety in basic condition using Et3N as a 
base and EtOH as a solvent. Following the reaction using LC-MS showed the formation of 
peak with desired MW (399.1) with a different retention time tR (2.18) while the retention time 
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tR of 3.20 is 2.23. In addition, the retention factor Rf of the TLC showed that the product was 
more polar than the previously prepared 3.20.  
 
Figure 3-5: Proposed mechanism of the guanidine moiety synthesis in 3.26. 
This result indicates that the other regioisomer with a guanidine moiety, 2-(4-(3-(5-chloro-2-
imino-3-isopropyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-2-hydroxypropoxy) phenyl) 
acetonitrile 3.26 was synthesised. The proposed mechanism of this reaction is illustrated in 
Figure 3-5. In addition, this reaction was carried out in neutral and acidic conditions to 
investigate the effect of these conditions on the regioisomer selectivity. Unfortunately, all the 
conditions produced the undesired product 3.26 according to TLC and LC-MS analysis in 
comparison to 3.20.  
The first evidence to support this hypothesis was analysing the biological activity of 3.26 in 
comparison to DMSO as a negative control and 3.20 as a positive control at 10 µM 
concentration (Figure 3-6). This analysis showed that the product of the reaction mentioned 
























































Figure 3-6: measuring the remaining activity of 3.26 and 3.20 as a positive control at 10μM concentration in cell-
based reporter gene assay employing PAO1-L CTX::PpqsA-lux strain.  
 
Furthermore, the comparison between 13C NMR spectra of the previously synthesised 
compound, 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile, 3.20 and the product of this reaction, 3.26 showed that 
the peaks of some carbons in the aromatic regions appear in different positions as shown in 





Figure 3-7: The 13C NMR spectra of 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile, 3.20 (above) and 2-(4-(3-(5-chloro-2-imino-3-isopropyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-2-hydroxypropoxy) phenyl) acetonitrile 3.26 (below) with enlarged section of the 
aromatic region, in DMSO-d6 solvent at 100.66 MHz.    
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3.3.4 The third synthetic route employing isothiocyanate moiety.  
Finally, the focus was directed to a more promising pathway employing isothiocyanate moiety 
3.27 which was reacted with 1,2-diaminobenzene 3.9 followed by cyclisation to the 
benzimidazole ring.  
(Scheme 3-5): the initial synthetic design employing isothiocynate 3.27.  
 
Reagent and conditions: (a) thio-CDI, DCM, inert atmosphere, rt, 16 h, 55%. (b) 3.27, EtOH, 70 ºC, 16 h. 
Preparation of isothiocynate 3.27. The preparation of isothiocyanate moiety was successful by 
reacting the amino functional group in 3.10 with thio-CDI to produce the required compound 
3.27.178 Subsequently, the generated intermediate 3.27 refluxed with benzene-1,2-diamine 3.9 
in ethanol. However, no product was detected from this coupling. The critical issue in this step 
was the presence of hydroxyl as a nucleophile and the carbon of isothiocyanate as an 
electrophile, which could lead to the internal cyclisation of the compound and as a result the 
coupling did not take place in the next step.  
Protection of hydroxyl functional group. Therefore, the alcohol was protected by employing 
Corey’s condition.179 It was reported that the use of tert-butyl dimethyl silyl chloride (TBDMS-
Cl) reacting with alcohol was not successful, even with elevated temperature or using excess 
reagent (TBDMS-Cl). However, using 2.5 equivalent of imidazole resulted in enhancement of 
the efficiency of the reaction with various alcohols to produce a range of silyl ethers.179  
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(Scheme 3-6): Protection of hydroxyl functional group in 3.10. 
 
Reagent and conditions: a) TBDMS-Cl, imidazole, DMF, rt, 16 h. 
  
The LC-MS detection of the product showed that the MW of the compound is 349 instead of 
the expected MW 321, which means a side reaction could have occurred. The Rf of the TLC 
and tR in the LC-MS hints that the product is more lipophilic than expected. In addition, the 
1H 
NMR of the product showed that there is an extra peak of around 8 ppm in the aromatic region; 
the expectation of this finding is that the hydroxyl group was protected with tert-butyl dimethyl 
silane, as well as the amino group interacting with the solvent 3.29. The proposed mechanism 
of this reaction is illustrated in Figure 3-8. It is worth mentioning that changing the solvent to 
DCM or MeCN diminished the efficiency of the reaction and no product was detected, which 
is in agreement with recent work reported by Patschinsk et al.180 This work demonstrated the 
catalytic activity of DMF over other polar solvents such as DCM and chloroform, even in the 
presence of highly active catalysts.   
 
Figure 3-8: The proposed mechanism of the side reaction with DMF. 
Therefore, it was important to open the epoxide moiety in 2.29 with a reagent that cannot 
undergo further reaction.  Sodium azide, which is a very well-known amine synthon, is a 
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reagent of choice and it could act as temporary protecting group in a subsequent alcohol 
protection reaction. Afterwards, the azide is reduced to the amine, employing the Staudinger 
reaction, which then was reacted with thio-CDI to afford the isothiocyanate moiety as proved 
by 
13
C-NMR (see the appendix).  
3.3.5 The design of the final synthetic route of 2-aminobenzimidazole series 
To sum up, all the findings from the previous approaches led to the design of the synthetic 
route illustrated in this section.  
Preparation of isothiocynate intermediate. The successful synthetic scheme started by opening 
the epoxide ring with NaN3 in a protic solvent in the presence of NH4Cl.
181 Following that, the 
hydroxyl functional group was protected with tert-butyl dimethyl silane.179 The azide moiety 
was then reduced to the corresponding amine using the Staudinger reaction which produced a 
cleaner reaction mixture than catalytic hydrogenation. The generated amine was reacted with 
thio-CDI to afford the desired isothiocyanate moiety (Scheme 3-7). 
(Scheme 3-7): synthesis of isothiocynate intermediate 3.36 - 3.38.  
 
Reagent and conditions: a) NaN3, NH4Cl, EtOH 40°C, 16 h, 99%. b) TBDMS-Cl, imidazole, DMF, rt, 16 h, 
84%. c) PPh3, 10% H2O; THF, rt, 16h, 90%. d) thio-CDI, DCM, inert atmosphere, rt, 16 h, 25%. 
Preparation of benzene-1,2-diamine 3.9 analogues. The synthesis of all benzene-1,2-diamine 
intermediates 3.12 and 3.58-3.71 followed the same procedure, for compound 3.9 (Scheme 
3-8). The synthetic pathway was initiated by substituting the fluorine atom in 1-fluoro-2-
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nitrobenzene with different amines, followed by reducing the nitro functional group to the 
corresponding amine.  
(Scheme 3-8): synthesis of benzene-1,2-diamine intermediates, 3.9, 3.12 and 3.56-3.69.  
 
Reagent and conditions: a) Different amines, MeOH, reflux, 16 h, 95%. b) Zn, NH4Cl, 10% CH3COOH in 
MeOH, rt, 1h, 95%.  
The cyclisation of thiourea moiety. Later on, the isothiocynate moiety was reacted with various 
substituted 1,2-diaminobenzenes.178 Depending on the literature, different conditions were 
examined to find out the best method to activate the sulfur and cyclise the thiourea moiety in 




Table 3-2: The most common methods for thiourea cyclisation. They were reviewed from 




















Entry 1 was selected as the best condition to provide ring closure of thioureas by sulfur 
activation with DIC with a good yield observed from LC-MS analysis.  
  
 
 Coupling reagent Temperature 
°C 
Solvent 
1 N,N′-Di-iso propyl carbodiimide (DIC) 80 DMF  
2 1,1′-Carbonyldiimidazole (CDI) 80 DMF  
3 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDCI) 
70 THF  
4 182 EDCI rt THF  
5 182 CH3I rt EtOH  
6 183 HgO, S 70 EtOH  
7 184 Benzotriazol-1-yl oxy tris (di-methyl 
amino) phosphonium hexafluorophosphate 
(BOP), 1,8-diazabicyclo [5.4.0] undec-7-
ene (DBU) 
rt CH3CN  
8 Acetic acid 90 EtOH 
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The deprotection of the silyl group. Finally, the deprotection of the silyl group was examined 
under two different conditions: TBAF in anhydrous THF under inert atmosphere, or 10% TFA 
in MeOH at room temperature. The first condition seems to be rather harsh, as the LC-MS 
detection of the reaction mixture did not show either the starting material or the desired product. 
The second condition was successful to show the desired product with a good yield, although 
the reaction was carried out over a long time (48h).  
(Scheme 3-9 illustrates the final synthetic route to synthesise the 2-aminobenzimidazole 
scaffold with different substitutions on the benzimidazole or the phenyl ring. 
(Scheme 3-9): General Synthesis of 2-aminobenzimidazole analogues, 3.20, 3.86 – 3.101.  
 
Reagent and conditions: a) EtOH, reflux, 16 h. b) DIC, Et3N, DMF, reflux, 16 h, 65%. c) 10 % TFA in MeOH, 
rt, 48h 60%. d) 3.20, 10% Pd on activated carbon (20% w/w), H2, MeOH, rt, 16 h, 95% 
 
Synthesis of 3.101 analogue. Employing 3.20 under catalytic hydrogenation with 10% Pd led 
to substituting the chlorine in R1 with hydrogen and produce 3.101 analogue. 
Synthesis of 3.103 analogue. The synthesis of 3.103 was challenging and there were many 
attempts carried out to synthesise this analogue, summarised in the following (Scheme 3-10). 
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(Scheme 3-10): different synthetic routes to synthesis 3.103. 
 
Reagent and conditions: a) EtOH, reflux, 16 h. b) DIC, Et3N, DMF, reflux, 16 h, 65%. c) 10 % TFA in MeOH, 
rt, 48h 60%. 
The initial attempt to synthesise 3.103 failed with 3.69 as a starting material, which has an 
unprotected hydroxyl group that could interfere with the coupling process, and therefore this 
alcohol should be protected. 
3.94 was prepared successfully according to the general procedure illustrated in (Scheme 3-8). 
However, the deprotection of the benzyl group was challenging and a series of hydrogenolytic 







Table 3-3: Different conditions were applied to remove the benzyl group. The progress of the reactions was 
monitored by TLC and LC-MS analysis. 
 
 Catalyst a or Scavenger b H2 source Solvent Temperature °C product 
1 Pd a Balloon of 
H2 
MeOH rt 3.104 
2 - 4 M HCl dioxan rt 3.105 
3 Triisopropyl silane b solvent  TFA 60 3.105 
4 Triisopropyl silane b 
 
solvent 50% TFA/MeOH rt, until reflux 3.94 
5 Zn a HCO2NH4 MeOH rt 3.94 
6 Pd a HCO2NH4 MeOH rt 3.105 
 
The initial attempt at using a catalytic amount of 10% Pd on activated carbon (20% w/w) in 
MeOH under hydrogen led to substitution of the chlorine on the aryl halide with a hydrogen 
atom 3.104. Application of strongly acidic conditions is reported in the literature as an efficient 
strategy in the hydrogenolysis  hydrolysis of the O-benzyl group. However, the conditions in 
entry 2 and 3 (Table 3-3) led to hydrolysation of the nitrile functional group to give the 
carboxylic acid 3.105. The role of triisopropyl silane in this reaction was to irreversibly 
scavenge the resulting reactive benzyl cation.185 On the other hand, reducing the concentration 
of TFA to 50% led to reduced efficiency of the reaction, and no product was obtained. 
Furthermore, using ammonium formate (entry 5 and 6) with Zn or Pd afforded the starting 
material 3.94 or 3.105, respectively.  
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Another approach to synthesise 3.103 using tert-butyl dimethyl silyl as a protection group was 
employed. This approach started by fluorine atom displacement in 3.7 with 2-((tert-butyl 
dimethyl silyl) oxy) ethan-1-amine and was subsequently reduced, employing acidic 
conditions. The silyl group is labile to these conditions (AcOH and zinc) and as a result the 
hydroxyl group was deprotected 3.69. Therefore, the synthetic design was modified as 
illustrated in (Scheme 3-11).  
(Scheme 3-11): synthesis of starting materials employed in 3.103 preparation.  
 
 
Reagent and conditions:  a) 2-((tert-butyl dimethyl silyl) oxy) ethanamine for 3.106 and 2-aminoethan-1-ol for 
3.55, MeOH, reflux, 16 h, 95%. b) Zn, NH4Cl, 10% CH3COOH in MeOH, rt, 1h, 95%. c) TBDMS-Cl, imidazole, 
DMF, rt, 16 h, 81%. d) 3.36, EtOH, reflux, 16 h. e) DIC, Et3N, DMF, reflux, 16 h, 65%. f) 10 % TFA in MeOH, 
rt, 48h 60%. 
The last synthetic route was successful and provided the desired product after deprotection of 
the silyl group in the last step of the synthetic procedure (Scheme 3-11) using 10% TFA in 
methanol.  
In conclusion, a synthetic procedure of 2-aminobenzimidazole series was developed here to 
furnish a range of analogues in good yield. The successful strategy was achieved by treating 
the substituted benzene-1,2-diamine with various isothiocyanates to afford substituted 
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thioureas, following by adding DIC as a coupling reagent to aid ring closure and TFA to 
deprotect the silyl group. This procedure was employed to synthesis large quantity of 3.20 (200 




3.4 Molecular analysis  
Unfortunately, employing the ITC experiment to evaluate the binding of 1H-
benzo[d]imidazole series was not an ideal method due to solubility issues. Therefore, the cell-
based assay was employed as an alternative method to evaluate the potency of the compounds 
and their ability to penetrate the bacterial cell wall and avoid efflux pump systems. However, 
it is difficult to determine the KD and ΔG binding of the synthesised compounds as well as the 
effect of employing different functional groups on binding by cell-based assay. In addition, 
cell-based assays are not sufficient to prove the direct binding of the synthesised compounds 
to PqsRCBD which limits the biological analysis presented in this work. 
A good alternative approach to prove the direct binding to PqsRCBD is determining the ligand 
crystal structure complex by employing a soaking experiment to identify the binding site of the 
ligand and the main interactions with the receptor. Determining the crystal structure ligand-
protein complex is an important form of analysis in medicinal chemistry that can provide 
qualitative data on the binding geometry and key compound-amino acids interaction within the 




3.4.1 Crystal structure of PqsRCBD complexed with active compounds belonging to the 








Figure 3-9: Schematic representation of the crystal structure of PqsRCBD complexed with PqsR antagonists (yellow 
sticks): 3.20, 3.95, 3.99 and 3.100, sequentially from the top, binding to PqsRCBD with hydrogen bonds shown as 
a dotted line. The racemic mixture of the above compounds was soaked, and the S enantiomer was observed.   This 
work was carried out by William Richardson (work in press). 
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All of the investigated analogues in the 1H-benzo[d]imidazole series adopted a similar binding 
mode to the 4-(3H)-quinazolinone series, with the benzimidazole moiety buried within pocket 
A whilst the para-phenyl acetonitrile faced Tyr258 in pocket B (Figure 3-9). The chlorine atom 
at position 6 pointed to the Thr265 residing in pocket A with a 4 Å distance. Additionally, the 
hydroxyl and the secondary amine in the linker exhibited hydrogen bonding with the backbones 
of Arg209, Leu207 and Leu208. Moreover, the isopropyl substitution at N1 in the benzimidazole 
ring had a hydrophobic interaction with the lipophilic residues (Leu207, Leu208, Ile236 and Ile263) 
surrounding that part of the binding pocket. This lipophilic interaction and H-bonding of the 
secondary amine in the linker accounted for the enhancement of inhibitory potency for this 
series when compared to 4-(3H)-quinazolinone series. The design strategy of 3.95 was to obtain 
further hydrogen bonding or lipophilic interaction with the Tyr258 by adding a fluorine atom at 
the R4 position. Additionally, oxygen atom insertion into the alkyl chains of 3.99 and 3.100 
aimed to decrease lipophilicity and obtain more hydrogen bonding with the backbone of the 
hydrophobic residues surrounding that area. Unfortunately, the crystal structures (Figure 3-9) 
indicated that neither the fluorine atom nor the oxygen atom established any further interactions 
with the receptor. However, a comparison of the biological activity of 3.20 and 3.95 suggested 
that the insertion of a fluorine atom could enhance π- π stacking interaction with Tyr258, which 
leads to a 2.6-fold increase in activity.  
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3.5 Structure activity relationship analysis 
3.5.1 SAR study of 2-aminobenzimidazole series 
An intensive SAR study was established to enrich the initial SAR reported at the beginning of 
this chapter (3.1), which showed that the 1-methyl-benzo[d]imidazole ring is the optimal 
replacement of the quinazolin-4(3H)-one ring, while the 2-amino group proved a better linking 
group than sulfur. 
Table 3-4: Summery of SAR study of 2-aminobenzimidazole series. The inhibition of PqsR activity measured 
initially in PAO1-L CTX::PpqsA-lux strain of P. aeruginosa at 10 µM concentration. Any compounds showed 
inhibition of activity by 50 % or less was further analysed by concentration-response curve measured in PAO1-L 
CTX::PpqsA-lux and PA14 CTX::PpqsA-lux strains. NA, not active at 10 µM concentration. NT, not tested in PA14 
CTX::PpqsA-lux strains. All the active compounds in this series did not show any effect on the bacterial growth. 
The asterisk (∗) indicates that this parameter was predicted using ChemDraw 19.0.1.28 
(http://www.chemaxon.com). The sign ($) indicates that the synthesis and biological evaluation was carried out 













IC50 (µM) PAO1-L 
CTX::PpqsA-lux 




$3.1 Cl H CH3 H H 0.21 ± 0.04 a 0.20 ± 0.01 a 3.2 
3.86 H Cl CH3 H H NA NT 3.2 
3.87 Cl Cl CH3 H H NA NT 3.8 
$3.109 CF3 H CH3 H H 1.5 ± 0.3 b NT 3.4 
$3.19 Cl H C2H5 H H 0.13 ± 0.03 a 0.08 ± 0.01 a 3.7 
3.20 Cl H CH(CH3)2 H H 0.14 ± 0.05 a 0.09 ± 0.01 a 4.0 
3.88 Cl H C(CH3)3 H H 0.22 ± 0.01 a 0.23 ± 0.01 a 4.4 
3.89 Cl H CH2C(CH3)3 H H 0.38 ± 0.01 b 0.55 ± 0.01 b 5.1 
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3.90 Cl H cyclo-propyl H H 0.06 ± 0.03 a 0.07 ± 0.01 a 3.8 
3.91 Cl H cyclo-butyl H H 0.16 ± 0.01 a 0.25 ± 0.10 a 4.1 
3.92 Cl H cyclo-pentyl H H 0.44 ± 0.1 a 0.55 ± 0.02 a 4.7 
3.93 Cl H cyclo-hexyl H H 0.75 ± 0.4 a 1.4 ± 0.1 a 5.2 
3.94 Cl H 
 
H H 1.05 ± 0.2 b NT 4.9 
3.95 Cl H CH(CH3)2 F H 0.05 ± 0.02 a 0.12 ± 0.02 a 4.1 
3.96 Cl H CH(CH3)2 H F 0.06 ± 0.03 a 0.12 ± 0.04 a 4.1 
3.101 H H CH(CH3)2 H H 0.77 ± 0.2 b 1.04 ± 0.2 b 3.3 
$3.110 Cl H CH(CH3)2 H H 0.50 ± 0.3 b NT 4.1 
3.97 Cl H C2H4N(CH3)2 H H NA NT 3.3 
3.98 Cl H 
 
H H NA NT 3.3 
3.99 Cl H 
 
H H 0.15 ± 0.01 a 0.32 ± 0.08 a 2.6 
3.100 Cl H C2H4OCH3 H H 0.18 ± 0.04 a 0.12 ± 0.04 a 3.1 
3.103 Cl H C2H4OH H H 0.18 ± 0.05 a 0.29 ± 0.03 a  2.4 
Values reported as Mean ± SEM of n = 6a or n = 3b. 
Exploration of the SAR for the R1 and R2 substituents demonstrated that the introduction of a 
chlorine atom at the 5-position (compounds 3.86, 3.87) or a trifluoromethyl group at the 6-
position 3.109 led to loss or decrease of activity, which could be due to a steric limitation in 
the binding pocket. Therefore, for all future SAR, R1= Cl was maintained. Exploration of the 
R3 position proved very enlightening and the optimal substitutions in the R3 position where the 
ethyl 3.19 and isopropyl 3.20 substituents. Furthermore, substitution at the R3 position with 
cyclo-alkanes showed a two-fold increase in activity over 3.1 with the cyclopropyl derivative 
3.90 being optimal. However, further increase in steric bulk (3.91 – 3.94) led to a decrease in 
activity, indicating the steric limitation of this recognition site in the receptor. Evidence for this 
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SAR was demonstrated through obtaining the co-crystal structure of 3.20 with PqsR (Section 
3.4.1 3.4.1). Finally, we aimed to introduce a fluorine atom at R4 and R5 in order to gain a 
further hydrogen bond interaction with the Tyr258 sidechain, and the biological evaluation of 
these compounds (3.95 & 3.96) showed a slight two-fold increase in activity compared to 3.20.  
The other aim of this study was to enhance the physiochemical properties of the series by 
employing different strategies. Firstly, removing the lipophilic chlorine atom from the 
benzimidazole ring 3.101 led to a 10-fold decrease in activity. Furthermore, polar functional 
groups were introduced in the R3 position to enhance the overall physical properties including 
increasing water solubility. We found that any nitrogen-containing alkyl groups (3.97 & 3.98), 
which is considered as a basic functional group with calculated pKa = 9 led to complete loss 
of the inhibitory activity. Interestingly, replacing the hydroxyl group 3.20 with an amino group 
3.110 gave a 7-fold reduction in activity. This finding could also be associated with 
permeability issues or substrate to a specific efflux mechanism.170 On the other hand, oxygen-
containing alkyl chains (3.99, 3.100 and 3.103) maintained biological activity with a 
corresponding reduction in lipophilicity. In light of the SAR study, 3.20 was chosen for further 
pharmacological evaluation.  
3.5.2 Comparison between 3.20 and 1.3 
 
 
Figure 3-10: The improvement of potency of 3.20 in comparison to 1.3. 1.3 is the well-known PqsR antagonist 




1.3 is a well-known PqsR antagonist with promising results in preclinical studies.103,112 The 
SAR of this antagonist provides the key structural features important for activity, including 
hydrogen bonding and the π-π interaction of the thioactamide and phenoxy group, respectively. 
The 1H-benzo[d]imidazole series interacted with the receptor in a similar manner to 1.3 with 
additional lipophilic interaction with the alkyl chain presented in N1. The presence of an 
electron withdrawing group at position 6 in this series seems important for activity, as removing 
the chlorine atom in 3.101 led to a 10 fold decrease in activity in comparison to 3.20. This is 
in agreement with 1.3, where a substituent in position 6 (a nitro group), has been shown to be 
superior in terms of potency over methyl, methoxy, and the non-substituted benzimidazole ring. 
However, there are no derivatives for the current SAR study with electron donating groups 
such as hydroxyl or methoxy substitution on position 6 of 3.20 to draw clear conclusions about 
the role of the chlorine atom in the binding of this series. 1.3 is higher in calculated lipophilicity 
to 3.20 by almost one log unit, which could refer to the presence of thioether in the linker and 
additional aromatic ring in the tail. Furthermore, the low activity of 1.3 in PA14 could be due 
to that, 1.3 a substrate to a specific reflux  efflux pump presented in PA14 or less preamble  has 
lower permeability which leads to a decrease in the activity of the compound.186 On the other 
hand, the 1H-benzo[d]imidazole series represented by the active compounds 3.1, 3.20, 3.90, 
3.95, 3.96, 3.99, 3.100 and 3.103 managed to show similar activity in both strains with a 2-fold 
difference. Therefore, 3.20 is considered as more promising candidate with better potency and 





3.5.3 Analysis of 3.20 enantiomers activity  
Synthesis. (Scheme 3-12): Synthesis of (S)-2-(4-(3-((6-chloro-1-isopropyl-1H-
benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) phenyl) acetonitrile, 3.114. 
 
Reagents and conditions: a) (S)-(+)-glycidyl nosylate, Cs2CO3, CH3CN, reflux, 16 h, 87%. b) NaN3, NH4Cl, 
EtOH, 40°C, 16 h, 99%. c) TBDMS-Cl, imidazole, DMF, rt, 16 h, 84%. d) PPh3, 10% H2O; THF, rt, 16h, 90%. 
e) thio-CDI, DCM, inert atmosphere, rt, 16 h, 25%. f) EtOH, reflux, 16 h. g) DIC, Et3N, DMF, reflux, 16 h, 65%. 
h) 10 % TFA in MeOH, rt, 48h, 60%.  
Here, a synthesis of enantiopure epoxide is presented employing the single enantiomer of 
glycidyl nosylate as a starting material to produce the desired enantiomerically pure product in 
high enantiomeric excess. In this case, employing the pure enantiomer of epichlorohydrin as 
the starting material to synthesis 3.109 is not ideal. This is because epichlorohydrin, in theory, 
has two electrophilic centres in the molecule, resulting in two possible stereochemical 




Figure 3-11: Theoretical mechanism of epoxide synthesis. The reaction employs pure enantiomer of 
epichlorohydrin or glycidyl nosylate to furnish the required enantiomer. Two electrophilic centres in the molecule, 
resulting in two possible stereochemical outcomes. The alkylation of the first electrophilic centre showed in red 
arrow whereas the blue one for the alkylation of the second electrophilic centre. 
Therefore, employing the single enantiomer of glycidyl nosylate as a starting material was 
more efficient to produce the desired enantiomerically pure product in high enantiomeric 
excess. The driving force of the selectivity here is the stability of the conjugate base making 
position 1 more electrophilic and more favourable in this reaction, as shown above.  
Following this, analytical chiral high performance liquid chromatography (HPLC) was 
employed to separate the final product (racemic compound 3.20) into enantiomerically pure 
isomers: 3.114 (S isomer) and 3.115 (R isomer). The principle of this technique depends on the 
differences in the affinity of each isomer to the column, and therefore each isomer is eluted at 
different times. The separation of 3.20 showed that the (S) enantiomer 3.114 has a lower affinity 
for the stationary phase, and therefore was eluted from the column first, followed by the (R) 
enantiomer 3.115 with enantiomeric excess (ee) 96.9 % and 96.1 %, respectively (more details 





Biological evaluation. The activity of the racemic 3.20 and both enantiomers, 3.114 and 3.115 
were evaluated in cell based assay employing PAO1-L Ppqsa::lux and PA14 Ppqsa::lux 
strains.  































































































Figure 3-12: Concentration-response curve of 3.20 and both enantiomers 3.114 and 3.115. The inhibition of 
PqsR activity measured in a) PAO1-L Ppqsa::lux. and b) PA14 Ppqsa::lux strains. The error bars indicate the 
SEM of the mean of one or two biological experiments. n = 6a or n = 3b biological replicates. 
The result showed that both enantiomers 3.114 & 3.115 are equally active within the limit of 
the biological assay in PAO1-L Ppqsa::lux. However, the analysis of enantiomers activity in 
PA14 Ppqsa::lux strain showed that 3.115 is 4.5- and 5-fold more active than 3.20 and 3.114, 
respectively with IC50 = 23 nM ± 2.4.   
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3.6 Conclusion and future work 
 
 
Figure 3-13: The improvement in activity of benzimidazole series by replacing the quinazolin-4(3H)-one scaffold 
by 1-methyl-1H-benzo[d]imidazol-2-amine ring. IC50 measured in PAO1-L Ppqsa::lux. 
The work presented in this chapter demonstrated a hit to lead optimisation study that employed 
1.13 as the hit compound, replacing the quinazolin-4(3H)-one scaffold with different 
heterocycles. The 1-methyl-1H-benzo[d]imidazol-2-amine ring 3.1 has been found as an 
optimal heterocycle that provides a key lipophilic interaction with the receptor at the N1 
position. The pharmacophore presented here emphasise that the antagonistic activity required 
the general structural features presented in the previous SAR study (Chapter 2), 1.3 and the 
current study which is including; EWG on the heterocycle ring, hydrogen bonding with the 
linker, as well as the π-π interaction with Tyr258. However, some analogues (3.19, 3.20, 3.90, 
3.91, 3.95, 3.96, 3.99, 3.100 and 3.103) presented in this study displayed similar or better 
activity compared to 1.3 against PAO1-L and an enhanced inhibition against PA14 with IC50 
values in sub-micromolar range. In light of the SAR study presented in this chapter, 3.20 was 
chosen for further pharmacological evaluations in order to prove the concept. Furthermore, 
cytotoxicity assays will be established for the most active compounds in the series to support 
them proceeding to further study.  
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4 Biological Characterisation of PqsR Inhibitors based on Crystal 
Structure and In Vitro Studies, and their Effect on Quorum 




The development of novel candidates with specific targets generally follows the same 
workflow regardless of the target’s nature. This work was started by in silico virtual screening 
of the PqsR ligand-binding domain (LBD) crystal structure PDB: 4JVI using the University of 
Nottingham Managed Chemical Compound Collection (MCCC). Virtual screening was 
complemented by a whole-cell biosensor reporter assay (Section 1.8.2) to confirm the activity 
of the highest-scoring compounds. Five hits were identified and 1.6 was selected as the ideal 
hit to establish a SAR study. Furthermore, another SAR study was performed by replacing the 
quinazolin-4(3H)-one core in 1.6 with a 1H-benzo[d]imidazole ring lead to produce a range of 




Figure 4-1: Structures of the active compounds in quinazolin-4(3H)-one and 1H-benzo[d]imidazole series. 
These compounds employed in various biological analysis presented in this chapter. 
The synthesised compounds in both series were evaluated using the aforementioned biosensor 
reporter assay (Section 1.8.2). Moreover, the crystal structures of key compounds in both series 
were generated to determine the key interactions with PqsRCBD.  
In this chapter, the active compounds were further tested against a mCTX::Pkm-lux PAO1-L 
strain to subtract potential undesired bias by unspecific interactions with the lux operon or with 
the bioluminescence metabolism (Section 4.2.1). In addition, 3.20 was selected as the lead 
candidate, and further phenotypic pharmacological evaluations were established to prove the 
concept and confirm the mechanism of action for this novel lead candidate and its 
analogues. Finally, once the activity of the candidate was confirmed, the relevant compound 
was studied regarding its ability to repress the pathogenicity of different phenotypes of P. 
aeruginosa. The next step is to evaluate, 3.20 in relevant in vivo infection models to investigate 




4.2 Primary in vitro assays 

























































































 2.34 2.35 3.1 3.90 3.95 3.96 3.100 
P value 0.0063 ˂0.0001 0.0439 0.0045 0.0257 0.0125 0.0068 
 
 
Figure 4-2: The active compounds presented in Chapters 2 and 3.  10 µM concentration of the active 
compounds were screened against the CTX::Pkm-lux PAO1-L strain to detect any potential non-specific 
interactions with the lux operon. Statistical significance was assessed using the unpaired t-test for each column in 
relative to control (DMSO 0.1%) with P value for significantly different values shown in the graph. The data 
shown are based on n = 6.  
An assay was performed in parallel to the concentration-response assay mentioned in chapters 
2 and 3 to guide the selection of active compounds by verifying the efficacy of the active 
compounds using the CTX::Pkm-lux PAO1-L strain. This strain is a constitutive reporter 
control strain that helps to detect and subtract any potential bias from non-specific interactions 
with the lux operon itself rather than the desired interaction with the targeted protein. All active 
compounds were incubated with this strain at 10 µM concentration. The results demonstrated 
that 1.13 and 3.20 did not significantly inhibit lux gene expression (Figure 4-2). This confirmed 
that the measured IC50 mainly reflected the impact on the PqsR protein rather than the effect 
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on the lux gene. On the other hand, some active compounds (2.34, 2.35, 3.1, 3.90, 3.95, 3.96 
and 3.99) in both series inhibit lux gene expression with percentage ranged between 5 and 15%.  
4.2.2 Growth measurement 
























































Figure 4-3: Growth curves of P. aeruginosa in the presence or absence of the active compounds. (a) PAO1-
L CTX::PpqsA-lux and (b) PA14 CTX::PpqsA-lux in the presence of 10 µM concentration of nanomolar-range active 
compounds or DMSO control.  
 
The main objective of this work was to identify an antivirulence candidate that antagonises 
PqsRCBD without affecting bacterial growth. Therefore, it was critical to prove the concept by 
measuring the impact of the active compounds on bacterial viability overnight. Figure 4-3 
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showed that all the active compounds with nanomolar range activity did not interfere with 
bacterial growth at 10 µM concentration, which is the highest concentration used in this 
experiment, in comparison to DMSO (0.1%) control. The initial evaluation of the synthesised 
compounds provided clear evidence of the compounds’ activity in both series involving pqs 
system inhibition rather than affecting the lux gene. Additionally, it has been proven that all 
active compounds did not affect the growth of bacteria, which leads to classify the compounds 
as antivirulence candidates. However, reducing light emission in the primary screening could 
be due to the pqs system being hampered at different levels, including HHQ and PQS 
biosynthesis as well as transport and signal perception. Therefore, the primary screening alone 
is not sufficient to prove the molecular interaction with PqsR. As such, there remains a need to 
prove the direct binding of the novel compounds with PqsR and the concept of this novel 
therapeutic strategy via secondary in vitro assays. 
4.3 Secondary in vitro assays 
Antagonising PqsR is a novel mechanism of action used to combat the virulence of P. 
aeruginosa that requires additional in-depth investigations. At this stage of the project, it is 
important to prove the concept of this novel strategy by measuring the secondary metabolites 
of the pqs system in the presence and absence of inhibitors. Such analyses are crucial to 
determine the effect of antagonising PqsR on pqs system activity and the pathogenicity of the 
bacteria in general. Additionally, as mentioned in Section 1.1.4, it is critical to determine the 
activity range of inhibitors against different isolates of P. aeruginosa (including the most 
resistant strains) and prove the applicability of targeting PqsR receptor as a core protein that is 
essential for the pathogenicity in a wide range of strains of this bacterium. 
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Figure 4-4: Pyocyanin production quantification. This occurred in the presence of the nanomolar-range active 
compounds in the series at 3 fold IC50 concentration relative to the DMSO negative control. The data shown are 
based on n = 9.  
 
Pyocyanin has emerged as an important virulence factor that is produced by P. aeruginosa and 
strongly regulated by the pqs system.187 Therefore, the measurement of pyocyanin production 
provides an indirect readout of pqs QS system activity. The most active compounds with IC50 
≤ 200 nM  in the 2-aminobenzimidazole series were screened against pyocyanin production in 
the PAO1-L wt strain (Figure 4-4). All of the compounds inhibited pyocyanin production to 
50% or less when used at concentration equivalents to three fold of their IC50 values. 
Compounds 3.20 and 3.88 showed a significant effect on pyocyanin production, with an 
approximately 80% reduction relative to the control. On the other hand, the weakest effects 































































Figure 4-5: Pyocyanin production quantification. This occurred in the presence and absence of 3.20 at 200 nM 
concentration in different genomic classes of P. aeruginosa. The data shown are based on n = 9. This analysis 
was carried out by Eduard Vico Oton.188 
 
P. aeruginosa is generally considered as an opportunistic pathogen but there are several 
widespread clones that appear to have become more specialised pathogens, particularly in 
cystic fibrosis patients, including the Liverpool epidemic strain (LES) which is found mainly 
in the UK,24 DK2 in Denmark, 189 and AUST-02 in Australia 190. In general, The population of 
P. aeruginosa can be divided into three main groups: PAO1, PA14 and the highly divergent 
PA7.191 PAO1 is considered as the major reference for genetic and functional studies in most 
laboratories while PA14 is a clinical isolate which considered as a more virulent strain than 
PAO1. 
Therefore, further analysis was established to determine the spectrum of 3.20 and its activity 
against different genomic classes of P. aeruginosa. This compound is considered as the most 
active compound based on pyocyanin inhibition analysis. The analysis was performed to 
quantify pyocyanin production in the presence of 200 nM concentration of the selected 
candidate. 3.20 successfully inhibited different isolates of P. aeruginosa—even the most 
antibiotic resistance strain (PA7-48191)—and the degree of inhibition was highly dependent on 
the pathogenicity of the strain (Figure 4-5).  
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Figure 4-6: AQ production quantification. This occurred in the presence of 3 µM of 1.13 or 0.2 µM of 3.20 
relative to DMSO (negative control) in different genomic classes of P. aeruginosa. a) HHQ and b) PQS.  The data 
shown are based on n = 9. This analysis was carried out by Eduard Vico Oton.188 
 
Previous discussions regarding the AQ biosynthetic pathway and pqs gene production 
(Sections 1.5.2 and 1.5.3) emphasised that AQ production measurements are a direct reflection 
of pqs system activity and thus serve as a useful tool for determining the efficiency of PqsR 
inhibitors. Additionally, previous studies have suggested that PQS is a multifunctional 
molecule that functions via several PqsR-dependent and PqsR-independent pathways and 
directly contributes to iron acquisition192 and microvesicle formation.193 The quantitative 
measurement of major AQ (HHQ and PQS) production using the LC-MS/MS technique is 
useful for evaluating the effectiveness of this strategy. The analysis involved different genomic 
classes of P. aeruginosa with the presence of 3 µM of 1.13 and 200 nM of 3.20. Although both 
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compounds demonstrated significant reductions of HHQ and PQS in PAO1-L WT, 1.13 
generally had little to no impact on the AQ production of other strains. On the other hand, 3.20 
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Figure 4-7: HQNO production quantification in the presence of 0.2 µM of 3.20  relative to DMSO (negative 
control) for different genomic classes of P. aeruginosa. The data shown are based on n = 9. This analysis was 
carried out by Eduard Vico Oton.188 
 
Moreover, regarding HQNO, the pqs system by-product promoting the environmental 
competition of P. aeruginosa in polymicrobial infections was also analysed in the presence and 
absence of 3.20. Notably, 3.20 showed a significant reduction in HQNO expression over the 
tested strains, except for LES and PAK. This result is in agreement with AQ production 
analysis, which could be due to the high pathogenicity of these strains 24,194 or the presence of 
a special efflux pump mechanism130 that targeted 3.20. Taken together, these results prove the 
concept of attenuating the pathogenicity of P. aeruginosa by targeting the PqsR receptor and 
indicate the potential of 3.20 as a wide spectrum antivirulence therapy against different isolates 
of P. aeruginosa.  
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4.4 Biofilm formation analysis 
 
The most challenging strategy employed by resistance strains of any bacterial species is biofilm 
formation. This strategy significantly reduces the sensitivity of bacteria to antibacterial agents 
and radiation, making this a serious threat to public health.195 Therefore, when analysing the 
effect of QS inhibitors on the biofilm formation process, the strategy used and the time of 
intervention are critical in the early stages of a drug discovery project. There are four possible 
antibiofilm strategies: prevention, weakening, disruption and direct killing. Moreover, QS 
inhibitors must be clinically useful to disrupt established biofilm to be eradicated via traditional 
antibiotics or phagocytosed and killed by the immune system. In-depth investigations of three-
dimensional biofilm are important in determining the effect of PqsR antagonists on this 
parameter.  
However, based on literature, conflicting results were obtained by different methods employed 
for biofilm formation and analysis as discussed in (Section 1.8.2) and the reasons were not 
investigated. This raises the question of whether biofilm experiments performed in the 
laboratory are useful for understanding how the novel candidates can inhibit QS and interfere 
with biofilm formation. Much of the existing knowledge regarding chronic infection comes 
from studying bacteria growing in test tubes with nutrient conditions that differ from 
pathological conditions, regardless of the significant differences between in vitro biofilms 
grown in the laboratory and in vivo biofilms. Additionally, as a research community, single-
species cultures are routinely examined. However, in reality, the majority of chronic infections 
caused by polymicrobial communities and the interactions between different species may 
critically influence various factors associated with chronic infection (e.g., virulence, biofilm 
nature and antimicrobial resistance).196  
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Therefore, Harrison and Diggle developed a version of the model that uses small sections of 
pig bronchiole to better represent P. aeruginosa biofilm during the long periods of relatively 
quiescent chronic infection that characterise CF.197 The ex vivo pig lung (EVPL) model is a 
tractable model for studying P. aeruginosa growth and virulence that uses a bio-surface area 
(lung tissue) to establish biofilm in an artificial sputum medium (ASM). This media has an 
advantage over complex commercially available laboratory media by providing nutritional 
conditions similar to CF sputum, which demonstrates the level of PQS and QS signalling seen 
in CF patients. Previous work using this model showed that adding an unrealistic amount of 
iron led to the siderophore gene being switched off in experiments, thereby confirming the 
significance of designing an experiment reflecting the pathological situation in an in vivo 
system. 
Additionally, ASM gives some complexity for the model when examining the ability of a 
compound to penetrate the media, which simulates the viscous condition of chronic lung 
infection and the ability to penetrate biofilm, tissue and bacterial cells. Other advantages of 
employing lung tissue instead of abiotic surfaces include this assay providing the ability to 
analyse histopathological changes in tissue that occur in the presence or absence of quorum 
sensing inhibitors (QSIs). Furthermore, cell-free suspensions of homogenised tissue could be 
assayed for a range of bacterial virulence factors such as QS signals, protease, pyocyanin and 
the siderophores pyoverdine and pyochelin. A key advantage of EVPL is that it provides the 
opportunity to study bacterial virulence factor production, growth, and cell-cell interactions in 
a spatially structured environment. The spatial structure of the tissue is retained, and microbes 
can be visualised within the tissue by conventional or confocal microscopy. 
On the other hand, this model still has limitations and further work is needed to address these. 
The initial work with this model involved evaluating the effect of 3.20 on biofilm formation 
and acknowledged the high variance in the data presented in the replicates of one experiment 
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and from one experiment to another. In the published protocol of the ex vivo model, bacterial 
cells were loaded by touching a sterile 29G insulin needle to the top of a colony on a Luria 
broth (LB) plate and then lightly touching the tissue with the needle.197 However, this strategy 
will not transfer a constant amount of bacterial load to each plate and variable data will be 
produced as a result. Therefore, the final concentration of bacterial load should be normalised 
in all well plate cells with an appropriate dosage that avoids the overgrowth of bacterial cells 
in each plate and simultaneously produces stable and long-lived infections. To overcome this 
issue, it was recommended to resuspend a colony in ASM and grow it to a specific optical 






















































































































Figure 4-8: The provisional data obtained from an ex vivo pig lung model. The biofilm was established for 
two time points (24 and 96h) before treatment with 0.2 µM of 3.20. The ex vivo pig lung assay and supernatant 
preparation was carried out by the author. The AQ was extracted and quantified according to the protocol 
presented in the experimental section by Nigel Halliday. The data shown are based on n = 3. 
The handling and processing of lung tissue have been addressed, which will facilitate the 
establishment of various types of analyses and investigations. The ability to process lungs in 
batches and easily cut several dozen regular cubes of tissue from each lung will facilitate high-
throughput screening. Furthermore, this method can provide an in-depth investigation of one 
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candidate by using different species of P. aeruginosa in a single experiment. The time of 
intervention (before or after biofilm establishment) with QS antagonists and the final 
concentration of the candidate must also be considered. Additionally, the treatment of infection 
with PqsR antagonist alone or in combination with an optimal concentration of different classes 
of antibiotics could be investigated. The initial results of this model indicate that the PQS and 
HHQ concentrations inside the biofilm decreased with 0.2 µM of 3.20 (relative to the control) 
without affecting the number of CFUs (data not shown). However, further optimisation and 
standardisation of this assay was terminated early due to the unexpected pandemic effect of 
(Covid-19). This assay was designed to evaluate the following: a) Bacterial cell growth by 
employing the PAO1-L CTX::PpqsA-lux strain to evaluate the growth of bacteria after treatment 
with 3.20 alone, antibiotics alone, or 3.20 and antibiotics combined; b) the production of 
virulence factors such as AQ, protease, pyocyanin and the siderophores pyoverdine and 
pyochelin; c) biofilm analysis performed with different therapeutic intervention points (before, 
during and after the biofilm formation process); d) the histopathological analysis of infected 
tissue in order to evaluate the efficacy of 3.20 alone, antibiotic alone or 3.20 and antibiotics 
combined in restoring the histology of normal non-infected tissue in comparison to non-treated 
tissue. 
Future work with this model could address changes in nutritional and oxygen levels within 
biofilm communities established on EVPL and how these factors affect the growth and 
virulence production of P. aeruginosa. Additionally, a comparison between treating an 
infection on lung cubes obtained from healthy pigs or genetically engineered pig lung that 
expresses human CF mutations could also be obtained using this method. Finally, the 
establishment of biofilm with multispecies microbes is an important condition that needs to be 
investigated in this model. All of these considerations should be accounted for in any novel 
antivirulence drug development project before proceeding with an in vivo study. 
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4.5 Cytotoxicity study 
 
Assessing the toxicity of a novel candidate is crucial in the early stage of a drug discovery 
project to predict any undesirable toxicological effects, determine the candidate therapeutic 
index and avoid any financial issues associated with proceeding with a candidate to preclinical 
and clinical studies.198 Here, the effects of four represented candidates (i.e., 3.20, 3.90, 3.95 
and 3.96) were investigated on A549 adenocarcinomic human alveolar basal epithelial cell line, 
which represents the site of most P. aeruginosa infections.8 The analysis employed a sensitive 
fluorometric assay (resazurin reduction assay) that is widely applied in drug discovery projects. 
This assay depends on the ability of living cells to reduce resazurin to the fluorescent compound 



























































































































































































































































































































Figure 4-9: Cytotoxicity study of the active compounds in benzimidazole series.  The Resazurin reduction 
assay of 3.20, 3.90, 3.95 and 3.96 in three concentrations in comparison to 1% DMSO (negative control) and 
potassium dichromate reagent (positive control) that killed the cells. The data shown are based on n = 9.  
The results obtained (Figure 4-9) indicate that all studied compounds (3.20, 3.90, 3.95 and 
3.96) are non-toxic at concentrations up to 100 µM, which indicates a wide therapeutic index 
for all compounds. However, further preclinical analyses are needed to confirm the safety and 
efficacy of this candidate in biological systems.  
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4.6 Conclusions and future work 
 
The initial investigations and secondary phenotype pharmacological assays presented in this 
chapter confirmed that 3.20 binds to PqsR as a transcriptional regulator of the pqs system and 
that the antagonising effect of this compound leads to the inhibition of AQ production and 
pyocyanin without affecting the viability of bacteria. However, the next stage in this work 
involved evaluating the effect of this compound in a pathological model to determine the effect 
of 3.20 on the pathogenicity of P. aeruginosa and the ability to prevent or disrupt the biofilm 
formation process obtained in an ex vivo model. The selection of experimental and nutritional 
conditions is critical to providing the field with a reliable biological assay that reflects a similar 
clinical situation of pathogenicity and gene expression. This will support the progress of QSI 
discovery projects and provide an in-depth understanding of how complex QS network systems 
are interconnected. 
Before progressing 3.20 to preclinical study, it is important to determine the stability of the 
candidate through in vitro plasma and hepatic stability assays to predict the stability and 
bioavailability of the compound in an in vivo system and determine the metabolites. The site 
of metabolic attack could be protected by applying the medicinal chemistry strategy to enhance 
the metabolic stability and bioavailability of the compound. 
Additionally, during preclinical studies, it is important to evaluate the stability of the compound 
in the lung (by measuring the residence time) and the rate of systemic clearance since 
pulmonary administration is the targeted route of administration. In this context, the target is 
long residence time and rapid systemic clearance to reduce the frequency of administration and 
side effects of the medication. This objective could be achieved by modifying the design of the 




5 General Discussion and Future Work 
5.1 Antivirulence drugs in the clinic 
 
After the golden age of using traditional antibiotics for the treatment of bacterial infections, the 
evolution and spread of antibiotic resistance resulted in the need to seek alternatives. A novel 
concept has emerged that focuses on pathoblockers or disarming the virulence weaponry of 
pathogens instead of directly killing them. The discovery of antivirulence compounds with a 
novel mechanism of action requires a profound understanding of the respective pathogenic 
mechanisms in combination with modern medicinal chemistry strategies to develop highly 
effective therapies. The pathoblocker approach could be achieved through several strategies, 
as among these is the interference with QS to disrupt bacterial communication and biofilm 
formation. This strategy—known as quorum quenching (QQ)—could be achieved by: 1) 
Interfering with the production or perception of autoinducers via QSIs; 2) Scavenging 
autoinducers using quorum quenching antibodies or macromolecules such as cyclodextrins; 3) 
Using extracellular hydrolysis of autoinducers using QQ enzymes. 200 The scope of this work 
primarily focuses on the first strategy by designing molecules that antagonise the 
transcriptional regulator PqsR and inhibit the synthesis of AQs (the autoinducer molecules for 
the pqs system). This system is the dominant QS in chronic P. aeruginosa infections and it is 
involved in antibiotic-tolerant and multi-drug resistant mechanisms. 106 In addition, the PqsR 
knockout strains of P. aeruginosa are significantly less virulent in in vivo infection models.109 
Also, the production of virulence factors such as pyocyanin and biofilm formation were 
drastically diminished.108,109 Furthermore, the rate of persister cell formation decreased, which 
makes bacterial populations more susceptible to antibiotic treatment.103 
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Although substantial progress has been achieved in antivirulence approaches, all current 
evidence supporting the hypothesis of QSI approach primarily depends on in vitro and in vivo 
studies. While the clinical proof of concept for QSI strategy applicability remains pending. 
Thus, the first clinical evaluation of QSI must select therapeutic indications and patient groups 
carefully to avoid failure at that stage. Currently, there is a limited number of known QSIs of 
natural and synthetic origin in the literature.201 To date, the only compound identified as a QSI 
in P. aeruginosa based on clinical observation is azithromycin, with only one terminated 
clinical trial (Clinicaltrials.gov identifier: NCT00610623). 
Therefore, it remains difficult to estimate whether QSI could be used as a prophylaxis for 
immunosuppressed or high-risk patients, as a monotherapy treatment or in combination with 
conventional antibiotics. Furthermore, predicting the propensity of bacteria to develop 
resistance to QSI drugs is also difficult because bacterial transmission and colonisation 
dynamics are complex, differ among species and are incompletely understood.107 For example, 
the hierarchy quorum sensing network in P. aeruginosa could overcome the inhibition of the 
pqs system and activate an alternative pathway to maintain the pathogenicity of bacteria in 
long-term treatment.73 Additionally, the narrow spectrum of PqsR antagonists could limit the 
efficacy of this approach in polymicrobial infections or lead to the domination of another 
microbial species at the infection site. The scientific community (i.e., academic groups and the 
pharmaceutical industry) must provide the field with more potent candidates and more robust 
biological assays to analyse the activity of the candidates and predict their effect in more 
complex systems at the early stages of antivirulence development projects. 
It becomes evident that the majority of PqsR antagonists identified to date function as useful 
probes for mechanistic studies for further drug development, rather than lead-like 
compounds.72 Therefore, more effort needs to be directed toward the design of drug-like 
molecules with favourable physicochemical properties. Following previous efforts, the work 
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performed in this thesis provides the field with a novel (SAR) analysis of two different series 
with quinazolin-4(3H)-one and 1H-benzo[d]imidazole derived scaffolds. 3.20 the lead 
candidate in this work showed a nano-molar range activity in two representative strains of P. 
aeruginosa. In addition, 3.20 inhibited the HHQ, PQS and HQNO production in different 
isolates of P. aeruginosa with the exception of PAK which is practically unaffected. These 
results support the proceeding of this candidate for further biological evaluation as a promising 





5.2 The pharmacophore of PqsR antagonists  
The pharmacophores of PqsR antagonists with quinazolin-4(3H)-one and 1H-
benzo[d]imidazole scaffolds in this study are consistent with previous studies.87,99,103 Most of 
the PqsR antagonists maintain the structural features highlighted in (Figure 5-1), which provide 
the ideal geometry to fit the receptor and maximise the van der Waals interactions. 
 
  
Figure 5-1: The pharmacophore of PqsR antagonists.  
Generally, the structural features for antagonistic activity include: 1) The fused heterocycle 
ring system, which is likely to improve the parameters of research compounds by decreasing 
the number of heavy atoms and the lipophilicity of the scaffold; 2) A flexible linker that 
contains heteroatoms that provide hydrogen bonding with the hinge region of PqsRCBD. Since 
H-bond interactions are highly sensitive to both distance and angle, the well-placed hydrogen 
bond between the linker and the receptor is critical for activity, as concluded by the SAR studies 
presented in this work; 3) A structural feature that provides lipophilic or π-π interactions 





Figure 5-2: The key interactions of NHQ, 2.12 87 and 1.13 and the improvement of antagonistic activity. EC50 
determined in a P. aeruginosa ΔpqsAH CTX::PpqsA-lux strain.  IC50 determined in a P. aeruginosa PAO1-L 
CTX::PpqsA-lux strain. 
 
NHQ mainly interacts with PqsRCBD via lipophilic interactions.87 On the other hand, the 
binding of 2.12 featured a hydrogen bond between the backbone oxygen of Leu207 and the 3-
amino hydrogen atoms. Additionally, the chlorine atom in position 7 can occupy a vacant sub 
pocket in the receptor and slightly change the conformation of the receptor.87 Furthermore, 
1.13 maintains the interaction with Thr265; even though, the chlorine position was moved to 
position 6. Additionally, although the interaction with Leu207 was lost in 1.13, the hydroxyl 
moiety maintains H-bonding with two amino acids in the hinge region and the acetonitrile 
facing the Tyr258, which enhances the antagonistic potency 5 fold in comparison to 2.12.  
 
 
Figure 5-3: The key interactions of 1.13, 1.3 and 3.20, and the improvement of antagonistic activity. IC50 





Consistent with previous findings, compounds presented in this work accommodate the 
receptor in a similar fashion to 1.3. The quinazolin-4(3H)-one in 1.13 or 1-alkyl-1H-
benzo[d]imidazol-2-amine core in 3.20 inserts deeply into the hydrophobic pocket whilst the 
hydroxyl moiety creates hydrogen bonding with the amino acids in the hinge region. Upon 
comparing 1.13 and 3.20, the enhancement of the antagonistic activity could be due to the 
additional hydrogen bond obtained by the secondary amine present in the linker within 3.20. 
Additionally, the lipophilic interaction between the alkyl substitutions in the 1H-
benzo[d]imidazol-2-amine series and lipophilic amino acids contributes to increasing the 
potency of the compounds. Unravelling the precise interactions of the receptor showed that the 
hydroxyl in 1.13 creates H-bonding with the Arg209 and Gln194, whilst the hydroxyl in 3.20 
creates H-bonding with Arg209 and Leu208. Additionally, the secondary amine in 3.20 creates 
additional H-bonding with Leu207. Furthermore, it was reported that the benzimidazole core in 
1.3 shows hydrophobic contacts with Ile149 and Ile236,112 which could explain the 8 fold drop in 
IC50 value after replacing quinazolin-4(3H)-one in 1.13 with a 1-isopropyl-1H-
benzo[d]imidazol-2-amine core in 3.20. 
All the analysed compounds presented in this work occupied the PqsRCBD domain in a similar 
manner to 2.12, 1.3 and the natural ligand (NHQ), thereby demonstrating that these antagonists 
are competitive inhibitors to AQ ligands. However, it has been found that moving from the 
lipophilic interactions of natural ligands to electrostatic interactions converts agonistic activity 
to antagonistic activity.87 Moreover, increasing the strength of these interactions with the 
receptor leads to enhanced antagonistic potency, as demonstrated in this work. The activity of 
PqsR antagonists is largely governed by intermolecular van der Waals attractive forces, H-
bonding interactions and repulsive forces (e.g., hydrophobic effects) that help to drive a 
molecule from an aqueous environment into the hydrophobic cavity of PqsRCBD.  
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5.3 Physicochemical properties analysis 
 
The drug development process targets the selectivity and potency of the candidate to the 
pharmacodynamic target as well as efficient delivery to the target site, which is achieved 
through maintaining proper physicochemical properties. Furthermore, the physicochemical 
properties determine the absorption, distribution, metabolism, excretion and toxicity properties 
to some extent, and ultimately affect the pharmacological activity of the drug molecule. 
Therefore, modifying the chemical structure and building a SAR analysis for candidates is 
critical to identifying the optimal balance between activity and physicochemical properties. A 
better understanding of the antibacterial property space is one of the many parameters essential 
to improving the future success rate of identifying of novel antibacterial drugs, especially 
indispensable compounds with activity against multi-drug-resistant gram-negative pathogens 
that are becoming more prevalent in nosocomial and community-based infections. The polarity 
of gram-negative antibacterials drugs is increasing substantially in comparison to other drugs 
in the comprehensive medicinal chemistry data set.118 This parameter is reflected in the relative 
polar surface area (tabulated surface contributions of polar atoms in a molecule with regard to 
their binding pattern202 divided by total surface area, relPSA %), hydrogen bond donor (HBD) 
and hydrogen bond acceptor (HBA), which are analysed in this study. Additionally, it is crucial 
to analyse the molecular weight (MW) and lipophilicity (the logarithm of the octanol-water 
distribution coefficient, clogP), since all of these parameters are primarily affected by the 
chemical structures of the molecules. The targeted physicochemical space of antibacterial 
drugs has slightly shifted to more polar and larger MW molecules when compared to other 
therapeutic categories of oral drugs118; therefore, it was crucial to enhance the polarity of both 
series presented in this work. The physicochemical proprieties analyses of current PqsR 
antagonists in the literature as well as the active compounds in the quinazolin-4(3H)-one and 
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1H-benzo[d]imidazole series are presented in this section whilst considering the ideal space of 
antibacterial drugs as a reference point. The ideal space of antibacterial drugs was defined 
based on the analysis of 64 anti-infective drugs launched from 1983–2002 and summarised as 
follows: MW is 456 Da, cLogP is 1.6, relPSA is 24.6%, HBD is 2.4 and HBA is 5.2.161 A study 
by O’Shea and Moser (2007) defined the proper space of synthesised antibacterial drugs with 
gram-negative activity represented by fluoroquinolone class as follows: MW is 371 Da, cLogP 
is 1.3, relPSA is 25.1%, HBD is 2.1 and HBA is 6.5.118 On the other hand, natural antibiotics 
(e.g., aminoglycosides) occupy a space with very high polarity (cLogP -2.9) with MWs 
between 400 and 600 Da. Analysing the physicochemical properties proprieties of the PqsR 
published in the literature and the active compounds identified in this work is critical to 
defining the current situation and guiding future projects. 
a) Structure IC50 (µM) MW cLogP 
1.3 
 
0.32 ± 0.14  420.0 5.2 
1.11 
 
0.31 ± 0.15  347.8 4.2 
1.12 
 
0.25 ± 0.12  442.5 3.5 
2.12 
 






b) R1 R2 R3 R4 IC50 (µM) MW cLogP 
1.6 H H CH2CN (S, R) OH 3.2 ± 1.0  369.1 1.9 
1.13 H H CH2CN (R) OH 1.1 ± 0.4 369.1 1.9 
2.34 H H OCH2CN (S, R) OH 4.5 ± 0.7  385.8 1.8  
2.35 F H CH2CN (S, R) OH 2.2 ± 0.2  387.8 2.3  
2.36 H F CH2CN (S, R) OH 6.4 ± 0.7  387.8 2.3  
 
 
c) R1 R2 R3 R4 IC50 (µM) MW cLogP 
3.1 Cl CH3 H H 0.21 ± 0.04  370.8 3.2 
3.109 CF3 CH3 H H 1.5 ± 0.3  404.4 3.4 
3.19 Cl C2H5 H H 0.13 ± 0.03  384.9 3.7 
3.20 Cl CH(CH3)2 H H 0.14 ± 0.05  398.9 4.0 
3.91 Cl C(CH3)3 H H 0.22 ± 0.01  412.9 4.4 
3.92 Cl CH2C(CH3)3 H H 0.38 ± 0.01  426.9 5.1 
3.90 Cl cyclo-propyl H H 0.06 ± 0.03  396.9 3.8 
3.91 Cl cyclo-butyl H H 0.16 ± 0.01  410.9 4.1 
3.92 Cl cyclo-pentyl H H 0.44 ± 0.1  424.9 4.7 
3.93 Cl cyclo-hexyl H H 0.75 ± 0.4  439.0 5.2 
3.94 Cl 
 
H H 1.05 ± 0.2  491.0 4.9 
3.95 Cl CH(CH3)2 F H 0.05 ± 0.02  416.9 4.1 
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3.96 Cl CH(CH3)2 H F 0.06 ± 0.03  416.9 4.1 
3.101 H CH(CH3)2 H H 0.77 ± 0.2  364.4 3.3 
3.99 Cl 
 
H H 0.15 ± 0.01  412.9 2.6 
3.100 Cl C2H4OCH3 H H 0.18 ± 0.04  414.9 3.1 
3.103 Cl C2H4OH H H 0.18 ± 0.05  400.9 2.4 
 
Table 5-1: Structures of compounds employed in physicochemical proprieties  properties analysis presented 
in this chapter. a) various PqsR antagonists presented in the literature and b) active compounds in the quinazolin-
4(3H)-one and c) 1H-benzo[d]imidazole series. IC50 determined in a P. aeruginosa PAO1-L CTX::PpqsA-lux strain. 
  
Notably, the candidate must reach the biophase and cross several bio-membranes in planktonic 
and eukaryotic cells. This process requires a balance between two contradictory parameters: 
lipophilicity and polarity. Lipophilicity is a key molecular descriptor influencing a variety of 
drug and candidate properties. This property essentially reflects the key event of molecular 
desolvation in transferring from aqueous phases to cell membranes and to protein binding sites, 
which are mostly hydrophobic. If lipophilicity is too high, there is an increased likelihood of 
poor solubility, poor metabolic clearance and binding to multiple targets (drug promiscuity), 
which leads to pharmacologically based toxicology. Another molecular descriptor that could 
evaluate the lipophilicity of compounds is relPSA %. Increasing the polarity by balancing 





5.3.1 Lipophilicity analysis 
 
 
Figure 5-4: Illustration of cLogP* values plotted against relPSA** %. a) PqsR antagonists presented in the 
literature, in addition to 1.13 and 3.20. b) Active compounds in the quinazolin-4(3H)-one and 1H-
benzo[d]imidazole series. c) Illustration of cLogP values plotted against the PIC50 of active compounds in the 
quinazolin-4(3H)-one and 1H-benzo[d]imidazole series. Red spots indicate the reference points of antibacterial 
























































c) cLogP* & PIC50
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using ChemDraw 19.0.1.28 (http://www.chemaxon.com). The asterisks (**) indicates that this parameter was 
predicted using SwissADME website (http://www.swissadme.ch). 
 
The only candidate that has a relPSA value similar to the reference point is 1.3; however, the 
cLogP of this candidate is 2.5 fold higher. The 1.13 hit of quinazolin-4(3H)-one series was the 
strongest candidate positioned within the high probability zone of the ideal space. Similarly, 
analysing the polarity of the active compounds in the quinazolin-4(3H)-one and 1H-
benzo[d]imidazole series (Figure 5-4b) showed that 2.34 is better than 1.13 at balancing 
between low cLogP and high relPSA. Additionally, 3.103 is the only compound from the 1H-
benzo[d]imidazole series that fits within the zone of quinazolin-4(3H)-one compunds. 
Notably, lipophilicity is a crucial factor that drives potency. Since PqsRCBD is generally 
lipophilic, it is essential to plot the activity versus the cLogP to remove this effect and 
determine the potent compounds with optimal physicochemical space. Leeson and 
Springthorpe introduced lipophilic ligand efficiency (LLE) (or LiPE) as a parameter to evaluate 
the quality of research compounds by linking potency and lipophilicity to estimate drug-
likeness.121 Additionally, LLE provides readily determined guideposts that are useful in 
decision making during the lead optimisation stage, especially in the absence of ITC data. This 
expression is defined as the difference of log P (or log D) and the negative logarithm of potency 
measures (pIC50). LLE describes the contribution of lipophilicity to potency and can be used 
in conjunction with log P, log D or clog D. For 3.95, LLE = (7.3-3.9) = 3.4, whilst 3.103 LLE 
= (6.7-2.5) = 4.2. This implies that even though 3.95 is the most potent compound in the present 
work, 3.103 is better in terms of balancing between potency and lipophilicity. The optimal 
target range for LLE is generally considered to be between 5 and 7.161 Unfortunately, the 
compounds presented in the literature and this work fail to fit in that range.  
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Figure 5-5: Illustration of MW* values plotted against relPSA* %. a) PqsR antagonists presented in the 
literature. b) Active compounds in the quinazolin-4(3H)-one and 1H-benzo[d]imidazole series. c) Illustration of 
MW values plotted against PIC50. The red spots are the reference points of antibacterial drugs’ ideal space, as 
defined in the literature.118,161 The asterisk (*) indicates that this parameter was predicted using ChemDraw 
19.0.1.28 (http://www.chemaxon.com). The asterisk (**) indicates that this parameter was predicted using 
SwissADME website (http://www.swissadme.ch). 
 
Another characteristic of antibacterial drugs is their high MW, especially in antibacterial drugs 
of natural origin. An increase in MW could increase the lipophilicity or relPSA, which are 
contraindicated proprieties to each other. To define the optimal space (i.e., high relPSA and 
high MW), these two parameters were plotted against each other (Figure 5-5a and Figure 5-5b). 
The results indicate that the compounds in both groups did not occupy the targeted space and 
that 1.3 is the only candidate that achieved relPSA and MW values similar to the reference 
points. On the other hand, the range of MW for the most potent compounds in the quinazolin-
4(3H)-one and 1H-benzo[d]imidazole series was between 400 and 420 Da, with a relPSA range 
between 14 and 15% (Figure 5-5c). 
3.94 showed the highest number of C atoms with one micromolar activity. Additionally, the 
restriction of conformation into the active conformer plays a role in driving potency since it 
appeared in comparison to the iso propyl 3.20 and cyclopropyl analogue 3.90, with an 
approximately 2 fold enhancement in potency. This could be driven by conformational 




5.3.3  Hydrogen bond donor and acceptor analysis 
 
Figure 5-6: Illustration of the number of hydrogen bond donor* plotted against the number of hydrogen bond 
acceptor* in PqsR antagonists presented in the literature and active compounds in the quinazolin-4(3H)-one and 
1H-benzo[d]imidazole series. The red spots are the reference points of antibacterial drugs’ ideal space, as defined 
in the literature.118,161 The asterisk (*) indicates that this parameter was predicted using SwissADME website 
(http://www.swissadme.ch). 
 
The number of HBD and HBA are additional parameters that describe property requirements 
and define the targeted space of the candidates. Nitrogen and oxygen are the most common 
heavy atoms that can act as both (HBD and HBA) with functional groups such as OH and NH2. 
The mean of HBD and HBA of 64 anti-infective drugs were 2.4 and 5.2, respectively. To some 
extent, these parameters affect the lipophilicity and relPSA % of the molecules as well as the 
ligand-protein interaction. 3.109 has the highest number of HBA, whilst 3.103 has the highest 
number of HBD in comparison to the reference point. 
The anti-infective drugs generally possessed the highest mean MW, lowest mean lipophilicity, 
highest HBA, and highest O and N atom counts in comparison to other therapeutic category 


























5.4 Conclusions and future work 
 
The work presented in this thesis further promotes the progression of PqsR antagonists by 
providing the field with potent compounds with sub-micromolar potency and acceptable 
physicochemical properties. These pqs inhibitors can be used as tools to unravel the current 
knowledge behind the role of the pqs system in certain complicated mechanisms such as 
bacterial biofilms.  
The PqsR antagonists presented here were obtained from in silico screening followed by in 
vitro validation and further chemical optimisation. Two SAR studies were established for the 
quinazolin-4(3H)-one and 1H-benzo[d]imidazol-2-amine series. The first study (Chapter 2) 
found that the R enantiomer 1.13 had a reasonable micromolar IC50 value in PAO1-L, with 
cLogP 2.1. The SAR analysis of 1.13 as a hit was limited since any small modification to the 
molecule led to a loss of activity. However, 2.34 was the only analogue in the series that 
exhibited slightly enhanced polarity, with a 4 fold decrease in potency. Further chemical 
optimisation (outlined in Chapter 3) led to the discovery of another series with a 1H-
benzo[d]imidazol-2-amine scaffold. The synthetic strategy of benzo[d]imidazol-2-amine series 
was optimised in this work leading to synthesis 3.20 in large quantity (100-200 mg) with high 
purity (≥ 95%) sufficient for further in vitro and in vivo assays. Although the quinazolin-4(3H)-
one core is almost 3 fold more polar than the 1H-benzo[d]imidazole ring (regardless of the 





Figure 5-7: The design of future work to support the current SAR study and improve the activity of the series.  
 
Further investigation of the series could be performed by replacing the chlorine atom in 3.20 
with methoxy 3.116 or hydroxy moiety 3.117 in order to probe the effect of H-bond donor on 
the binding as well as enhance the lipophilicity of the compound. Another optimization strategy 
could be applied to enhance the accumulation of the PqsR antagonists inside the bacterial cells, 
especially the resistance strains, by introducing a microbial siderophore functional group such 
as catechol, in 3.118 and 3.119. These compounds are likely to chelate iron in the extracellular 
environment and form iron–siderophore complex which is recognized by high-affinity receptor 
proteins in the bacterial cell wall. These proteins utilize active transport to internalize the 
iron.203 In addition, linking the molecule to a sugar moiety, different siderophore or siderophore 
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mimic functional groups, 3.120 could be an effective strategy to enhance the uptake and release 
the free PqsR antagonist, 3.20 inside the bacterial cell. The last two strategies could enhance 
the accumulation of the compound as well as the potency.  
Additionally, in rich media (LB) and aerobic conditions, using 3.20 as a lead candidate (200 
nM concentration) inhibited the production of pyocyanin in all strains. At this concentration, 
the AQ production of PAO1-L WT was close to the production detected in a ΔpqsR mutant.188 
The inhibition was also significant in clinical isolates.188 On the other hand, 1.13 demonstrated 
a significant reduction of HHQ and PQS in PAO1-L WT and little to no impact on the AQ 
production of other strains. Additionally, upon comparing the IC50 values of 3.20 to the 
previously reported PqsR antagonist in the literature (1.3), it was evident that 3.20 successfully 
exhibited a wide spectrum of potency against different phenotypes of P. aeruginosa with PAK 
CF isolate (one of the more resistant strains) as an exception. It is worth mentioning that the 
action of phenylalanine arginyl β-naphthylamide (an efflux pump inhibitor) has been observed 
to increase the action of 3.20 against a PAK CF isolate.188  
Furthermore, there is a need to investigate the effect of 3.20 on biofilm assay as well as in vivo 
studies to determine the compound’s efficacy in a biological system. Additionally, the effect 
of 3.20 should be investigated in aerobic and anaerobic settings to examine the relevance of 
pqs inhibition under these conditions. A biological evaluation of 1.3 has proven that it can 
significantly decrease the number of persister cells in a culture, which is highly relevant to the 
clinical environment.103 Persisters cells are dormant, non-dividing cells that exhibit multidrug 
tolerance and survive under antibiotic treatment. Consequently, when the course treatment is 
completed, these cells can resume their growth and increase the size of the bacterial 
population.  Therefore, it remains critical to assess the effect of 3.20 over persister cells in 
future work to prove this concept.  
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Additionally, various pharmacokinetic models involving solubility, permeability across an 
artificial membrane, hERG inhibition and cytochromes P450 (CYPs) enzyme inhibition need 
to be established to evaluate the safety and stability of this novel compound. Furthermore, 
different pharmaceutical formulations could be employed to increase the half-life of the 
candidate in desired sites whilst also increasing its accumulation within bacterial cells. 
However, the lack of methodological standardisation in assessing QSI candidates including the 
use of single laboratory-adapted P. aeruginosa strains and abiotic surface biofilm that may be 
distinct from relevant clinical infections is the major challenge in this field. Therefore, it 
remains critical to employ different laboratory strains as well as clinical isolates to test the 
spectrum of the candidate’s activity. In addition, there is a need to provide the field with reliable 
biological assays that represent a chronically infected human lung with a similar clinical 
situation of pathogenicity and gene expression. This will support the progress of QSI discovery 
projects and provide an in-depth understanding of how complex QS network systems are 





6.1 Chemistry  
6.1.1 Reagents and instruments  
Chemical Synthesis.  Chemicals and solvents were purchased from commercial sources 
(typically, Sigma Aldrich, Alpha Aesar, Fisher Scientic, Acros Organics, or Fluorochem), and 
used without further purification. Anhydrous solvents were purchased from Sigma Aldrich and 
used without further distillation. All reactions involving air- or moisture- sensitive reagents 
were performed under nitrogen atmosphere. all compounds were dried under high vacuum 
either at rt or within an oven at 40 ºC. 




C-NMR were obtained at RT using a Bruker 
AV(III) HD 400 NMR spectrometer, spectrometer operated at 400 MHz and equipped with a 
5 mm BBFOþ probe, recording1H and 13C NMR at 400.25 MHz and 100.66 MHz respectively; 
or a Bruker AV(III) 500 NMR spectrometer equipped with a 5 mm dual 1H/13C helium-cooled 
cryoprobe, recording1H and 13C NMR at 500.13 MHz and125.77 MHz respectively. The 
samples were prepared in deuterated solvent; DMSO-d6. The data was processed using iNMR 
(version 5.5.7) referencing spectra to residual solvents and the chemical shifts (δ) were 
recorded in ppm relative to trimethylsilan (TMS) and coupling constants (J) were recorded in 
Hz. Abbreviations used in the description of spectra are: s (singlet), br (broad), d (doublet), dd 
(doublet of doublets), t (triplet), q (quartet), sp septet and m (multiplet). The spectra were 
analysed using Topspin 3.0 and MestReNova 14.1.1-24571 softwares and the assignment of 
the peaks are CHAr for aromatic region and CHAl for aliphatic region. 
Mass spectrometry. LC-MS data was recorded on a Shimadzu UFLCXR HPLC system 
coupled to an Applied Biosystems API2000 electrospray ionization mass spectrometer (ESI-
MS). The column used was a Phenomenex Gemini-NX 3μm 110 Å C-18, 50 x 2 mm 
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thermostated at 40 °C. The flow rate was 0.5 mL / min of a solvent system of increasing 
gradient of acetonitrile (5-95%) in water, each containing 0.1% formic acid. UV detection was 
at 220 nm and 254 nm. m/z values are reported in Daltons to one decimal place and retention 
times (tR) are provided in minutes to two decimal places. 
Chromatography. Thin-layer chromatography (TLC) was performed, UV light and standard 
TLC stains were used to visualise the Merck Silica gel 60 Å F254 plates. Compounds were 
purified via column chromatography using either a Thompson pump or normal phase Interchim 
Purifl ash pre-packed cartridges consisting of 50 μM silica, or a glass column using Merck 
Geduran silica gel 60 Å (230-240 μm). Column size selected was generally 40-60 times the 
loading amount.  
The compounds presented in this chapter are novel unless they referred to the literature with 




C-NMR. The HRMS analysis was carried out by Dr. Fadi 
Soukarieh for the purpose of publication.   
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6.1.2 Experimental of chapter 2 
6-Chloroquinazolin-4(3H)-one (2.20).117 
A solution of 5-chloroanthranilic acid (20 g, 0.11 mol) in Formamide 
(45 mL) was refluxed and stirred at 150 °C for 16 h, forming a brown precipitate. The reaction 
mixture was cooled to room temperature and left to stand for 1 h, then the precipitate filtered 
and concentrate in vacuo. Brown microcrystals (21 g, 100 %).1H NMR (400 MHz, DMSO-d6) 
δ 12.37 (br s, 1H, NH), 8.13 (s, 1H, C8H), 8.00 (d, J = 2.5 Hz, 1H, C6H), 7.80 (dd, J = 8.8, 2.5 
Hz, 1H, C2H), 7.66 (d, J = 8.8 Hz, 1H, C3H).
13C NMR (101 MHz, DMSO-d6) δ 160.3, 147.9, 
146.4, 134.7, 131.4, 129.8, 125.2, 124.3. LCMS m/z calc for C8H5ClN2O
+ [M+H]+ : 181.0, 
found 180.8 with tR 2.25 min.  
General procedure (2.A) for preparation (2.25-2.27).  
To a solution of different methoxides in DCM at 0 °C was treated with dropwise of BBr3 (1M 
in DCM, 10 mL/g). The mixture was allowed to warm to rt and stirred overnight. H2O (10 mL) 
was added dropwise to the mixture which then stirred for 30 min at rt. The organic layer was 
concentrated in vacuo to the dryness and the residue was dissolved in ethyl acetate and washed 
with water. The organic phase was concentrated in vacuo to afford the desired product as a 




2-(4-Hydroxyphenoxy) acetonitrile (2.25) 204 
The title compound was prepared in the manner similar to the 
general procedure (2.A) by utilizing 2-(4-hydroxyphenoxy) acetonitrile 2.21 (1g, 6mmol) as 
the starting material. Brown oil (0.8g, 80 %). 1H NMR (400 MHz, DMSO-d6) δ 6.81 (m, 2H, 
CHAr), 6.75 (m, 2H, CHAr), 5.03 (s, 2H, C9H). 
13C NMR (101 MHz, DMSO-d6) δ 151.4, 148.9, 
116.9, 116.2, 68.0. 
2-(3-Fluoro-4-hydroxyphenyl) acetonitrile (2.26) 
The title compound was prepared in the manner similar to the general 
procedure (2.A) by utilizing 2-(3-fluoro-4-methoxyphenyl) acetonitrile 2.22 (5g, 0.03mol) as 
the starting material. Brown oil (3.2g, 70 %).  1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 1H, 
OH), 7.14 (dd, J = 12.3, 1.9 Hz, 1H, CHAr), 7.03 – 6.87 (m, 2H, CHAr), 3.91 (s, 2H, C8H).
13C 
NMR (101 MHz, DMSO-d6) δ 151.2 (d, J = 242.7 Hz), 144.8 (d, J = 12.6 Hz), 124.8 (d, J = 
3.5 Hz), 122.6 (d, J = 7.8 Hz), 119.7, 118.5 (d, J = 4.2 Hz), 116.6 (d, J = 19.2 Hz), 21.8. 
2-(2-Fluoro-4-hydroxyphenyl) acetonitrile (2.27).  
The title compound was prepared in the manner similar to the general 
procedure (2.A) by utilizing 2-(2-fluoro-4-methoxyphenyl) acetonitrile 2.23 (5g, 0.03mol) as 
the starting material. Brown oil (4.1g, 86 %). 1H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 1H, 




(101 MHz, DMSO-d6) δ 160.9 (d, J = 243.3 Hz), 159.2 (d, J = 11.9 Hz), 131.3 (d, J = 5.5 Hz), 
118.9, 112.3 (d, J = 3.0 Hz), 108.6 (d, J = 17.3 Hz), 103.4 (d, J = 21.6 Hz), 16.6. 
General procedure (2.B) for preparation (2.29-33). 
To a stirred solution of different phenols (1eq) in MeCN (50 mL), was added Cs2CO3 (2 eq), 
then epichlorohydrin (1.2 eq). The reaction mixture was heated at 85 °C for 16h. The mixture 
was filtered and purified using column chromatography eluting the desired compound with 
80:20 Petroleum Ether: Ethyl Acetate.  
2-(4-Oxiran-2-ylmethoxy) phenyl) acetonitrile (2.29)  
The title compound was prepared in the manner similar to the 
general procedure (2.B) by utilizing 4-hydroxyphenylacetonitrile 2.24 (20g, 0.15mol) as the 
starting material. White solid (7g, 25 %). 1H NMR (400 MHz, DMSO-d6) δ 7.30 – 7.24 (m, 
2H, CHAr), 7.02 – 6.95 (m, 2H, CHAr), 4.33 (dd, J = 11.3, 2.7 Hz, 1H, CHAl), 3.95 (s, 2H, 
C12H), 3.83 (dd, J = 11.3, 6.5 Hz, 1H, CHAl), 3.33 – 3.30 (m, 1H, CHAl),  2.85 (t, J = 4.7 Hz, 
1H, CHAl), 2.71 (dd, J = 5.1, 2.7 Hz, 1H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 158.1, 
129.7, 123.8, 119.9, 115.4, 69.4, 50.1, 44.2, 22.0.  
2-(4-(Oxiran-2-ylmethoxy) phenoxy) acetonitrile (2.30) 
The title compound was prepared in the manner similar to the 
general procedure (2.B) by utilizing 2-(4-hydroxyphenoxy) acetonitrile 2.25 (0.8g, 5mmol) as 
the starting material. White solid (0.6g, 54 %). 1H NMR (400 MHz, DMSO-d6) δ 7.10 – 6.86 
(m, 4H, CHAr), 5.10 (s, 2H, C8H), 4.29 (dd, J = 11.4, 2.7 Hz, 1H, CHAl), 3.80 (dd, J = 11.4, 6.6 
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Hz, 1H, CHAl), 3.33 – 3.28 (m, 1H, CHAl), 2.84 (dd, J = 5.1, 4.2 Hz, 1H, CHAl), 2.70 (dd, J = 
5.1, 2.7 Hz, 1H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 154.1, 151.0, 117.2, 116.6, 116.0, 
69.8, 54.6, 50.2, 44.2. 
2-(3-Fluoro-4-(oxiran-2-ylmethoxy) phenyl) acetonitrile (2.31) 
The title compound was prepared in the manner similar to the 
general procedure (2.B) by utilizing 2-(3-fluoro-4-hydroxyphenyl) acetonitrile 2.26 (3.2g, 
0.01mol) as the starting material. White solid (1.5g, 35 %). 1H NMR (400 MHz, DMSO-d6) δ 
7.27 – 7.17 (m, 2H, CHAr), 7.16 – 7.10 (m, 1H, CHAr), 4.42 (m, 1H, CHAl), 3.97 (s, 2H, C12H), 
3.92 (m, 1H, CHAl), 3.43 – 3.36 (m, 1H, CHAl), 2.87 (m, 1H, CHAl), 2.77 – 2.68 (m, 1H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 151.9 (d, J = 245.8 Hz), 146.0 (d, J = 10.5 Hz) 124.9 (d, J 
= 4.2 Hz), 119.5, 116.6 (d, J = 21.0 Hz), 116.0 (d, J = 1.5 Hz), 70.6, 49.9, 44.1, 21.9. 
2-(2-Fluoro-4-(oxiran-2-ylmethoxy) phenyl) acetonitrile (2.32) 
The title compound was prepared in the manner similar to the 
general procedure (2.B) by utilizing 2-(2-fluoro-4-hydroxyphenyl) acetonitrile 2.27 (4.1g, 
0.02mol) as the starting material. White solid (2g, 36 %).  1H NMR (400 MHz, DMSO-d6) δ 
7.37 (t, J = 8.8 Hz, 1H, C3H), 6.96 (d, J = 2.6 Hz, 1H, C6H), 6.86 (dd, J = 8.8, 2.6 Hz, 1H, 
C2H), 4.38 (dd, J = 11.5, 2.6 Hz, 1H, CAlH), 3.96 (s, 2H, C12H), 3.86 (dd, J = 11.5, 6.6 Hz, 1H, 
CHAl), 3.37 – 3.30 (m, 1H, CHAl), 2.90 – 2.81 (m, 1H, CHAl), 2.71 (dd, J = 5.1, 2.7 Hz, 1H, 
CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 161.1 (d, J = 226.9 Hz), 159.7 (d, J = 8.7 Hz), 131.4 
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(d, J = 5.1 Hz), 118.8, 111.7 (d, J = 3.6 Hz), 110.9 (d, J = 15.3 Hz), 102.8 (d, J = 24.5 Hz), 
69.9, 49.9, 44.1, 16.6. 
2-((4-Phenoxyphenoxy) methyl) oxirane (2.33) 
The title compound was prepared in the manner similar to the 
general procedure (2.B) by utilizing 4-phenoxy phenol 2.28 (2g, 0.01mol) as the starting 
material. White solid (0.6g, 23 %). 1H NMR (400 MHz, DMSO-d6) δ 7.32 (t, J = 9.6, 8.7 Hz, 
2H, CHAr), 7.06 (t, J = 7.3 Hz, 1H, CHAr), 6.99 (d, J = 6.6, 3.8 Hz, 4H, CHAr), 6.92 (t, J = 8.7, 
7.2 Hz, 2H, CHAr), 4.27 – 3.75 (m, 4H, CHAl), 3.44 (s, 1H, CHAl). 
13C NMR (101 MHz, DMSO-
d6) δ 158.4, 155.4, 150.0, 130.3, 123.03, 121.1, 117.8, 116.3, 68.76, 51.11, 44.21.  
General procedure (2.C) for preparation (1.6, 2.34-2.37).  
To a stirred solution of 6-chloroquinazolin-4(3H)-one 2.20 (1eq) in MeCN, a mixture of 
different epoxides (2.29-2.33) (1.2 eq), Cs2CO3 (2 eq) and TBAI (0.1 eq) was added. The 
reaction mixture was heated at 100 °C for 16 h. The mixture was filtered, concentrated in vacuo 
and purified using column chromatography eluting the desired compound with 80:20 Ethyl 
Acetate: Petroleum Ether.  
2-(4-(3-(6-Chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 
(1.6) 
The title compound was prepared in the manner 
similar to the general procedure (2.C) by utilizing 2-(4-oxiran-2-ylmethoxy) phenyl) 
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acetonitrile 2.29 (7.3g, 0.039 mol) as the starting material. The mixture was filtered and 
purified using column chromatography eluting the desired compound with 80:20 Ethyl 
Acetate: Petroleum Ether. Yellow solid (3.2 g, 24 %). 1H NMR (400 MHz, DMSO-d6) δ 8.32 
(s, 1H, C8H), 8.11 (d, J = 2.5 Hz, 1H, C6H), 7.88 (dd, J = 8.8, 2.5 Hz, 1H, C2H), 7.73 (d, J = 
8.8 Hz, 1H, C3H), 7.32 – 7.23 (m, 2H, CHAr), 7.03 – 6.93 (m, 2H, CHAr), 5.52 (d, J = 5.6 Hz, 
1H, OH), 4.35 (dd, J = 13.4, 3.8 Hz, 1H, C15H), 4.19 (ddd, J = 9.1, 5.6, 3.8 Hz, 1H, C14H), 4.08 
– 3.95 (m, 2H, C13H), 3.95 (s, 2H, C24H), 3.95 – 3.87 (m, 1H, C15H).
13C NMR (101 MHz, 
DMSO-d6) δ 159.9, 158.3, 149.7, 147.2, 134.8, 132.0, 129.9, 129.7, 125.4, 123.7, 123.3, 120.0, 
115.8, 70.7, 66.4, 50.0, 22.0. LCMS m/z calc for C19H17ClN3O3
+ [M+H]+: 370.1, found 369.9 
with tR 2.68 min. HRMS m/z calc for C19H17ClN3O3
+[M + H]+: 370.1 found 370.1. Purity of the 
compound was confirmed to be >95% by LCMS using a long method run. 
2-(4-(3-(6-Chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenoxy) acetonitrile 
(2.34) 
The title compound was prepared in the manner 
similar to the general procedure (2.C) by utilizing 2-(4-(oxiran-2-ylmethoxy) phenoxy) 
acetonitrile 2.30 (0.6 g, 3 mmol) as the starting material. White solid (0.3 g, 26 %). 1H NMR 
(400 MHz, DMSO-d6) δ 8.32 (s, 1H, C8H), 8.10 (d, J = 2.5 Hz, 1H, C6H), 7.85 (dd, J = 8.7, 2.5 
Hz, 1H, C2H), 7.71 (d, J = 8.7 Hz, 1H, C3H), 7.07 – 6.97 (m, 2H, CHAr), 7.00 – 6.91 (m, 2H, 
CHAr), 5.51 (d, J = 5.6 Hz, 1H, OH), 5.10 (s, 2H, C25H), 4.40 – 4.31 (m, 1H, C15H), 4.23 – 4.12 
(m, 1H, C13H), 3.99 (dd, J = 5.6, 1.8 Hz, 2H, C13,14H), 3.91 (dd, J = 13.5, 8.6 Hz, 1H, C15H). 
13C NMR (101 MHz, DMSO-d6) δ 159.9, 154.3, 150.9, 149.6, 147.1, 134.8, 131.6, 129.8, 




[M+H]+: 386.0, found 386.4 with tR 2.66 min. Purity of the compound was confirmed to be 
>95 % by LCMS using a long method run. 
2-(4-(3-(6-Chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy)-3-fluorophenyl) 
acetonitrile (2.35) 
The title compound was prepared in the manner 
similar to the general procedure (2.C) by utilizing 2-(3-fluoro-4-(oxiran-2-ylmethoxy) phenyl) 
acetonitrile 2.31 (0.18 g, 8 mmol) as the starting material. White solid (90 mg, 24 %). 1H NMR 
(400 MHz, DMSO-d6) δ 8.31 (s, 1H, C8H), 8.15 – 8.05 (m, 1H, C6H), 7.87 (ddd, J = 9.0, 6.5, 
2.5 Hz, 1H, C2H), 7.72 (dd, J = 9.0, 6.5 Hz, 1H, C3H), 7.27 – 7.19 (m, 2H, CHAr), 7.14 (dd, J 
= 9.0, 1.9 Hz, 1H, CHAr), 5.56 (d, J = 5.6 Hz, 1H, OH), 4.34 (dd, J = 13.4, 3.7 Hz, 1H, C15H), 
4.21 (d, J = 10.3 Hz, 1H, C13H), 4.10 (dd, J = 5.6, 2.6 Hz, 2H, C13,14H), 3.98 (s, 2H, C24H), 
3.92 (dd, J = 13.4, 8.5 Hz, 1H, C15H). 
13C NMR (101 MHz, DMSO-d6) δ 160.0, 154.0 (d, J = 
247.3 Hz), 147.2, 146.4, 134.9 (d, J = 10.2 Hz), 131.6 (d, J = 2.7 Hz), 129.9 (d, J = 19.7 Hz), 
125.3 (d, J = 1.5 Hz), 124.3, 123.3, 119.5, 116.4, 116.0, 72.1, 66.4, 50.1, 21.9. LCMS m/z calc 
for C19H15ClFN3O3
+ [M+H]+: 388.0, found 388.3 with tR 2.68 min. Purity of the compound 





The title compound was prepared in the manner similar 
to the general procedure (2.C) by utilizing 2-(2-fluoro-4-(oxiran-2-ylmethoxy) phenyl) 
acetonitrile 2.32 (0.2, 10 mmol) as the starting material. White solid (93 mg, 25 %). 1H NMR 
(400 MHz, DMSO-d6) δ 8.31 (s, 1H, C8H), 8.11 (d, J = 2.4 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.4 
Hz, 1H, C2H), 7.72 (d, J = 8.7 Hz, 1H, C3H), 7.36 (t, J = 8.8 Hz, 1H, CHAr), 6.95 – 6.88 (m, 
1H, CHAr), 6.83 (dd, J = 8.5, 2.5 Hz, 1H, CHAr), ), 5.54 (d, J = 5.6 Hz, 1H, OH), 4.32 (dd, J = 
13.4, 3.6 Hz, 1H, C15H), 4.18 (ddt, J = 13.9, 9.1, 5.6 Hz, 1H, C14H), 4.13 – 3.99 (m, 2H, CHAl), 
3.99 – 3.88 (m, 3H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 161.1 (d, J = 226.9 Hz), 159.9, 
159.7 (d, J = 8.7 Hz), 149.6, 147.2, 134.8, 131.4 (d, J = 5.1 Hz), 129.9, 125.3, 123.3, 118.8, 
111.7 (d, J = 3.6 Hz), 110.9 (d, J = 15.3 Hz), 102.8 (d, J = 24.5 Hz), 71.1, 66.3, 49.9, 16.6. 
LCMS m/z calc for C19H15ClFN3O3
+ [M+H]+: 388.0, found 388.3 with tR 2.71 min. Purity of 
the compound was confirmed to be >95 % by LCMS using a long method run. 
6-Chloro-3-(2-hydroxy-3-(4-phenoxyphenoxy) propyl) quinazolin-4(3H)-one (2.37) 
The title compound was prepared in the manner 
similar to the general procedure (2.C) by utilizing 2-((4-phenoxyphenoxy) methyl) oxirane 2.33 
(0.6 g, 24 mmol) as the starting material. White solid (85 mg, 24 %).1H NMR (400 MHz, 
DMSO-d6) δ 8.33 (s, 1H C8H), 8.11 (d, J = 2.5 Hz, 1H C6H), 7.88 (dd, J = 8.7, 2.5 Hz, 1H 
C2H), 7.73 (d, J = 8.7 Hz, 1H C3H), 7.35 (t, J = 9.7, 6.0, 2.3 Hz, 2H, CHAr), 7.08 (t, J = 7.4 Hz, 
1H, CHAr), 6.99 (d, J = 1.7 Hz, 4H, CHAr), 6.95 – 6.90 (m, 2H, CHAr), 5.51 (d, J = 5.6 Hz, 1H 
OH), 4.35 (dd, J = 13.4, 3.7 Hz, 1H, C15H), 4.23 – 4.14 (m, 1H, C14H), 4.08 – 3.97 (m, 2H, 
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C13H), 3.92 (dd, J = 13.4, 8.6 Hz, 1H, C15H). 
13C NMR (101 MHz, DMSO-d6) δ 159.9, 158.4, 
155.2, 150.1, 149.7, 147.2, 134.8, 131.6, 130.3, 129.9, 125.4, 123.3, 121.2, 118.0, 116.3, 115.9, 
71.1, 66.5, 50.0. LCMS m/z calc for C23H19ClN2O4
+ [M+H]+ : 423.1, found 423.4 with tR 3.27 
min. Purity of the compound was confirmed to be >95 % by LCMS using a long method run. 
Preparation of 1-(6-chloro-4-oxoquinazolin-3(4H)-yl)-3-(4-(cyanomethyl) phenoxy) 
propan-2-yl 4-methylbenzenesulfonate (2.41) 
 To a stirred solution of 2-(4-(3-(6-chloro-4-oxoquinazolin-
3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6 (1 g, 3 mmol) in  DCE: 5% THF, was 
added, p- toluenesulfonyl chloride (1.5 gm, 8 mmol), NEt3 (0.8 g, 8 mmol), DMAP (0.3 g, 3 
mmol). The mixture was stirred for 16 h at rt. The mixture was purified using column 
chromatography eluting the desired compound with 40:60 Ethyl Acetate: Petroleum Ether. 
White solid (0.8 g, 57 %). LCMS m/z calc for C26H22ClN3O5S
+ [M+H]+ : 524.1 found 524.1 
with  tR 3.11 min. 
Preparation of 2-(4-(2-azido-3-(6-chloro-4-oxoquinazolin-3(4H)-yl) propoxy) phenyl) 
acetonitrile (2.39) 
Method A: to a stirred solution of 2-(4-(3-(6-chloro-4-
oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6 (2 g, 5 mmol) in 
anhydrous THF (100 mL), the Ph3P (2 g, 8 mmol) was added under anhydrous condition at rt. 
After 5 min the mixture was cooled over ice bath before addition of DIAD (1.6 g, 8 mmol) 
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which is followed by DPPA (2.2 g, 8 mmol). The mixture was stirred for 5 min in ice bath, in 
addition to another 5 min at rt. This mixture was then allowed to stir at 45°C overnight. The 
mixture was purified using column chromatography eluting the desired compound with 40:60 
Ethyl Acetate: Petroleum Ether. Yellow solid (1 g, 33 %). 
Method B: to a stirred solution of 1-(6-chloro-4-oxoquinazolin-3(4H)-yl)-3-(4-(cyanomethyl) 
phenoxy) propan-2-yl 4-methylbenzenesulfonate 2.41 (0.8 g, 1.5 mmol) in DMF, was added 
NaN3 (0.3 g, 4.5 mmol). The mixture was stirred for 16 h at 60°C. The mixture was purified 
using column chromatography eluting the desired compound with 40:60 Ethyl Acetate: 
Petroleum Ether. Yellow solid (0.4 g, 65 %). 
1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H, C8H), 8.14 (d, J = 2.5 Hz, 1H, C6H), 7.91 (dd, 
J = 8.8, 2.5 Hz, 1H, C2H), 7.76 (d, J = 8.8,  Hz, 1H, C3H), 7.35 – 7.26 (m, 2H, CHAr), 7.13 – 
6.96 (m, 2H, CHAr), 4.49 – 4.28 (m, 3H, CHAl), 4.22 – 4.10 (m, 2H, CHAl), 3.97 (s, 2H, 
C24H).
13C NMR (101 MHz, DMSO-d6) δ 160.0, 157.7, 149.0, 147.0, 135.1, 131.9, 130.0, 
129.9, 125.6, 124.3, 123.2, 119.9, 115.5, 68.8, 59.1, 46.7, 22.0. LCMS m/z calc for 
C19H16ClN6O2
+ [M+H]+: 395.1, found 395.0 with tR 2.90 min. 
Preparation of 2-(4-(2-amino-3-(6-chloro-4-oxoquinazolin-3(4H)-yl) propoxy) phenyl) 
acetonitrile (2.40). 
To a mixture of 2-(4-(2-azido-3-(6-chloro-4-
oxoquinazolin-3(4H)-yl) propoxy) phenyl) acetonitrile 2.39 (1 g, 2.5 mmol) and Ph3P (1 g, 3.7 
mmol), THF (100 mL) was added and stirred for 2 h at 65°C. Then, 10 % water with 0.5 mL 
of ammonia hydroxide was added and stirred overnight at rt. The mixture was purified using 
column chromatography eluting the desired compound with 90:10 Ethyl Acetate: MeOH 
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containing NH3 (0.7 N). White solid (100 mg, 11 %). 
1H NMR (400 MHz, DMSO-d6) δ 8.38 
(s, 1H, C8H), 8.10 (d, J = 2.5 Hz, 1H, C6H), 7.87 (dd, J = 8.8, 2.5 Hz, 1H, C2H), 7.72 (d, J = 
8.8 Hz, 1H, C3H), 7.27 (d, J = 8.3 Hz, 2H, CHAr), 6.94 (d, J = 8.3 Hz, 2H, CHAr), 4.29 (dd, J = 
13.3, 4.2 Hz, 1H, C15H), 3.94 (d, J = 10.9 Hz, 4H, C13,24H), 3.83 (dd, J = 13.3, 8.5 Hz, 1H, 
C15H), 3.38 (t, J = 4.2 Hz, 1H, C14H). 
13C NMR (101 MHz, DMSO-d6) δ 160.0, 158.3, 149.7, 
147.2, 134.7, 131.5, 129.8, 125.4, 123.7, 123.4, 120.0, 115.4, 71.8, 60.2, 49.4, 21.9. LCMS m/z 
calc for C19H18ClN4O2
+ [M+H]+: 369.1, found 369.1 with tR 2.13 min. HRMS m/z calc for 
C19H18ClN4O2
+ [M + H]+: 369.1, found 369.1. Purity of the compound was confirmed to be 
>95 % by LCMS using a long method run. 
Preparation of N-(1-(6-chloro-4-oxoquinazolin-3(4H)-yl)-3-(4-(cyanomethyl) phenoxy) 
propan-2-yl) acetamide (2.47) 
 To 4 mL of acetic acid anhydride, 2-(4-(2-amino-3-(6-chloro-4-
oxoquinazolin-3(4H)-yl) propoxy) phenyl) acetonitrile 2.40 (50 mg, 0.1 mmol) was added and 
stirred at 30 °C for 3h. The reaction was concentrated to the dryness and the residue was 
dissolved in ethyl acetate and washed with saturated aqueous NaOH and water. The organic 
phase was concentrated to afford the desired product without further purification. White solid 
(53 mg, 95 %).1H NMR (400 MHz, DMSO-d6) δ 8.28 (s, 1H, C8H), 8.17 – 8.07 (m, 2H, C6H, 
NH), 7.87 (dd, J = 8.7, 2.5 Hz, 1H, C2H), 7.72 (d, J = 8.7 Hz, 1H, C3H), 7.28 (m, CHAr), 7.02 
– 6.94 (m, 2H, CHAr), 4.55 (tt, J = 8.9, 4.8 Hz, 1H, C14H), 4.39 (dd, J = 13.6, 4.5 Hz, 1H, C15H), 
4.07 (dd, J = 5.3, 1.6 Hz, 2H, C13H), 4.01 – 3.90 (m, 3H, C15,24H), 1.76 (s, 3H, C27H).
13C NMR 
(101 MHz, DMSO-d6) δ 170.0, 159.9, 158.0, 149.0, 147.0, 134.9, 131.7, 129.9, 129.8, 125.5, 
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124.0, 123.1, 119.9, 115.5, 68.4, 47.8, 47.3, 22.9, 22.0. LCMS m/z calc for C21H20ClN4O3
+ 
[M+H]+: 411.1, found 411.1 with tR 2.62 min. Purity of the compound was confirmed to be >95 
% by LCMS using a long method run. 
Preparation of N-(1-(6-chloro-4-oxoquinazolin-3(4H)-yl)-3-(4-(cyanomethyl) phenoxy) 
propan-2-yl)-2-(dimethylamino) acetamide (2.48) 
To a stirred solution of (dimethyl amino) acetic acid (12 mg, 0.12 
mmol) in DMF (20 mL), was added a mixture of 2-(4-(2-amino-3-(6-chloro-4-oxoquinazolin-
3(4H)-yl) propoxy) phenyl) acetonitrile 2.40 (60 mg, 0.16 mmol), PyBrop (0.1g, 0.24 mmol) 
and trimethylamine (46 mg, 0.36 mmol). The mixture was stirred for 4h at rt. The mixture was 
purified using column chromatography eluting the desired compound with DCM: 10% MeOH 
containing NH3 (0.7 N). White solid (28 mg, 54 %). 
1H NMR (400 MHz, DMSO-d6) δ 8.32 (s, 
1H, C8H), 8.10 (d, J = 2.5 Hz, 1H, C6H), 8.02 (d, J = 9.2 Hz, 1H, NH), 7.87 (dd, J = 8.7, 2.5 
Hz, 1H, C2H), 7.71 (d, J = 8.7 Hz, 1H, C3H), 7.29 (d, J = 8.7 Hz, 2H, CHAr), 7.03 – 6.95 (m, 
2H, CHAr), 4.63 (d, J = 9.2 Hz, 1H, C14H), 4.39 (dd, J = 13.5, 4.1 Hz, 1H, C15H), 4.16 – 4.04 
(m, 3H, C13,15H), 3.96 (s, 2H, C24H), 2.76 (d, J = 1.3 Hz, 2H, C27H), 2.12 (s, 6H, C30-31H).
13C 
NMR (101 MHz, DMSO-d6) δ 170.5, 159.9, 158.1, 149.0, 147.0, 134.9, 131.7, 129.9, 129.8, 
125.5, 124.0, 123.1, 119.9, 115.5, 68.3, 63.1, 47.5, 46.3, 45.8, 22.0. LCMS m/z calc for 
C23H25ClN5O3
+ [M+H]+ : 454.1, found 453.9 with tR 2.17 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
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Preparation of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-(ethylamino) propoxy) 
phenyl) acetonitrile (2.50) 
To a stirred solution of 2-(4-(2-amino-3-(6-chloro-4-
oxoquinazolin-3(4H)-yl) propoxy) phenyl) acetonitrile 2.40 (20 mg, 0.054 mmol) in MeCN 
(20 mL), a mixture of iodoethan (40 uL, 0.54 mmol) and Cs2CO3 (13 mg, 0.10 mmol) was 
added. The mixture was stirred at 60 °C for 16 h. The mixture was purified using column 
chromatography eluting the desired compound with 95:5 Ethyl Acetate: MeOH containing NH3 
(0.7 N). White solid (13 mg, 65 %). 1H NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H, C8H), 8.10 
(d, J = 2.5 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.5 Hz, 1H, C2H), 7.72 (d, J = 8.7 Hz, 1H, C3H), 
7.26 (d, J = 8.4 Hz, 2H, CHAr), 6.92 (d, J = 8.4 Hz, 2H, CHAr), 4.23 (dd, J = 13.5, 5.5 Hz, 1H, 
C15H), 4.00 (dd, J = 10.0, 5.2 Hz, 3H, C11,12H), 3.94 (s, 2H, C24H), 3.23 (s, 1H, C26H), 2.69 
(dq, J = 13.5, 7.1 Hz, 1H, C15H), 1.90 (s, 1H, C26H), 0.91 (t, J = 7.1 Hz, 3H, C27H).
13C NMR 
(101 MHz, DMSO-d6) δ 160.0, 158.2, 149.7, 147.2, 134.8, 131.6, 129.9, 129.7, 125.5, 123.7, 
123.2, 120.0,115.4, 68.7, 55.0, 48.6, 41.2, 21.9, 15.9. LCMS m/z calc for C21H22ClN4O2
+ 
[M+H]+ : 397.1, found 397.0 with tR 2.65 min. Purity of the compound was confirmed to be 
>95 % by LCMS using a long method run. 
Preparation of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-oxopropoxy) phenyl) 
acetonitrile (2.38) 
To a mixture of 2-(4-(3-(6-chloro-4-oxoquinazolin-
3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6 (0.5g, 1.3 mmol) in DCM (50 mL), 
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Dess–Martin periodinane (1g, 2.3 mmol) was added and stirred overnight at rt. The mixture 
was washed with 1M NaOH, another wash with H2O, dry it with Na2SO4 anhydrous and 
concentrate the mixture. The residue was purified using column chromatography eluting the 
desired compound with 70:30 Ethyl Acetate: Petroleum Ether.  White solid (0.4g, 76 %). 1H 
NMR (400 MHz, DMSO-d6) δ 8.32 (s, 1H, C8H), 8.09 (d, J = 2.5 Hz, 1H, C6H), 7.88 (dd, J = 
8.8, 2.5 Hz, 1H, C2H), 7.75 (d, J = 8.8 Hz, 1H, C8H), 7.30 (d, J = 8.5 Hz, 2H, CHAr), 7.02 (d, 
J = 8.5 Hz, 2H, CHAr), 5.16 (s, 2H, C15H), 5.09 (s, 2H, C13H), 3.96 (s, 2H, C24H). 
13C NMR 
(101 MHz, DMSO-d6) δ 200.3, 159.5, 157.4, 148.9, 147.1, 135.2, 132.0, 130.0, 129.8, 125.5, 
124.3, 122.9, 119.9, 115.5, 71.5, 52.6, 22.0. LCMS m/z calc for C19H15ClN3O3
+ [M+H]+ : 368.1, 
found 367.7 with tR 2.75 min. HRMS m/z calc for C19H15ClN3O3
+ [M + H]+: 368.1, found 367.7. 
Purity of the compound was confirmed to be >95 % by LCMS using a long method run. 
Preparation of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) 
acetamide (2.51) 
 A solution of 2-(4-(3-(6-chloro-4-
oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6 (0.1g, 0.27 mmol), 
Cs2CO3 (0.3g, 0.54 mmol) in DMSO: 30 % H2O2 (100 mL) was stirred for 30 minutes in rt. 
The mixture was purified using column chromatography eluting the desired compound with 
100 % Ethyl Acetate. White solid (0.1g, 96 %). 1H NMR (400 MHz, DMSO-d6) δ 8.32 (s, 1H, 
C8H), 8.12 (d, J = 2.5 Hz, 1H, C6H), 7.88 (dd, J = 8.6, 2.5 Hz, 1H, C2H), 7.73 (d, J = 8.6 Hz, 
1H, C3H), 7.40 (s, 1H, NH), 7.18 (d, J = 8.2 Hz, 2H, CHAr), 6.91 – 6.86 (dd, 2H, CHAr), 6.83 
(s, 1H, NH), 5.50 (d, J = 5.6 Hz, 1H, OH), 4.35 (dd, J = 13.4, 3.6 Hz, 1H, C14H), 4.18 (m, 1H, 
C13H), 4.02 – 3.84 (m, 3H, C12,14H), 3.30 (s, 2H, C24H).
13C NMR (101 MHz, DMSO-d6) δ 
173.0, 159.9, 157.4, 149.7, 147.2, 134.8, 131.6, 130.5, 129.9, 129.2, 125.5, 123.3, 114.7, 70.6, 
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66.5, 50.0, 41.82. LCMS m/z calc for C19H19ClN3O4
+ [M+H]+ : 388.1, found 387.9 with tR 2.42 
min. Purity of the compound was confirmed to be >95 % by LCMS using a long method run.  
Preparation of 6-chloro-3-(2-hydroxy-3-(4-((3-methyl-1H-1,2,4-triazol-5-yl) methyl) 
phenoxy) propyl) quinazolin -4(3H)-one (2.53) 
To a stirred solution of 2-(4-(3-(6-chloro-4-
oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6 (0.3g, 0.8 mmol) in 
methanol (50 mL), acetylhydrazine (0.17g, 2.4 mmol) and 0.1g of sodium methoxide was 
added. The mixture was refluxed at 80 °C for 16 h. The mixture was diluted with ethyl acetate 
(50 mL). Then, the ethyl acetate was washed with water (3 x 50 mL), dry it with Na2SO4 
anhydrous and concentrate the mixture. The residue was purified using column 
chromatography eluting the desired compound with 95:5 ethyl acetate: MeOH containing NH3 
(0.7 N). White solid (50 mg, 14 %).1H NMR (400 MHz, DMSO-d6) δ 13.27 (s, 1H, NH), 8.31 
(s, 1H, C8H), 8.10 (d, J = 2.6 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.6 Hz, 1H, C2H), 7.72 (d, J = 
8.7 Hz, 1H, C3H), 7.16 (d, J = 8.0 Hz, 2H, CHAr), 6.86 (d, J = 8.0 Hz, 2H, CHAr), 5.50 (d, J = 
5.7 Hz, 1H, OH), 4.34 (dd, J = 13.4, 3.7 Hz, 1H, C15H), 4.21 – 4.12 (m, 1H, C14H), 3.97 (s, 2H, 
C24H), 3.93 – 3.80 (m, 3H, C13,15H), 2.25 (s, 3H, C30H). 
13C NMR (101 MHz, DMSO-d6) δ 
13C 
NMR (126 MHz, DMSO-d6) δ 172.3, 162.7, 159.9, 157.2, 153.1, 149.7, 147.2, 134.8, 131.6, 
130.1, 129.9, 125.4, 123.3, 114.8, 70.6, 66.4, 50.0, 33.6, 12.0. LCMS m/z calc for 
C21H21ClN5O3
+ [M+H]+ : 426.1, found 426.2 with tR 2.35 min. Purity of the compound was 




Preparation of 3-(3-(4-((1H-tetrazol-5-yl) methyl) phenoxy)-2-hydroxypropyl)-6-
chloroquinazolin-4(3H)-one (2.54). 
To a stirred solution of 2-(4-(3-(6-chloro-4-
oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) acetonitrile 1.6  (0.3g, 8 mmol) in DMF 
(50 mL), NaN3 (0.15 g, 24 mmol) and Et3N.HCl (0.3g, 24 mmol) were added. The reaction 
mixture was heated at 130 °C for 16 h. The reaction was concentrated to the dryness and the 
desired product was isolated using column chromatography eluting the desired compound with 
95:5 Ethyl Acetate: acetic acid. Brown solid (250 mg, 75 %). 1H NMR (400 MHz, DMSO-d6) 
δ 8.32 (s, 1H, C8H), 8.11 (d, J = 2.5 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.5 Hz, 1H, C2H), 7.72 
(d, J = 8.7 Hz, 1H, C3H), 7.13 (d, J = 8.4 Hz, 2H, CHAr), 6.86 – 6.74 (d, J = 8.4 Hz, 2H, CHAr), 
5.64 (s, 1H, OH), 4.34 (dd, J = 13.4, 3.6 Hz, 1H, C14H), 4.14 (dt, J = 9.0, 4.4 Hz, 1H, C13H), 
3.95 (d, J = 5.2 Hz, 2H, C12H), 3.91 (s, 2H, C22H), 3.90 – 3.86 (m, 1H, C14H). 
13C NMR (101 
MHz, DMSO-d6) δ 163.9, 160.3, 159.9, 156.8, 149.7, 147.2, 134.8, 133.5, 131.5, 129.9, 125.5, 
123.3, 114.5, 70.7, 66.5, 50.0, 31.2. LCMS m/z calc for C19H17ClN6O3
+ [M+H]+ : 413.1, found 
412.7 with tR 2.71 min. Purity of the compound was confirmed to be >95 % by LCMS using a 
long method run. 
Preparation of 6-chloro-3-(oxiran-2-ylmethyl) quinazolin-4(3H)-one (2.55). 
A mixture of 6-chloroquinazolin-4(3H)-one 2.20 (0.5g, 2 mmol), 
Cs2Co3 (1.3 g, 4 mmol) and TBAI (70 mg, 0.2 mmol) in MeCN (70 mL), (±) epichlorohydrin 
(250 µL, 3 mmol) was added. The reaction mixture was refluxed overnight. The mixture was 
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purified using column chromatography eluting the desired compound with 70:30 Ethyl 
Acetate: Petroleum Ether. White solid (250 mg, 38 %). 1H NMR (400 MHz, DMSO-d6) δ 8.32 
(s, 1H, C8H), 8.12 (d, J = 2.5 Hz, 1H, C6H), 7.89 (dd, J = 8.7, 2.5 Hz, 1H C2H), 7.74 (d, J = 
8.7 Hz, 1H, C3H), 4.33 (dd, J = 14.4, 3.7 Hz, 1H, C15H), 4.10 (dd, J = 14.4, 5.4 Hz, 1H C15H), 
3.38 – 3.34 (m, 1H, C14H), 2.81 (t, J = 4.4 Hz, 1H, C13H), 2.59 (dd, J = 4.9, 2.6 Hz, 1H, 
C13H).
13C NMR (101 MHz, DMSO-d6) δ 159.8, 148.9, 147.1, 135.1, 131.9, 130.0, 125.5, 
123.1, 49.5, 47.4, 45.6. LCMS m/z calc for C11H10ClN2O2
+ [M+H]+ : 237.0, found 236.9 with 
tR 2.49 min.  
Preparation of 2-(4-((3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropyl) amino) 
phenyl) acetonitrile (2.56). 
To a 5 mL of ethanol, 6-chloro-3-(oxiran-2-ylmethyl) 
quinazolin-4(3H)-one 2.55 (50 mg, 0.21 mmol), 2-((4-aminophenyl) acetonitrile) (23 mg, 0.17 
mmol), Cs2CO3 (130 mg, 0.39 mmol) was dispensed in microwave tube for 30 minutes at 125 
°C. The mixture was purified using column chromatography eluting the desired compound with 
70:30 Ethyl Acetate: Petroleum Ether. White solid; (37 mg, 47 %). 1H NMR (400 MHz, 
DMSO-d6) δ 8.29 (s, 1H, C8H), 8.11 (d, J = 2.4 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.5 Hz, 1H, 
C2H), 7.72 (d, J = 8.7 Hz, 1H, C3H), 7.06 (d, J = 8.3 Hz, 2H, CHAr), 6.65 (d, J = 8.3 Hz, 2H, 
CHAr), 5.73 (t, J = 6.1 Hz, 1H, NH), 5.30 (d, J = 5.4 Hz, 1H, OH), 4.31 (dd, J = 13.3, 3.1 Hz, 
1H, CHAl), 4.05 – 3.93 (m, 1H, CHAl), 3.84 – 3.74 (m, 3H, CHAl), 3.22 (s, 2H, C24H).
13C NMR 
(101 MHz, DMSO-d6) δ 159.9, 149.7, 148.6, 147.2, 134.8, 131.5, 129.9, 129.2, 125.4, 123.3, 
120.3, 118.1, 112.9, 66.7, 50.9, 47.6, 21.9. LCMS m/z calc for 19H18ClN4O2
+ [M+H]+ : 369.1, 
found 369.3 with tR 2.70 min. Purity of the compound was confirmed to be >95 % by LCMS 
using a long method run.  
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General procedure (2.D) for preparation (2.57, 2.58).  
A mixture of 6-chloroquinazolin-4(3H)-one 2.20 (0.3 g, 1.6 mmol), 1-bromo-3-chloro-2-
propane for 2.57 and 1-bromo-3-chloro-2-methylpropane for 2.58 (0.3 g, 1.9 mmol), Cs2CO3 
(1 g, 3.2 mmol), TBAI (59 mg, 0.16 mmol) in MeCN (50 mL) was heated at 100 °C, overnight. 
The mixture was filtered and purified with 50:50 Petroleum Ether: Ethyl Acetate. 
6-Chloro-3-(3-chloropropyl) quinazolin-4(3H)-one (2.57) 
The title compound was prepared in the manner similar to the general 
procedure (2D) by utilizing 1-bromo-3-chloropropane as the starting material. White solid 
(0.3g, 73 %). 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H, C8H), 8.09 (d, J = 2.5 Hz, 1H, 
C6H), 7.86 (dd, J = 8.7, 2.5 Hz, 1H, C2H), 7.71 (d, J = 8.7 Hz, 1H, C3H), 4.11 (t, J = 6.6 Hz, 
2H, C13H), 3.72 (t, J = 6.6 Hz, 2H, C15H), 2.19 (p, J = 6.6 Hz, 2H, C14H).
13C NMR (101 MHz, 
DMSO-d6) δ 159.8, 148.9, 147.1, 134.8, 131.7, 129.9, 125.4, 123.3, 44.6, 43.0, 31.5. LCMS 
m/z calc for C11H11Cl2N2O
+ [M+H]+ : 257.0, found 259.1 with tR 2.74 min.  
6-Chloro-3-(3-chloro-2-methylpropyl) quinazolin-4(3H)-one (2.58) 
The title compound was prepared in the manner similar to the 
general procedure (2D) by utilizing 1-bromo-3-chloro-2-methylpropane as the starting 
material. White solid (0.3g, 71 %). 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H, C8H), 8.10 
(d, J = 2.5 Hz, 1H, C6H), 7.86 (dd, J = 8.8, 2.5 1H, C2H), 7.72 (d, J = 8.8 Hz, 1H, C3H), 4.08 
– 3.88 (m, 2H, C13H), 3.73 – 3.60 (m, 2H, C15H), 2.49 – 2.41 (m, 1H, C14H), 0.99 (d, J = 6.8 
Hz, 3H, C17H).
13C NMR (101 MHz, DMSO-d6) δ 160.02, 149.05, 147.08, 134.98, 131.81, 
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130.05, 125.63, 123.32, 50.79, 49.03, 34.73, 15.55. LCMS m/z calc for C12H13Cl2N2O
+ [M+H]+ 
: 271.0, found 270.8 with tR 2.83 min.  
General procedure (2.E) for preparation (2.59, 2.60).  
To a stirred solution of 2.57 or 2.58 (0.3g, 1 mmol), TBAI (37 mg, 0.1 mmol) and Cs2CO3 (1 
g, 1.3 mmol) in MeCN (100 mL), 4-hydroxyphenyl acetonitrile (0.15g, 1.1 mmol) was added. 
The mixture was heated at 100°C, overnight. The mixture was filtered and purified using 
column chromatography eluting the desired compound with 40:60 Petroleum Ether: Ethyl 
Acetate.  
2-(4-(3-(6-Chloro-4-oxoquinazolin-3(4H)-yl) propoxy) phenyl) acetonitrile (2.59) 
The title compound was prepared in the manner similar to 
the general procedure by utilizing 6-chloro-3-(3-chloropropyl) quinazolin-4(3H)-one 2.57 as 
the starting material. White solid (100 mg, 40 %). 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 
1H, C8H), 8.10 (d, J = 2.6 Hz, 1H, C6H), 7.87 (dd, J = 8.7, 2.6 Hz, 1H, C2H), 7.72 (d, J = 8.7 
Hz, 1H, C3H), 7.28 – 7.19 (m, 2H, CHAr), 6.91 – 6.83 (m, 2H, CHAr), 4.18 (t, J = 6.4 Hz, 2H, 
C15H), 4.05 (t, J = 6.4 Hz, 2H, C13H), 3.93 (s, 2H, C23H), 2.18 (p, J = 6.4 Hz, 2H, C14H).
13C 
NMR (101 MHz, DMSO-d6) δ 159.8, 158.1, 149.1, 147.2, 134.8, 131.7, 129.9, 129.7, 125.4, 
123.6, 123.3, 120.0, 115.3, 65.7, 44.5, 28.2, 21.9. LCMS m/z calc for C19H17ClN3O2
+ [M+H]+ 
: 354.1, found 354.0 with 2.72 tR min. Purity of the compound was confirmed to be >95 % by 




2-(4-(3-(6-Chloro-4-oxoquinazolin-3(4H)-yl)-2-methylpropoxy) phenyl) acetonitrile. 
(2.60) 
The title compound was prepared in the manner 
similar to the general procedure by utilizing 6-chloro-3-(3-chloro-2-methylpropyl) quinazolin-
4(3H)-one 2.58 as the starting material. White solid (200 mg, 49 %).1H NMR (400 MHz, 
DMSO-d6) δ 8.39 (s, 1H C8H), 8.09 (d, J = 2.5 Hz, 1H C6H), 7.87 (dd, J = 8.7, 2.5 Hz, 1H 
C2H), 7.72 (d, J = 8.7 Hz, 1H C3H), 7.24 – 7.20 (m, 2H CHAr), 6.86 – 6.79 (m, 2H CHAr), 4.12 
(m, 2H, C15H), 4.01 (m, 1H, C14H), 3.92 (d, J = 5.5 Hz, 4H, C13,24H), 1.02 (d, J = 6.8 Hz, 3H 
C17H).
13C NMR (101 MHz, DMSO-d6) δ 160.0, 158.2, 149.2, 147.1, 134.8, 131.7, 129.9, 
129.6, 125.5, 123.6, 123.3, 119.9, 115.2, 70.9, 50.0, 21.9, 14.9. LCMS m/z calc for 
C20H19ClN3O2
+ [M+H]+ : 368.1, found 367.7 with tR 2.92 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run.   
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6.1.3 Experimental of chapter 3 
General procedure (3.A) for preparation of N-alkyl-2-nitroaniline (3.8, 3.41-3.55).  
To a solution of 1 g of different substituted (mono or di) chloro-fluoro-1-nitrobenzene 
(compounds 3.7, 3.39-3.40) in MeOH (20 mL), was added the corresponding amines (5 mL). 
The mixture was stirred for overnight at 80 °C. The reaction was concentrated to the dryness, 
and the desired product was used without further purification.  
5-Chloro-N-methyl-2-nitroaniline (3.8) 205 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and methylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 9.1 Hz, 1H, C3H), 7.01 (d, J = 
2.2 Hz, 1H, C6H), 6.68 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 2.95 (d, J = 5.0 Hz, 3H, C10H).
 13C NMR 
(101 MHz, DMSO-d6) δ 146.8, 142.0, 130.3, 128.5, 115.4, 113.8, 30.2.  
4-Chloro-N-methyl-2-nitroaniline (3.41) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-1-fluoro-2-nitrobenzene 3.39 and methylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 2.7 Hz, 1H, C3H), 7.59 (dd, J 
= 9.3, 2.7 Hz, 1H, C1H), 7.05 (d, J = 9.3 Hz, 1H, C6H), 3.17 (s, 3H, C8H). 
13C NMR (101 MHz, 




The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 1,2-dichloro-4-fluoro-5-nitrobenzene 3.40 and methylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.24 (s, 1H, C3H), 7.27 (s, 1H, C6H), 2.96 
(d, J = 5.0 Hz, 3H, C8H).
13C NMR (101 MHz, DMSO-d6) δ 145.3, 139.3, 129.6, 127.5, 119.1, 
116.2, 30.4.  
5-Chloro-N-isopropyl-2-nitroaniline (3.43) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and iso-propylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 
1H NMR (400 MHz, DMSO) δ 8.09 (d, J 
= 9.2 Hz, 1H, C3H), 7.15 (d, J = 2.1 Hz, 1H, C6H), 6.70 (dd, J = 9.2, 2.1 Hz, 1H, C2H), 3.20 – 
3.02 (m, 1H, C10H), 1.25 (d, J = 6.3 Hz, 6H, C12,13H).  
N-(tert-butyl)-5-chloro-2-nitroaniline (3.44) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and tert-butylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (d, J = 9.2 Hz, 1H, C3H), 7.17 (d, J = 
2.2 Hz, 1H, C6H), 6.73 (dd, J = 9.2, 2.2 Hz, 1H, C2H), 1.47 (s, 9H, C11-13H).
13C NMR (101 




The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and neopentylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 9.1 Hz, 1H, C3H), 7.24 (d, J = 
2.2 Hz, 1H, C6H), 6.70 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 3.21 (d, J = 5.9 Hz, 2H, C10H), 0.99 (s, 
9 H, C12-14H). 
13C NMR (101 MHz, DMSO-d6) δ 146.8, 142.3, 130.1, 128.7, 115.8, 114.2, 
53.9, 32.3, 27.5. 
5-Chloro-N-cyclopropyl-2-nitroaniline (3.46) 205 
The title compound was prepared in the manner similar to the general 
procedure (3.A)  by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and cyclopropylamine as 
the starting material.1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 9.1 Hz, 1H, C3H), 7.38 (d, 
J = 2.2 Hz, 1H, C6H), 6.80 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 2.69 – 2.63 (m, 1H, C9H), 0.92 – 
0.87 (m, 2H, CHAl), 0.69 – 0.61 (m, 2H, CHAl).
13C NMR (101 MHz, DMSO-d6) δ 146.9, 141.6, 
130.8, 128.5, 116.5, 115.0, 25.1, 7.9.  
5-Chloro-N-cyclobutyl-2-nitroaniline (3.47) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and cyclobutylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.08 (d, J = 9.2 Hz, 1H, C3H), 6.94 (d, J = 
2.2 Hz, 1H, C6H), 6.74 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 3.45 – 3.31 (m, 1H, C9H), 2.48 – 2.37 
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(m, 2H, CHAl), 2.18 – 1.95 (m, 2H, CHAl), 1.87 – 1.70 (m, 2H, C12H). 
13C NMR (101 MHz, 
DMSO-d6) δ 144.7, 142.0, 130.4, 128.7, 116.1, 114.3, 47.6, 31.3, 15.3. 
5-Chloro-N-cyclopentyl-2-nitroaniline (3.48) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and cyclopentylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 9.2 Hz, 1H, C3H), 7.15 (d, J = 
2.1 Hz, 1H, C6H), 6.73 (dd, J = 9.2, 2.1 Hz, 1H, C2H), 4.09 (m, 1H, C9H), 3.27 (m, 1H, CHAl), 
2.08 (m, 1H, CHAl), 1.81 – 1.41 (m, 5H, CHAl), 1.37 – 1.26 (m, 1H, CHAl).
13C NMR (101 MHz, 
DMSO-d6) δ 145.6, 142.1, 130.4, 128.7, 115.9, 114.5, 54.0, 33.0, 24.0. 
5-Chloro-N-cyclohexyl-2-nitroaniline (3.49) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and cyclohexylamine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 8.6 Hz, 1H, C3H), 7.20 (d, J = 
2.2 Hz, 1H, C6H), 6.70 (dd, J = 8.6, 2.2 Hz, 1H, C2H), 1.93 (m, 1H, C9H), 1.80 – 0.96 (m, 10H, 
C11-15H).
13C NMR (101 MHz, DMSO-d6) δ 145.2, 142.3, 130.1, 128.9, 115.8, 114.2, 50.5, 34.3, 
25.4, 24.4.  
N-(2-(benzyloxy) ethyl)-5-chloro-2-nitroaniline (3.50) 
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The title compound was prepared in the manner similar to the 
general procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and 2-(benzyloxy) 
ethan-amine as the starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 9.2 Hz, 1H, 
C3H), 7.40 – 7.24 (m, 5H, CHAr), 7.20 (d, J = 2.2 Hz, 1H, C6H), 6.72 (dd, J = 9.2, 2.2 Hz, 1H, 
C2H), 4.55 (s, 2H, C13H), 3.70 (t, J = 5.2 Hz, 2H, C11H), 3.59 (t, J = 5.2 Hz, 2H, C9H).  
N1-(5-chloro-2-nitrophenyl)-N2, N2-dimethylethane-1,2-diamine (3.51) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and 2- (dimethyl amino) 
ethylamine as the starting material. 1H NMR (400 MHz, DMSO-d6) δ  8.08 (d, J = 9.1 Hz, 1H, 
C3H), 7.09 (d, J = 2.2 Hz, 1H, C6H), 6.71 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 2.22 (s, 6H, C13,14H), 
2.13 (s, 4H, C9,11H).
13C NMR (101 MHz, DMSO-d6) δ 146.0, 142.0, 130.2, 128.6, 115.7, 114.4, 
57.1, 45.6, 45.3. 
N-(5-chloro-2-nitrophenyl)-1-methylpiperidin-4-amine (3.52) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and 1-methyl piperidin-4-
amine as the starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.08 (d, J = 9.1 Hz, 1H, C3H), 
7.20 (d, J = 2.0 Hz, 1H, C6H), 6.70 (dd, J = 9.1, 2.0 Hz, 1H, C2H), 3.69 (m, 1H, C9H), 2.77 – 
2.56 (m, 2H, CHAl), 2.19 (s, 3H, C16H), 2.16 (dd, J = 11.1, 2.6 Hz, 2H, CHAl), 2.04 – 1.84 (m, 
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2H, CHAl), 1.57 (m, 2H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 145.2, 142.3, 130.3, 128.8, 
116.0, 114.3, 53.9, 53.8, 46.4, 31.5.  
N-(5-chloro-2-nitrophenyl) oxetan-3-amine (3.53) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and oxetan-3-amine as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.17 – 8.03 (m, 1H, C3H), 6.81 (d, J = 8.3 
Hz, 2H, C6,2H), 4.97 – 4.78 (m, 3H, C9H, CHAl), 4.58 (t, J = 5.5 Hz, 2H, CHAl). 
13C NMR (101 
MHz, DMSO-d6) δ 144.3, 142.1, 131.2, 128.8, 116.9, 114.0, 77.2, 47.6. 
5-Chloro-N-(2-methoxyethyl)-2-nitroaniline (3.54) 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and 2-methoxyethylamine 
as the starting material. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 9.1 Hz, 1H, C3H), 7.17 
(d, J = 2.2 Hz, 1H, C6H), 6.72 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 3.61 – 3.50 (m, 5H, CHAl), 3.35 
(t, J = 5.6 Hz, 1H, CHAl), 3.26 (s, 1H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 146.2, 142.1, 
130.4, 128.7, 115.9, 114.3, 70.4, 58.4, 42.5.  
2-((5-Chloro-2-nitrophenyl) amino) ethan-1-ol (3.55) 205 
The title compound was prepared in the manner similar to the general 
procedure (3.A) by utilizing 4-chloro-2-fluoro-1-nitrobenzene 3.7 and 2-aminoethanol as the 
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starting material. 1H NMR (400 MHz, DMSO-d6) δ  8.09 (d, J = 9.1 Hz, 1H, C3H), 7.17 (d, J 
= 2.2 Hz, 1H, C6H), 6.71 (dd, J = 9.1, 2.2 Hz, 1H, C2H), 6.16 (s, 1H, OH), 3.64 (t, J = 5.5 Hz, 
2H, C11H), 3.42 (t, J = 5.5 Hz, 2H, C9H). 
13C NMR (101 MHz, DMSO-d6) δ 146.4, 142.0, 
130.3, 128.7, 115.7, 114.3, 59.4, 45.3. 
General procedure (3.B) for preparation of N-(alkyl) benzene-1,2-diamine (3.9, 3.56-
3.69). 
To a solution of the corresponding (chloro-N1-(alkyl)-2-nitroaniline), prepared previously 3.8, 
3.41-3.55 in MeOH (20 mL) was added zinc (10 equiv), NH4Cl (5 equiv) and 10 % CH3COOH. 
The mixture was stirred overnight at rt. The reaction was concentrated to the dryness, and the 
desired product was extracted using ethyl acetate and saturated aqueous NaHCO3. The organic 
layer was dried to afford the desire product as a black solid, which was used in the next step 
without further purification. 
5-Chloro-N1-methylbenzene-1,2-diamine (3.9) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-methyl-2-nitroaniline 3.8 as the starting material. 1H 
NMR (400 MHz, DMSO-d6) δ 6.51 (dd, J = 14.9, 7.8 Hz, 1H, CHAr), 6.44 – 6.36 (m, 1H, 
CHAr), 6.30 (d, J = 2.4 Hz, 1H, CHAr), 2.69 (d, J = 3.3 Hz, 3H, C10H). 
13C NMR (101 MHz, 
DMSO-d6) δ 138.9, 134.4, 121.6, 115.8, 114.5, 108.7, 21.6.  
4-Chloro-N1-methylbenzene-1, 2-diamine (3.56) 
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 The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 4-chloro-N-methyl-2-nitroaniline 3.41 as the starting material. 1H 
NMR (400 MHz, DMSO-d6) δ 6.59 – 6.45 (m, 2H, CHAr), 6.31 (d, J = 8.3 Hz, 1H, CHAr), 2.69 
(d, J = 5.0 Hz, 3H, C8H). 
13C NMR (101 MHz, DMSO-d6) δ 137.3, 136.3, 120.5, 116.7, 113.0, 
110.1, 30.6.  
4, 5-Dichloro-N1-methylbenzene-1, 2-diamine (3.57) 206 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 4,5-dichloro-N-methyl-2-nitroaniline 3.42 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.65 (s, 1H, CHAr), 6.40 (s, 1H, CHAr), 2.70 (d, J = 5.0 Hz, 
3H, C8H).
13C NMR (101 MHz, DMSO-d6) δ 137.8, 136.2, 118.3, 117.3, 113.7, 109.6, 30.4.  
5-Chloro-N1-isopropylbenzene-1,2-diamine (3.12) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-isopropyl-2-nitroaniline 3.43 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.49 (d, J = 7.8 Hz, 1H, CHAr), 6.43 – 6.31 (m, 2H, CHAr), 
3.52 (dt, J = 12.9, 6.2 Hz, 1H, C10H), 1.15 (d, J = 6.2 Hz, 6H, C12,13H).
13C NMR (101 MHz, 




The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing N-(tert-butyl)-5-chloro-2-nitroaniline 3.44 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.66 – 6.54 (m, 2H, CHAr), 6.50 (dd, J = 8.3, 2.4 Hz, 1H, 
CHAr), 1.27 (s, 9H, C11-13H). 
13C NMR (101 MHz, DMSO-d6) δ 138.0, 135.3, 120.7 115.9, 
114.5, 111.2, 51.7, 29.9. 
5-Chloro-N1-neopentylbenzene-1,2-diamine (3.59)  
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-neopentyl-2-nitroaniline 3.45 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.52 (d, J = 8.0 Hz, 1H, CHAr), 6.42 – 6.37 (m, 2H, CHAr), 
2.84 – 2.79 (m, 2H, C10H), 0.98 (s, 9H, C12-14H).
13C NMR (101 MHz, DMSO-d6) δ 138.6, 
134.4, 121.5, 115.8, 115.1, 109.4, 55.5, 32.4, 28.0. 
5-Chloro-N1-cyclopropylbenzene-1,2-diamine (3.60) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-cyclopropyl-2-nitroaniline 3.46 as the starting 
material. 1H NMR (400 MHz, DMSO-d6) δ 6.78 (dd, J = 8.1, 1.5 Hz, 1H, CHAr), 6.55 – 6.49 
(m, 1H, CHAr), 6.49 – 6.39 (m, 1H, CHAr), 2.32 (m, 1H, C9H), 0.70 (m, 2H, CHAl), 0.39 (m, 
2H, CHAl).  
5-Chloro-N1-cyclobutylbenzene-1,2-diamine (3.61)   
197 
 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-cyclobutyl-2-nitroaniline 3.47 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.48 (d, J = 8.2 Hz, 1H, C3H), 6.39 (dd, J = 8.2, 2.3 Hz, 1H, 
C2H), 6.21 (d, J = 2.3 Hz, 1H, C6H), 3.80 (h, J = 7.1 Hz, 1H, C9H), 1.91 – 1.66 (m, 6H, C11-
13H). 
13C NMR (101 MHz, DMSO-d6) δ 136.3, 134.5, 121.2, 116.2, 114.8, 109.8, 48.6, 30.6, 
15.4. 
5-Chloro-N1-cyclopentylbenzene-1,2-diamine (3.62)   
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-cyclopentyl-2-nitroaniline 3.48 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.48 (d, J = 8.0 Hz, 1H, CHAr), 6.39 – 6.33 (m, 2H, CHAr), 
3.68 (m, 1H, C9H), 1.94 (m, 2H, CHAl), 1.76 – 1.41 (m, 6H, CHAl). 
13C NMR (101 MHz, 
DMSO-d6) δ 137.2, 134.5, 121.3, 115.7, 114.7, 109.9, 54.1, 33.0, 24.3.  
5-Chloro-N1-cyclohexylbenzene-1, 2-diamine (3.63) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-cyclohexyl-2-nitroaniline 3.49 as the starting material. 
1H NMR (400 MHz, DMSO-d6) δ 6.53 – 6.44 (m, 1H, CHAr), 6.35 (d, J = 6.4 Hz, 2H, CHAr), 
1.92 (m, 3H, CHAl), 1.73 (m, 2H, CHAl), 1.62 (m, 1H, CHAl), 1.35 (m, 2H, CHAl), 1.28 – 1.05 
(m, 3H, CHAl).
13C NMR (101 MHz, DMSO-d6) δ 136.7, 133.9, 121.8, 115.7, 111.2, 109.8, 
51.2, 33.0, 26.1, 25.1. 
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N1-(2-(benzyloxy) ethyl)-5-chlorobenzene-1,2-diamine (3.64) 
 The title compound was prepared in the manner similar to the 
general procedure (3.B) by utilizing N-(2-(benzyloxy) ethyl)-5-chloro-2-nitroaniline 3.50 as 
the starting material.  1H NMR (400 MHz, DMSO-d6) δ 7.39 – 7.31 (m, 5H, CHAr), 7.25 (d, J 
= 7.5 Hz, 1H, CHAr), 7.18 (d, J = 7.5 Hz, 1H, CHAr), 7.15 – 7.11 (m, 1H, CHAr), 4.53 (s, 2H, 
C13H), 3.63 (t, J = 5.7 Hz, 2H, C11H), 3.26 (d, J = 5.7 Hz, 2H, C9H).  
5-Chloro-N1-(2-(dimethylamino) ethyl) benzene-1, 2-diamine (3.65) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing N1-(5-chloro-2-nitrophenyl)-N2, N2-dimethylethane-1,2-diamine 
3.51 as the starting material. 1H NMR (400 MHz, DMSO-d6) δ 6.55 – 6.51 (m, 1H, CHAr), 6.47 
– 6.42 (m, 2H, CHAr), 3.23 (t, J = 6.3 Hz, 2H, C9H), 2.88 (t, J = 6.3 Hz, 2H, C11H), 2.49 (s, 6H, 
C13,14H).
13C NMR (101 MHz, DMSO-d6) δ 137.8, 134.7, 121.7, 116.4, 115.1, 109.6, 57.6, 45.1, 
40.9. 
5-Chloro-N1-(1-methylpiperidin-4-yl) benzene-1, 2-diamine (3.66) 
  The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing N-(5-chloro-2-nitrophenyl)-1-methylpiperidin-4-amine 3.52 as the 
starting material. 1H NMR (400 MHz, DMSO-d6) δ 6.61 – 6.55 (m, 1H, CHAr), 6.53 – 6.38 (m, 
2H, CHAr), 3.45 (d, J = 26.7 Hz, 2H, CHAl), 3.17 (s, 1H, CHAl), 3.07 (m, 2H, CHAl), 2.70 (s, 
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3H, C16H), 2.16 – 2.04 (m, 2H, CHAl), 1.79 (m, 2H, CHAl).
13C NMR (101 MHz, DMSO-d6) δ 
136.4, 134.3, 117.9, 117.8, 114.9, 111.6, 52.3, 46.50, 42.9, 29.1.  
5-Chloro-N1-(oxetan-3-yl) benzene-1,2-diamine (3.67) 
 The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing N-(5-chloro-2-nitrophenyl) oxetan-3-amine 3.53 as the starting 
material. 1H NMR (400 MHz, DMSO) δ 6.53 (d, J = 8.2 Hz, 1H, C3H), 6.46 (dd, J = 8.2, 2.3 
Hz, 1H, C2H), 6.06 (d, J = 2.3 Hz, 1H, C6H), 4.87 (t, J = 6.2 Hz, 2H, CHAl), 4.50 (dt, J = 12.1, 
6.2 Hz, 1H, C9H), 4.43 (t, J = 6.2 Hz, 2H, CHAl). 
13C NMR (101 MHz, DMSO) δ 135.6, 135.1, 
121.1, 117.3, 115.0, 109.8, 78.0, 48.1. 
5-Chloro-N1-(2-methoxyethyl) benzene-1, 2-diamine (3.68) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 5-chloro-N-(2-methoxyethyl)-2-nitroaniline 3.54 as the starting 
material. 1H NMR (400 MHz, DMSO-d6) δ 6.52 (d, J = 8.0 Hz, 1H, CHAr), 6.43 – 6.38 (m, 2H, 
CHAr), 3.53 (t, J = 5.6 Hz, 2H, C11H), 3.30 (s, 3H, C13H), 3.23 – 3.14 (m, 2H, C9H).
13C NMR 
(101 MHz, DMSO-d6) δ 137.7, 134.4, 121.6, 116.2, 115.1, 109.4, 70.8, 58.4, 43.3. 
2-((2-Amino-5-chlorophenyl) amino) ethan-1-ol (3.69) 
The title compound was prepared in the manner similar to the general 
procedure (3.B) by utilizing 2-((5-chloro-2-nitrophenyl) amino) ethan-1-ol 3.55 as the starting 
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material. 1H NMR (400 MHz, DMSO-d6) δ 6.51 (d, J = 7.9 Hz, 1H, CHAr), 6.41 – 6.36 (m, 2H, 
CHAr), 3.59 (t, J = 5.9 Hz, 2H, C11H), 3.08 (t, J = 5.9 Hz, 2H, C9H). 
13C NMR (101 MHz, 
DMSO-d6) δ 138.0, 134.5, 121.6, 116.1, 115.0, 109.36, 59.8, 46.2. 
N1-(2-((tert-butyl dimethyl silyl) oxy) ethyl)-5-chlorobenzene-1,2-diamine (3.107) 
 To a solution of tert-butyl(chloro) dimethyl silane (TBDMSCl) (1g, 
7 mmol) in DMF (20 mL) was added imidazole (0.8g, 12 mmol). The mixture was stirred for 
1 hour at rt. Then the compound 2-((2-amino-5-chlorophenyl) amino) ethan-1-ol 3.69 (1g, 
5mmol) was added to the reaction and stirred overnight. The reaction was concentrated to the 
dryness and the desired product was isolated using column chromatography eluting the desired 
compound with 50:50 Petroleum Ether: Ethyl Acetate. 1H NMR (400 MHz, DMSO-d6) δ 6.52 
(d, J = 7.9 Hz, 2H, CHAr), 6.41 (d, J = 7.9 Hz, 2H, CHAr), 4.71 (t, J = 5.9 Hz, 1H, N7H), 4.58 
(s, 2H, N9H), 3.75 (t, J = 5.9 Hz, 2H, C11H), 3.16 (t, J = 5.9 Hz, 2H, C10H), 0.88 (s, 9H, C17-
19H), 0.05 (s, 6H, C14,15H).
13C NMR (101 MHz, DMSO) δ 137.7, 134.5, 121.6, 116.2, 116.1, 
109.6, 61.9, 46.6, 29.7, 26.2, -2.72, -4.84.  
Preparation of 6-chloro-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-thione (3.21). 
 To a solution of 5-chloro-N1-methylbenzene-1,2-diamine 3.9 (1g, 
6mmol) in EtOH, was added CS2 (10 mL) and Et3N (6g, 0.06 mol). The mixture was stirred 
overnight at rt. The reaction was concentrated to the dryness, and the desired product was 
isolated using column chromatography eluting the desired compound with 50:50 Petroleum 
Ether: Ethyl Acetate. Colourless oil (1g, 83 %).1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 




13C NMR (101 MHz, DMSO-d6) δ 170.1, 134.6, 130.0, 127.2, 123.1, 111.0, 110.1, 
30.7. 
Preparation of 6-chloro-1-methyl-2-(methyl thio)-1H-benzo[d]imidazole (3.22). 
 To a solution of 6-chloro-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-
2-thione 3.21 (1g, 5.0 mmol) in 3:1 MeOH: diethyl ether, a methyl iodide CH3I (0.8g, 6.0 
mmol) and  2 eq of 1N NaOH was added and stirred at rt for 16 h. The reaction was concentrated 
to the dryness, and the desired product was isolated using column chromatography eluting the 
desired compound with 50:50 Petroleum Ether: Ethyl Acetate. Colourless oil (0.6g, 56 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.53 (d, J = 1.8 Hz, 1H, C6H), 7.46 (dd, J = 8.4, 1.8 Hz, 1H, 
C2H), 7.15 (d, J = 8.4 Hz, 1H, C3H), 3.67 (d, J = 3.9 Hz, 3H, C9H), 2.73 (d, J = 3.9 Hz, 3H, 
C13H). 
13C NMR (101 MHz, DMSO-d6) δ 153.0, 143.3, 137.4, 126.4, 121.9, 118.9, 117.9, 30.4, 
14.7. 
Preparation of 6-chloro-1-methyl-2-(methyl sulfonyl)-1H-benzo[d]imidazole (3.24) 
 To a solution of 6-chloro-1-methyl-2-(methyl thio)-1H-
benzo[d]imidazole 3.22 (0.6g, 2.9 mmol) in 1:1 MeOH: H2O, a (5g, 17 mmol) of oxone was 
added and the mixture was stirred at rt for 16 h. The reaction was concentrated to the dryness, 
and the desired product was isolated using column chromatography eluting the desired 
compound with 50:50 Petroleum Ether: Ethyl Acetate. Colourless oil (0.3g, 42 %). 1H NMR 
(400 MHz, DMSO-d6) δ 7.57 (d, J = 1.8 Hz, 1H, C6H), 7.49 (dd, J = 8.4, 1.8 Hz, 1H, C2H), 
7.19 (d, J = 8.4 Hz, 1H, C3H), 4.14 (d, J = 3.9 Hz, 3H, C9H), 2.95 (d, J = 3.9 Hz, 3H, C15H). 
13C NMR (101 MHz, DMSO-d6) δ 155.0, 143.9, 138.0, 127.2, 122.5, 119.7, 118.9, 42.8, 32.6. 
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Preparation of 2-(4-(3-amino-2-hydroxypropoxy) phenyl) acetonitrile (3.10) 
A (1 g) of the previously prepared 2-(4-oxiran-2-ylmethoxy) 
phenyl) acetonitrile 2.29 was stirred in 10 mL of NH3/MeOH at rt for 16 h. The reaction was 
concentrated to the dryness, and the desired product was isolated using column 
chromatography eluting the desired compound with 90:10 Ethyl Acetate: Methanol. White 
solid (0.9g, 80 %). 1H NMR (400 MHz, DMSO-d6) δ 7.26 (d, J = 8.3 Hz, 2H, CHAr), 6.95 (d, 
J = 8.3 Hz, 2H, CHAr), 3.94 (s, 2H, C7H), 3.90 – 3.70 (m, 3H, CHAl), 3.17 – 2.96 (m, 1H, CHAl), 
2.79 – 2.54 (m, 1H, CHAl). 
13C NMR (101 MHz, DMSO-d6) δ 158.6, 129.7, 123.4, 120.0, 
115.4, 70.7, 70.1, 44.8, 21.9.  
Preparation of 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-amine (3.25) 
 To a solution of previously prepared 5-chloro-N1-isopropylbenzene-1,2-
diamine 3.12 (3g, 18mm) was dissolved in 1:1 MeOH: H2O, a (6g, 54mm) of cyanogen 
bromide (CNBr) was added and the mixture was stirred at 30 ºC for 3 h. The reaction was 
concentrated to the dryness, and the desired product was isolated using column 
chromatography eluting the desired compound with 50:50 Petroleum Ether: Ethyl Acetate. 
Brown solid (2.8g, 85 %) 1H NMR (400 MHz, DMSO-d6) δ 7.96 (br s, 2H, NH2), 7.65 (d, J = 
1.9 Hz, 1H, C6H), 7.31 (d, J = 8.5 Hz, 1H, C3H), 7.17 (dd, J = 8.5, 9.1 Hz, 1H, C2H), 4.75 
(hept, J = 6.9 Hz, 1H, C10H), 1.51 (d, J = 6.9 Hz, 6H, C13,14H). 
13C NMR (101 MHz, DMSO-





1-yl)-2-hydroxypropoxy) phenyl) acetonitrile (3.26) 
To a solution of 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-amine 3.25 
(50mg, 0.2mmol) was stirred in MeCN. A (160mg, 0.5 mmol) of Cs2CO3 and (50mg, 0.3 
mmol) of 2-(4-oxiran-2-yl methoxy) phenyl) acetonitrile 2.29 was stirred at 100 °C for 16 h. 
The reaction was concentrated to the dryness, and the desired product was isolated using 
column chromatography eluting the desired compound with 100 % Ethyl acetate. White solid 
(76mg, 80 %) 1H NMR (400 MHz, DMSO-d6) δ 7.78 (s, 1H, C6H), 7.54 (d, J = 8.8 Hz, 1H, 
C2H), 7.30 (dd, J = 12.6, 8.8 Hz, 3H, C3H, CHAr), 7.04 – 6.94 (m, 2H, CHAr), 4.85 (p, J = 6.9 
Hz, 1H, C11H), 4.34 – 4.18 (m, 3H, CHAl), 4.18 – 3.99 (m, 2H, CHAl), 3.96 (s, 2H, C26H), 1.55 
(d, J = 6.9 Hz, 6H, C12,13H). 
13C NMR (101 MHz, DMSO-d6) δ 158.3, 150.5, 130.5, 129.7, 
129.5, 123.7, 123.1, 120.0, 115.46, 111.9, 108.7, 70.0, 67.1, 48.1, 46.5, 22.0, 19.7. LCMS m/z 
calc for C21H23ClN4O2
+ [M+H]+ : 399.2, found 399.1 with tR 2.18 min. Purity of the compound 
was confirmed to be >95 % by LCMS using a long method run. 
Preparation of (S)-2-(4-(oxiran-2-ylmethoxy) phenoxy) acetonitrile (3.109) 
To a stirred solution of 4-hydroxyphenylacetonitrile 2.24 (5g, 
0.036mol) in MeCN (50 mL), was added Cs2CO3 (24g, 0.074mol) then (S)-(+)-glycidyl 3-
nitrobenzenesulfonate (11g, 0.043mol). The reaction mixture was heated at 85 °C for 16h. The 
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mixture was filtered and purified using column chromatography eluting the desired compound 
with 80:20 Petroleum Ether: Ethyl Acetate. White solid (5g, 70 %). 1H NMR (400 MHz, 
DMSO-d6) δ 7.30 – 7.24 (m, 2H, CArH), 7.01 – 6.95 (m, 2H, CArH), 4.33 (dd, J = 11.4, 2.6 Hz, 
1H, CAlH), 3.94 (s, 2H, C8H), 3.88 – 3.74 (m, 1H, CAlH), 3.33 – 3.30 (m, 1H, CAlH), 2.85 (dd, 
J = 5.1, 4.3 Hz, 1H, CAlH), 2.71 (dd, J = 5.0, 2.6 Hz, 1H, CAlH).
13C NMR (101 MHz, DMSO-
d6) δ 158.1, 129.8, 123.8, 119.9, 115.4, 69.4, 50.1, 44.2, 21.9. 
General procedure (3.C) for preparation of (3.30-3.32, 3.110).  
To a solution of 2.29, 2.31-2.32, 3.109 (1 eq) in EtOH (100 mL) was added NaN3 (1.1 eq) and 
NH4Cl (2 eq). The mixture was stirred at rt for 16 h. The reaction was concentrated to the 
dryness and the residue was dissolved in ethyl acetate and washed with water. The organic 
phase was concentrated to afford the desired product as a colourless oil which was used in the 
next step without further purification. 
2-(4-(3-Azido-2-hydroxypropoxy) phenyl) acetonitrile (3.30) 
 The title compound was prepared in the manner similar to the 
general procedure (3.C) by utilizing 2-(4-oxiran-2-ylmethoxy) phenyl) acetonitrile 2.29 as a 
starting material (8g, 0.04 mmol). Colourless oil (9 g, 91 %).1H NMR (400 MHz, DMSO-d6) 
δ 1H NMR (400 MHz, DMSO) δ 7.27 (d, J = 8.2 Hz, 2H, CHAr), 6.97 (d, J = 8.2 Hz, 2H, CHAr), 
5.57 (d, J = 5.1 Hz, 1H, OH), 4.10 – 3.99 (m, 1H, CHAl), 3.93 (s, 4H, C8H, CHAl), 3.46 – 3.30 
(m, 2H, CHAl).
13C NMR (101 MHz, DMSO-d6) δ 158.2, 129.7, 123.7, 119.9, 115.4, 69.8, 68.7, 





2-(4-(3-Azido-2-hydroxypropoxy)-3-fluorophenyl) acetonitrile (3.31) 
The title compound was prepared in the manner similar to the 
general procedure (3.C) by utilizing 2-(3-fluoro-4-(oxiran-2-ylmethoxy) phenyl) acetonitrile 
2.31 as a starting material (0.6g, 2mmol). Colourless oil (0.6g, 83 %). 1H NMR (400 MHz, 
DMSO-d6) δ 7.27 – 7.18 (m, 2H, CHAr), 7.13 (dd, J = 8.8, 2.0 Hz, 1H, CHAr), 5.61 (dd, J = 5.0, 
2.4 Hz, 1H, OH), 4.03 (dt, J = 4.1, 2.0 Hz, 3H, C10,11H), 3.97 (s, 2H, C8H), 3.44 – 3.34 (m, 2H, 
C12H). 
13C NMR (101 MHz, DMSO-d6) δ 151.9 (d, J = 247.2 Hz), 146.1 (d, J = 10.2 Hz), 124.9 
(d, J = 2.7 Hz), 119.5, 116.4 (d, J = 19.7 Hz), 116.0 (d, J = 1.5 Hz), 70.9, 68.6, 53.6, 21.9.  
2-(4-(3-Azido-2-hydroxypropoxy)-2-fluorophenyl) acetonitrile (3.32) 
The title compound was prepared in the manner similar to the 
general procedure (3.C) by utilizing 2-(2-fluoro-4-(oxiran-2-ylmethoxy) phenyl) acetonitrile 
2.32 as a starting material (1.1g, 5mmol). Colourless oil (1g, 75 % yield). 1H NMR (400 MHz, 
DMSO-d6) δ 7.36 (t, J = 8.8 Hz, 1H, CHAr), 6.99 – 6.79 (m, 2H, CHAr), 5.58 (d, J = 5.1 Hz, 
1H, OH), 4.09 – 3.98 (m, 1H, CHAl), 3.95 (s, 4H, C8H, CHAl), 3.46 – 3.35 (m, 2H, CHAl).
13C 
NMR (101 MHz, DMSO-d6) δ 161.13 (d, J = 208.5 Hz), 159.88 (d, J = 26.1 Hz), 131.32 (d, J 
= 4.9 Hz), 118.82, 111.72 (d, J = 3.1 Hz), 110.61 (d, J = 15.5 Hz), 102.84 (d, J = 24.3 Hz), 






 (S)-2-(4-(3-azido-2-hydroxypropoxy) phenyl) acetonitrile (3.110) 
The title compound was prepared in the manner similar to the 
general procedure (3.C) by utilizing (S)-2-(4-(oxiran-2-ylmethoxy) phenoxy) acetonitrile 3.109 
as a starting material (5g, 26mmol). Colourless oil (6g, 81 % yield). 1H NMR (400 MHz, 
DMSO-d6) δ 7.31 – 7.22 (m, 2H, CHAr), 7.01 – 6.93 (m, 2H, CHAr), 5.56 (d, J = 5.2 Hz, 1H, 
OH), 4.01 (m, 1H, CHAl), 3.93 (d, J = 6.9 Hz, 4H, C8H, CHAl), 3.44 – 3.37 (m, 1H, CHAl), 3.27 
(d, J = 5.2 Hz, 1H, CHAl). 
13C NMR (101 MHz, DMSO) δ 158.2, 129.7, 123.7, 120.0, 115.4, 
69.8, 68.7, 53.7, 22.0. 
General procedure (3.D) for preparation of (3.33-3.35, 3.111 step1) 
To a solution of TBDMSCl (1.3 eq) in DMF (100 mL) was added imidazole (2.5 eq). The 
mixture was stirred for 1 hour at rt. Then the compound 3.30-3.32, 3.110 (1 eq) was added to 
the reaction and stirred for 16h. The reaction was concentrated to the dryness and the desired 
product was isolated using column chromatography eluting the desired compound with 80:20 
Petroleum Ether: Ethyl Acetate.  
2-(4-(3-Azido-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) acetonitrile (3.33 step1) 
The title compound was prepared in the manner similar to the 
general procedure (3.D) by utilizing 2-(4-(3-azido-2-hydroxypropoxy) phenyl) acetonitrile 
3.30 (9g, 38 mmol). colourless oil (11g, 82 %). 1H NMR (400 MHz, DMSO-d6) δ 7.27 (d, J = 
8.6 Hz 2H, CHAr), 6.93 (d, J = 8.6 Hz, 2H, CHAr), 4.08 (m, 1H, CHAl), 3.95 (s, 2H, C8H), 3.91 
(m, 1H, CHAl), 3.54 (dd, J = 12.9, 3.6 Hz, 1H, CHAl), 3.33 (dd, J = 12.9, 5.5 Hz, 2H, CHAl), 
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0.89 (s, 9H, C19-21H), 0.13 (d, J = 13.8 Hz, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 
158.1, 129.8, 123.8, 119.9, 115.2, 70.8, 69.8, 54.0, 26.0, 22.0, 18.2, -4.2.  
2-(4-(3-Azido-2-((tert-butyl dimethyl silyl) oxy) propoxy)-3-fluorophenyl) acetonitrile 
(3.34 step1) 
The title compound was prepared in the manner similar to the 
general procedure (3.D) by utilizing 2-(4-(3-azido-2-hydroxypropoxy)-3-fluorophenyl) 
acetonitrile 3.31 (1g,4 mmol) as the starting material. Colourless oil (0.9 g, 62 % yield). 1H 
NMR (400 MHz, DMSO-d6) δ 7.26 – 7.18 (m, 2H, CHAr), 7.12 (ddd, J = 8.3, 2.2, 1.0 Hz, 1H, 
CHAr), 4.29 – 4.19 (m, 1H, CHAl), 4.10 – 3.99 (m, 2H, CHAl), 3.97 (s, 2H, C8H), 3.55 (dd, J = 
12.8, 3.6 Hz, 1H, CHAl), 3.33 (m, 1H, CH), 0.87 (d, J = 4.7 Hz, 9H, C19-21H), 0.11 (dd, J = 
18.7, 6.1 Hz, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 151.8 (d, J = 245.3 Hz), 146.0 
(d, J = 11.2 Hz), 124.9 (d, J = 4.9 Hz), 119.5, 116.4 (d, J = 18.6 Hz), 115.6 (d, J = 1.8 Hz), 
71.0, 70.7, 54.0, 26.0, 21.9, 18.1, -4.4. 
2-(4-(3-Azido-2-((tert-butyl dimethyl silyl) oxy) propoxy) -2-fluorophenyl) acetonitrile 
(3.35 step1) 
The title compound was prepared in the manner similar to the 
general procedure (3.D) by utilizing 2-(4-(3-azido-2-hydroxypropoxy)-2-fluorophenyl) 
acetonitrile 3.32 (1g, 4 mmol) as the starting material. Colourless oil (0.8 g, 54 %). 1H NMR 
(400 MHz, DMSO-d6) δ 7.37 (t, J = 8.8 Hz, 1H, CHAr), 6.95 – 6.79 (m, 2H, CHAr), 4.20 (ddt, 
J = 7.9, 5.7, 2.7 Hz, 1H, CHAl), 4.03 (dd, J = 10.0, 4.4 Hz, 1H, CHAl), 3.96 (d, J = 8.0 Hz, 3H, 
C8H, CHAl), 3.53 (dd, J = 12.9, 3.6 Hz, 1H, CHAl), 3.43 – 3.23 (m, 1H, CHAl), 0.88 (s, 9H, C19-
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21H), 0.12 (d, J = 14.0 Hz, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 162.2 (d, J = 230.6 
Hz), 159.9 (d, J = 4.6 Hz), 131.3 (d, J = 5.3 Hz), 118.7, 111.6 (d, J = 3.2 Hz), 110.8 (d, J = 
17.7 Hz), 102.6 (d, J = 24.8 Hz), 70.6, 70.4, 54.0, 26.0, 18.2, 16.6, -4.2. 
 (S)-2-(4-(3-azido-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) acetonitrile (3.111 
step1) 
The title compound was prepared in the manner similar to the 
general procedure (3.D) by utilizing (S)-2-(4-(3-azido-2-hydroxypropoxy) phenyl) acetonitrile 
3.110 (5g, 25mmol) as the starting material. Colourless oil (5.2g, 70 %). 1H NMR (400 MHz, 
DMSO-d6) δ 7.30 – 7.25 (m, 2H, CHAr), 6.99 – 6.92 (m, 2H, CHAr), 4.26 – 4.14 (m, 1H, CHAl), 
4.10 – 3.96 (m, 1H, CHAl), 3.94 (s, 3H, C8H, CHAl), 3.54 (dd, J = 12.8, 3.6 Hz, 1H, CHAl), 0.89 
(s, 9H, C19-21H), 0.13 (d, J = 13.6 Hz, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 158.1, 
129.8, 123.8, 119.8, 115.2, 70.8, 69.8, 54.1, 26.0, 22.0, 18.2, -4.2. 
General procedure (3.E) for preparation of (3.33-3.35, 3.111 step2) 
To a solution of 3.33-3.35, 3.111 step1 (1 equiv) in THF (20 mL) was added Ph3P (1.5 equiv) 
and stirred at rt for 2 hours. Then 20 % water was added and stirred the reaction at rt for 16 h. 
The reaction was concentrated to the dryness and the desired product was isolated using column 
chromatography eluting the desired compound with 100 % Ethyl Acetate. 
2-(4-(3-Amino-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) acetonitrile (3.33 step2) 
 The title compound was prepared in the manner similar to the 
general procedure (3.E) by utilizing 2-(4-(3-azido-2-((tert-butyl dimethyl silyl) oxy) propoxy) 
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phenyl) acetonitrile 3.33 step1 (11g, 31mmol) as the starting material. Colourless oil (7g, 70 
%). 1H NMR (400 MHz, DMSO) δ 7.26 (d, J = 8.5 Hz, 2H, CHAr), 6.96 – 6.90 (d, J = 8.5 Hz, 
2H, CHAr), 4.07 (dd, J = 9.8, 3.3 Hz, 1H, CHAl), 3.96 – 3.87 (m, 3H, C8H, CHAl), 3.82 (dd, J = 
9.8, 7.1 Hz, 1H, CHAl), 2.71 – 2.58 (m, 2H, CHAl), 0.87 (s, 9H, C19-21H), 0.08 (d, J = 12.9 Hz, 
6H, C16,17H). 
13C NMR (101 MHz, DMSO) δ 158.5, 129.7, 123.4, 120.0, 115.2, 73.3, 70.9, 
45.6, 26.2, 21.9, 18.3, -3.9, -4.2. 
2-(4-(3-Amino-2-((tert-butyl dimethyl silyl) oxy) propoxy)-3-fluorophenyl) acetonitrile 
(3.34 step2) 
The title compound was prepared in the manner similar to the 
general procedure (3.E) by utilizing 2-(4-(3-azido-2-((tert-butyl dimethyl silyl) oxy) propoxy)-
3-fluorophenyl) acetonitrile 3.34 step1 (0.9g, 2 mmol) as the starting material. Colourless oil 
(0.4g, 47 %). 1H NMR (400 MHz, DMSO-d6) δ 7.26 – 7.09 (m, 3H, CHAr), 4.14 (td, J = 9.2, 
3.0 Hz, 1H, CHAl), 4.03 – 3.86 (m, 4H, C8H, CHAl), 2.67 (dd, J = 5.3, 2.6 Hz, 2H, CHAl), 0.92 
– 0.77 (m, 9H, C19-21H), 0.14 – -0.02 (m, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 151.8 
(d, J = 243.4 Hz), 146.4 (d, J = 10.6 Hz), 124.8 (d, J = 3.6 Hz), 124.2 (d, J = 6.7 Hz) 119.5, 
116.3 (d, J = 23.2 Hz), 115.3 (d, J = 1.8 Hz), 73.1, 71.9, 45.4, 26.1, 21.8, 18.2, -4.3. 
2-(4-(3-Amino-2-((tert-butyl dimethyl silyl) oxy) propoxy)-2-fluorophenyl) acetonitrile 
(3.35 step2) 
The title compound was prepared in the manner similar to the 
general procedure (3.E) by utilizing 2-(4-(3-azido-2-((tert-butyl dimethyl silyl) oxy) propoxy) 
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-2-fluorophenyl) acetonitrile 3.35 step1 (0.8g, 2 mmol) as the starting material. Colourless oil 
(0.6g, 71 % yield). 1H NMR (400 MHz, DMSO-d6) δ 7.36 (td, J = 8.8, 6.2 Hz, 1H, CHAr), 6.94 
– 6.77 (m, 2H, CHAr), 4.09 (td, J = 10.4, 9.9, 3.4 Hz, 2H, CHAl), 4.02 – 3.90 (m, 3H, C8H, 
CHAl), 3.90 – 3.79 (m, 1H, CHAl), 2.69 – 2.59 (m, 2H, CHAl), 0.90 – 0.83 (m, 9H, C19-21H), 
0.08 (d, J = 13.3 Hz, 6H, C16,17H).
13C NMR (101 MHz, DMSO-d6) δ 162.2 (d, J = 230.6 Hz), 
159.9 (d, J = 4.6 Hz), 131.3 (d, J = 5.3 Hz), 118.7, 111.6 (d, J = 3.2 Hz), 110.8 (d, J = 17.7 
Hz), 102.6 (d, J = 24.8 Hz), 70.6, 70.4, 54.0, 26.0, 18.2, 16.6, -4.2, -4.5.  
 (S)-2-(4-(3-Amino-2-((tert-butyldimethylsilyl) oxy) propoxy) phenyl) acetonitrile (3.111 
step2) 
The title compound was prepared in the manner similar to the 
general procedure (3.E) by utilizing (S)-2-(4-(3-azido-2-((tert-butyl dimethyl silyl) oxy) 
propoxy) phenyl) acetonitrile 3.111 step1 (5.2g, 16mmol) as the starting material. Colourless 
oil (3g, 65 %). 1H NMR (400 MHz, DMSO-d6) δ 7.29 – 7.21 (m, 2H, CHAr), 6.97 – 6.88 (m, 
2H, CHAr), 4.07 – 4.04 (m, 1H, CHAl), 3.93 (s, 3H, C8H, CHAl), 3.88 – 3.77 (m, 1H, CHAl), 
2.73 – 2.60 (m, 2H, CHAl), 0.91 – 0.80 (m, 9 H, C19-21H), 0.08 (dd, J = 13.0, 2.8 Hz, 6H, 
C16,17H).
13C NMR (101 MHz, DMSO-d6) δ 158.5, 129.7, 123.4, 119.9, 115.1, 73.3, 70.9, 49.0, 
26.2, 21.9, 18.3, -4.0, -4.2. 
General procedure (3.F) for preparation of (3.36-3.38).  
To a solution of 3.33-3.35, 3.111 step2 (1 eq) in DCM was added 1,1'-
thiocarbonyldiimidazole (TCDI) (3 eq) and stirred for 16h at rt. The reaction was concentrated 
to the dryness and the desired product was isolated using column chromatography eluting the 
desired compound with 80:20 Petroleum Ether: Ethyl Acetate.  
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2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) acetonitrile 
(3.36) 
 The title compound was prepared in the manner similar to the general 
procedure (3.F) by utilizing 2-(4-(3-amino-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) 
acetonitrile 3.33 step2 (1g, 3 mmol) as starting material. Brown oil (0.7g, 63 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.33 – 7.21 (m, 2H, CHAr), 7.04 – 6.92 (m, 2H, CHAr), 4.29 (qd, J = 5.8, 
4.0 Hz, 1H, CHAl), 3.98 (dd, J = 10.0, 4.0 Hz, 1H, CHAl), 3.95 – 3.88 (m, 4H, C8H, CHAl), 3.78 
(dd, J = 15.1, 5.8 Hz, 1H, CHAl), 0.89 (s, 9H, C19-21H), 0.13 (d, J = 15.1 Hz, 6H, C16,17H). 
13C 
NMR (101 MHz, DMSO-d6) δ 158.0, 129.8, 129.5, 123.9, 119.9, 115.3, 69.7, 69.6, 48.8, 26.1, 
21.9, 18.1, -4.1, -4.4.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) -3-fluorophenyl) 
acetonitrile (3.37) 
 The title compound was prepared in the manner similar to the general 
procedure (3.F) by utilizing 2-(4-(3-amino-2-((tert-butyl dimethyl silyl) oxy) propoxy)-3-
fluorophenyl) acetonitrile 3.34 step2 (0.4g, 1.1mmol) as starting material. Colourless oil (0.2g, 
44 %). 1H NMR (400 MHz, DMSO-d6) δ 7.29 – 7.19 (m, 2H, CHAr), 7.13 (ddd, J = 8.4, 2.1, 
0.9 Hz, 1H, CHAr), 4.32 (tt, J = 6.1, 4.1 Hz, 1H, CHAl), 4.15 – 4.01 (m, 2H, CHAl), 3.93 (dd, J 
= 14.8, 3.8 Hz, 1H, CHAl), 3.77 (dd, J = 14.7, 5.7 Hz, 1H, CHAl), 0.88 (s, 9H, C19-21H), 0.17 – 
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0.07 (m, 6H, C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 151.8 (d, J = 246.3 Hz), 145.9 (d, J 
= 11.5 Hz), 129.7, 125.0 (d, J = 3.7 Hz) 124.9 (d, J = 6.8 Hz), 119.5, 116.4 (d, J = 18.1 Hz), 
115.8 (d, J = 1.5 Hz), 70.8, 69.5, 48.7, 26.0, 21.9, 18.1, -4.5.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy)-2-fluorophenyl) 
acetonitrile (3.38) 
The title compound was prepared in similar manner to the general 
procedure (3.F) by utilizing 2-(4-(3-amino-2-((tert-butyl dimethyl silyl) oxy) propoxy)-2-
fluorophenyl) acetonitrile 3.35 step (0.6g, 2 mmol) as the starting material. Colourless oil 
(0.4g, 45 %). 1H NMR (400 MHz, DMSO-d6) δ 7.37 (m, 1H, CHAr), 6.93 (m, 1H, CHAr), 6.84 
(m, 1H, CHAr), 4.34 – 4.19 (m, 1H, CHAl), 4.12 – 4.00 (m, 1H, CHAl), 4.00 – 3.89 (m, 3H, C8H, 
CHAl), 3.83 – 3.66 (m, 2H, CHAl), 0.88 (d, J = 4.7 Hz, 9H, C19-21H), 0.17 – 0.05 (m, 6H, 
C16,17H). 
13C NMR (101 MHz, DMSO-d6) δ 161.0 (d, J = 228.5 Hz), 159.7 (d, J = 6.6 Hz), 
131.4 (d, J = 5.3 Hz), 129.6, 118.7, 111.6 (d, J = 4.6 Hz), 110.7 (d, J = 17.2 Hz), 102.9 (d, J = 
23.9 Hz), 70.4, 69.4, 48.7, 47.0, 26.1, 18.2, -4.1, -4.3.  
 (S)-2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) acetonitrile 
(3.112) 
 The title compound was prepared in similar manner to the general 
procedure (3.F) by utilizing (S)-2-(4-(3-amino-2-((tert-butyldimethylsilyl) oxy) propoxy) 
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phenyl) acetonitrile 3.111 step2 step2 (0.4g, 1 mmol) as the starting material. Colourless oil 
(0.3g, 57 %). 
General procedure (3.G) for preparation of (3.70-3.86, 3.111).  
To a solution of (1 eq) of the corresponding chloro-N1-(alkyl) benzene-1, 2-diamine (3.12, 
3.56- 3.69, 3.110) in EtOH (20 mL) was added (1 eq) of the corresponding isothiocynate (3.36-
3.38, 3.112) and stirred for 16h at 70 °C. The reaction was concentrated and then dissolved in 
DMF (20 mL). DIC (1.2 eq) and Et3N (2 eq) were added to the mixture and stirred for 16h at 
80 °C. The reaction was concentrated to the dryness and the desired product was isolated using 
column chromatography eluting the desired compound with 50:50 Petroleum Ether: Ethyl 
Acetate for most of the compounds.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy) – 3 - ((5-chloro-1-methyl-1H-benzo[d]imidazol-2-
yl) amino) propoxy) phenyl) acetonitrile (3.70) 
The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 4-chloro-N1-methylbenzene-1,2-diamine 3.56 (0.2g, 
1mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.4g, 1mmol) as starting materials. Brown oil (0.1g, 20 %) 1H NMR (400 
MHz, DMSO-d6) δ 7.30 – 7.23 (m, 2H, CHAr), 6.96 – 6.80 (m, 4H, CHAr), 6.55 (ddd, J = 15.4, 
8.3, 2.4 Hz, 1H, CHAr), 4.26 (s, 1H, CHAl), 3.94 (s, 3H, C22H, CHAl), 3.85 – 3.69 (m, 2H, CHAl), 
3.37 (d, J = 8.8 Hz, 4H, C31H, CHAl), 0.89 – 0.69 (m, 9H, C28-29H), 0.06 (d, J = 2.7 Hz, 6H, 
C25,26H). 
13C NMR (101 MHz, DMSO-d6) δ 158.5, 155.0, 133.3, 129.7, 128.5, 126.8, 126.0, 
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123.5, 120.0, 115.4, 113.7, 109.7, 70.6, 68.1, 46.4, 30.9, 29.2, 26.2, 21.9, -4.1. LCMS m/z calc 
for C25H33ClN4O2Si
+ [M+H]+ : 485.2, found 485.1 with tR 2.56 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy) -3 - ((5, 6-dichloro-1-methyl-1H-benzo[d]imidazol-
2-yl) amino) propoxy) phenyl) acetonitrile (3.71) 
The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 4, 5-dichloro-N1-methylbenzene-1, 2-diamine 3.57 (0.2g, 
0.8mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.3g, 0.8mmol) as a starting material. Brown oil (0.1g, 20 %).1H NMR (400 
MHz, DMSO-d6) δ 7.46 (s, 1H, CHAr), 7.35 (s, 1H, CHAr), 7.29 – 7.24 (m, 2H, CHAr), 7.14 (t, 
J = 5.7 Hz, 1H, CHAr), 6.96 – 6.91 (m, 2H, CHAr), 4.39 (qd, J = 6.5, 3.0 Hz, 1H, CHAl), 4.09 
(dd, J = 10.1, 3.0 Hz, 1H, CHAl), 3.98 – 3.86 (m, 3H, CHAl), 3.58 – 3.41 (m, 5H, CHAl), 0.83 
(s, 9H, C28-30H), 0.02 (d, J = 8.4 Hz, 6H, C25,26H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 
157.0, 143.1, 135.7, 129.8, 123.5, 122.7, 120.4, 119.9, 116.0, 115.2, 109.2, 71.2, 69.9, 46.0, 
29.0, 26.1, 21.9, 18.3, -4.1. LCMS m/z calc for C25H32Cl2N4O2Si
+ [M+H]+ : 519.1, found 518.7 
with tR 2.91 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol -2-
yl) amino) propoxy) phenyl) acetonitrile (3.72) 
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The title compound was prepared in the manner similar to 
the general procedure (3.G) by utilizing 5-chloro-N1-isopropylbenzene-1,2-diamine 3.12 (0.3g, 
2mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.7g, 2mmol) as starting materials. Brown oil (0.3g, 33 %).1H NMR (400 
MHz, DMSO-d6) δ 7.37 (d, J = 2.0 Hz, 1H, C6H), 7.26 (dd, J = 8.6, 2.0 Hz, 2H, C2H, CHAr), 
7.17 (d, J = 8.6 Hz, 1H, C3H), 6.97 – 6.91 (m, 3H, CHAr), 6.82 (t, J = 5.6 Hz, 1H, NH), 4.61 
(h, J = 6.9 Hz, 1H, C32H), 4.41 (qd, J = 6.9, 3.0 Hz, 1H, CHAl), 4.09 (dd, J = 10.3, 3.0 Hz, 1H, 
CHAl) 3.93 (s, 2H, C23H), 3.92 – 3.86 (m, 1H, CHAl), 3.57 – 3.39 (m, 2H, CHAl), 1.48 (dd, J = 
6.9, 1.7 Hz, 6H, C33,34H), 0.85 (s, 9H, C29-31H), 0.04 (s, 6H, C26,27H). LCMS m/z calc for 
C27H37ClN4O2Si
+ [M+H]+ : 513.2, found 513.2 with tR 2.64 min. 
2-(4-(3-((1-(tert-Butyl)-6-chloro-1H-benzo[d]imidazol-2-yl)amino)-2-((tert-butyl dimethyl 
silyl) oxy) propoxy) phenyl) acetonitrile (3.73)  
The title compound was prepared in the manner similar to 
the general procedure (3.G) by utilizing N1-(tert-butyl)-5-chlorobenzene-1,2-diamine 3.58 
(0.16g, 0.8mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) 
phenyl) acetonitrile 3.36 (0.3g, 0.8mmol) as starting materials. Brown oil (0.12g, 30 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.49 (d, J = 2.0 Hz, 1H, C6H), 7.25 (dd, J = 8.6, 2.0 Hz, 2H, 
C2H, CHAr), 7.16 (d, J = 8.6 Hz, 1H, C3H), 7.01 – 6.88 (m, 3H, CHAr), 6.05 (t, J = 5.4 Hz, 1H 
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NH), 4.46 (qd, J = 6.7, 3.0 Hz, 1H, CHAl), 4.10 (dd, J = 10.3, 3.0 Hz, 1H, CHAl), 3.96 – 3.89 
(m, 3H, C23H, CHAl), 3.61 – 3.45 (m, 2H, CHAl), 1.75 (s, 9H, C33-35H), 0.87 (s, 9H, C29-31H), 
0.08 (d, J = 5.1 Hz, 6H, C26,27H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 156.1, 141.6, 135.3, 
129.8,  123.5, 122.7, 120.5, 119.9, 116.6, 115.1, 112.5, 71.6, 69.7, 58.2, 47.2, 41.2, 30.0, 26.2, 
21.9, -4.1. LCMS m/z calc for C28H39ClN4O2Si
+ [M+H]+ : 527.2, found 527.0 with tR 2.83 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-neopentyl-1H-benzo[d]imidazol-2-
yl) amino) propoxy) phenyl) acetonitrile (3.74) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-neopentylbenzene-1,2-diamine 3.59 (0.17g, 
0.8mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.3g, 0.8mmol) as a starting material. Brown oil (0.10g, 21 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.32 – 7.22 (m, 3H, CHAr), 7.14 (d, J = 8.3 Hz, 1H, CHAr), 6.97 – 6.86 (m, 
3H, CHAr), 6.70 (s, 1H, NH), 4.40 (dq, J = 7.6, 3.6, 2.5 Hz, 1H, CHAl), 4.10 (dd, J = 10.4, 2.8 
Hz, 1H, CHAl), 3.95 – 3.87 (m, 3H, CHAl), 3.82 (s, 2H, C32H), 3.55 – 3.46 (m, 2H, CHAl), 0.95 
(s, 9H, C34-36H), 0.85 (s, 9H, C29-31H), 0.08 (d, J = 4.8 Hz, 6H, C26,27H). 
13C NMR (101 MHz, 
DMSO-d6) δ 158.4, 156.4, 141.6, 137.1, 129.8, 123.5, 122.8, 120.5, 119.9, 116.0, 115.1, 109.3, 
71.3, 70.0, 52.2, 46.2, 28.2, 26.2, 24.5, 21.9, 18.3, -4.1. LCMS m/z calc for C29H41ClN4O2Si
+ 
[M+H]+ : 541.2, found 540.7 with tR 2.86 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclopropyl-1H-benzo[d]imidazol-
2-yl) amino) propoxy) phenyl) acetonitrile (3.75) 
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The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 5-chloro-N1-cyclopropylbenzene-1,2-diamine 3.60 (0.15g, 
0.8mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.3g, 0.8mmol) as starting materials. Brown oil (0.08g, 18 %).  1H NMR (400 
MHz, DMSO-d6) δ 7.29 – 7.24 (m, 2H, CHAr), 7.21 – 7.13 (m, 2H, CHAr), 6.94 (m, 3H, CHAr), 
6.57 (t, J = 5.9 Hz, 1H, NH), 4.42 (m, 1H, CHAl), 4.11 (dd, J = 10.2, 3.0 Hz, 1H, CHAl), 3.96 
– 3.87 (m, 3H, C22H, CHAl), 3.51 (t, J = 6.0 Hz, 2H, CHAl), 2.98 (tt, J = 7.1, 3.7 Hz, 1H, C24H), 
1.48 – 1.36 (m, 2H, C33 or 34H), 1.36 – 1.23 (m, 2H, C33 or 34H), 0.87 – 0.84 (m, 9H, C30-32H), 
0.07 (s, 6H, C26,27H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 156.6, 141.7, 136.5, 129.8, 
123.5, 122.9, 120.7, 119.9, 116.4, 115.2, 108.5, 71.3, 69.9, 46.2, 26.2, 22.9, 21.9, 18.3, 8.3, -
4.2. LCMS m/z calc for C27H35ClN4O2Si [M+H]
+ : 511.2, found  511.0 with 2.65 tR  min. 
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclobutyl-1H-benzo[d]imidazol-2-
yl) amino) propoxy) phenyl) acetonitrile (3.76) 
 The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 5-chloro-N1-cyclobutylbenzene-1,2-diamine 3.61 (0.2g, 
1mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
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acetonitrile 3.36 (0.4g, 1mmol) as starting materials. Brown oil (0.13g, 23 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.47 (d, J = 2.0 Hz, 1H, C6H), 7.29 – 7.16 (m, 3H, CHAr), 7.00 – 6.91 (m, 
3H, CHAr), 6.76 (t, J = 5.7 Hz, 1H NH), 4.89 (m, 1H, CHAl), 4.40 (m, 2.9 Hz, 1H, CHAl), 4.12 
– 3.99 (m, 2H, C23H), 3.99 – 3.86 (m, 3H, CHAl), 2.84 – 2.69 (m, 2H, C33, 34 or 35H), 2.41 – 2.29 
(m, 2H, C33, 34 or 35H), 1.99 (d, J = 2.1 Hz, 1H, C32H), 1.98 – 1.71 (m, 2H, C33, 34 or 35H), 0.84 (s, 
9H, C29-31H). 0.02 (d, J = 4.4 Hz, 6H, C26,27H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 155.3, 
142.4, 134.8, 129.7, 123.5, 122.8, 120.7, 119.9, 116.6, 115.2, 109.6, 71.3, 69.8, 47.7, 46.3, 
28.3, 26.1, 24.5, 21.9, 18.3, -4.2. LCMS m/z calc for C28H37ClN4O2Si
+ [M+H]+ : 525.2, found 
524.6 with tR 2.79 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclopentyl-1H-benzo[d]imidazol-
2-yl) amino) propoxy) phenyl) acetonitrile (3.77) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-cyclopentylbenzene-1,2-diamine 3.62 (0.20g, 0.9 
mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.35g, 0.9mmo) as starting materials. Brown oil (0.12g, 25 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.29 – 7.24 (m, 2H, CHAr), 7.20 – 7.16 (m, 2H, CHAr), 6.99 – 6.92 (m, 3H, 
CHAr), 6.88 (t, J = 5.7 Hz, 1H, NH), 4.75 (m, 1H, CHAl), 4.41 (m, 1H, CHAl), 4.09 (dd, J = 
10.3, 3.0 Hz, 1H, CHAl), 3.94 (s, 3H, C23H, CHAl), 3.57 – 3.39 (m, 2H, CHAl), 2.07 – 1.86 (m, 
J = 7.9, 6.9 Hz, 6H, CHAl), 1.74 – 1.60 (m, 2H, CHAl), 0.84 (s, 9H, C29-31H), 0.02 (d, J = 1.3 
Hz, 6H, C26,27H). 
13C NMR (101 MHz, DMSO-d6) δ 158.4, 155.6, 142.5, 133.6, 129.8, 123.5, 
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122.6, 120.5, 120.0, 116.6, 115.2, 109.3, 71.3, 69.8, 46.4, 41.2, 28.9, 26.2, 24.7, 21.9, 18.3, -
4.1. LCMS m/z calc for C29H39ClN4O2Si
+ [M+H]+ : 539.2, found 540.1 with tR 2.75 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclo hexyl-1H-benzo[d] imidazol-
2-yl) amino) propoxy) phenyl) acetonitrile (3.78) 
The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 5-chloro-N1-cyclohexylbenzene-1, 2-diamine 3.63 (0.17g, 
0.7mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.28g, 0.7mmol) as starting materials. Brown oil (0.09g, 22 %). 1H NMR 
(400 MHz, DMSO-d6) δ 7.41 (d, J = 2.0 Hz, 1H, C6H), 7.26 (d, J = 8.6 Hz, 2H, C2H, CHAr), 
7.17 (d, J = 8.6 Hz, 1H, C3H), 6.99 – 6.92 (m, 3H, CHAr), 6.88 (s, 1H, NH), 4.44 – 4.37 (m, 
1H, CHAl), 4.19 (m, 1H, CHAl), 4.09 (dd, J = 10.3, 3.1 Hz, 1H, CHAl), 3.93 (s, 2H C23H), 3.54 
(m, 1H, CHAl), 3.43 (m, 1H, CHAl), 2.16 – 2.02 (m, 2H, CHAl), 1.77 – 1.61 (m, 3H, CHAl), 1.47 
– 1.36 (m, 3H, CHAl), 1.17 – 1.08 (m, 3H, CHAl), 0.85 (s, 9H, C29-31H), 0.04 (s, 6H, C26,27H) 
.13C NMR (101 MHz, DMSO-d6) δ 158.4, 155.1, 142.2, 134.3, 129.8, 123.5, 122.7, 120.4, 
119.9, 116.4, 115.2, 110.1, 71.3, 69.9, 46.5, 42.8, 30.3, 26.2, 24.8, 22.1, 20.8, 18.3, -4.1. LCMS 
m/z calc for C30H41ClN4O2Si
+ [M+H]+ : 553.2, found 553.2 with tR 2.84 min.  
2-(4-(3-((1-(2-(Benzyloxy) ethyl)-6-chloro-1H-benzo[d]imidazol-2-yl) amino)-2-((tert-
butyl dimethyl silyl) oxy) propoxy) phenyl) acetonitrile (3.79) 
220 
 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing N1-(2-(benzyloxy) ethyl)-5-chlorobenzene-1,2-diamine 3.64 
(0.46g, 1.6mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) 
phenyl) acetonitrile 3.36 (0.60g, 1.6mmol) as starting materials. Brown oil (0.31g, 33 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.31 (d, J = 2.1 Hz, 1H, CHAr), 7.28 – 7.21 (m, 5H, CHAr), 7.18 
– 7.12 (m, 3H, CHAr), 6.95 (dd, J = 8.3, 2.1 Hz, 1H, CHAr), 6.93 – 6.87 (m, 2H, CHAr), 6.83 (t, 
J = 5.7 Hz, 1H, NH), 4.44 (s, 2H, C35H), 4.22 (q, J = 4.6 Hz, 3H, CHAl), 4.11 – 3.99 (m, 3H, 
CHAl), 3.93 (s, 2H, C23H), 3.88 (dd, J = 10.2, 6.9 Hz, 1H, CHAl), 3.68 (t, J = 5.2 Hz, 2H, CHAl), 
3.47 (t, J = 6.2 Hz, 2H, CHAl), 0.85 (s, 9H, C29-31H), 0.06 (d, J = 1.8 Hz, 6H, C26,27H). LCMS 
m/z calc for C33H41ClN4O3
+ [M+H]+ : 605.3, found 604.5 with tR 2.72 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-
yl) amino) propoxy)-3-fluorophenyl) acetonitrile (3.80) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-isopropylbenzene-1,2-diamine 3.12 (0.1g, 0.5 mmol) 
and 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) -3-fluorophenyl) 
acetonitrile 3.37 (0.2g, 0.5 mmol) as starting materials. Brown oil (0.13g, 45 %). 1H NMR (400 
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MHz, DMSO-d6) δ 7.38 (d, J = 1.9 Hz, 1H, C6H), 7.23 (dd, J = 12.0, 2.1 Hz, 1H, CHAr), 7.17 
(dt, J = 8.5, 4.3 Hz, 2H, CHAr), 7.11 (dd, J = 8.6, 2.1 Hz, 1H, CHAr), 6.95 (dd, J = 8.4, 2.0 Hz, 
1H, CHAr), 6.83 (t, J = 5.6 Hz, 1H, NH), 4.61 (p, J = 6.9 Hz, 1H, C24H), 4.44 (qd, J = 6.5, 2.6 
Hz, 1H, CHAl), 4.16 (dd, J = 10.3, 2.9 Hz, 1H, CHAl), 4.10 – 3.99 (m, 1H, CHAl), 3.96 (s, 2H, 
C22H), 3.58 – 3.40 (m, 2H, CHAl), 1.48 (dd, J = 6.9, 1.6 Hz, 6H, C26,27H), 0.84 (s, 9H, C29,30H), 
0.03 (d, J = 6.0 Hz, 6H, C32-34H).
13C NMR (101 MHz, DMSO-d6) δ 155.0, 151.9 (d, J = 241.1 
Hz), 146.4 (d, J = 10.5 Hz), 142.4, 134.1, 124.8 (d, J = 3.8 Hz), 124.4 (d, J = 6.8 Hz), 122.6, 
120.4, 119.5, 116.5 (d, J = 6.5 Hz), 115.4, 109.7, 72.3, 69.8, 46.3, 45.7, 26.1, 21.8, 20.6, 18.3, 
-4.4. LCMS m/z calc for C27H36ClFN4O2Si
+ [M+H]+ : 531,2, found 531.0 with tR 2.66 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-
yl) amino) propoxy) -2-fluorophenyl) acetonitrile (3.81) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-isopropylbenzene-1,2-diamine 3.12 (0.15g, 0.8 
mmol) and 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy)-2-fluorophenyl) 
acetonitrile 3.38 (0.30g, 0.8 mmol) as starting materials. Brown oil (0.16g, 37 %). 1H NMR 
(400 MHz, DMSO-d6) δ 7.40 – 7.31 (m, 2H, CHAr), 6.95 (dd, J = 8.5, 1.9 Hz, 1H, CHAr), 6.93 
– 6.77 (m, 3H, CHAr), 4.65 – 4.56 (m, 2H, CHAl), 4.45 – 4.37 (m, 1H, CHAl), 3.95 (s, 3H, C22H, 
CHAl), 3.55 – 3.39 (m, 2H, CHAl), 1.53 – 1.45 (m, 6H, C26,27H), 0.86 (d, J = 10.2 Hz, 9H, 
C32,34H), 0.03 (d, J = 1.9 Hz, 6H, C29,30H), 
13C NMR (101 MHz, DMSO-d6) δ 160.9 (d, J = 
244.8 Hz), 160.4 (d, J = 10.9 Hz), 155.4, 142.0, 134.1, 131.3 (d, J = 5.3 Hz), 122.8, 120.4, 
118.8, 116.3, 111.7 (d, J = 3.1 Hz), 110.4 (d, J = 16.2 Hz), 109.8, 102.8 (d, J = 24.9 Hz), 71.4, 
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68.1, 46.5, 45.8, 26.1, 20.6, 18.2, 16.6, -4.3. LCMS m/z calc for C27H36ClFN4O2Si
+ [M+H]+ : 
531,2, found 531.0 with tR 2.67 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(2-(dimethyl amino) ethyl)-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.82)  
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-(2-(dimethylamino) ethyl) benzene-1, 2-diamine 3.67 
(0.18g, 0.8 mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) 
phenyl) acetonitrile 3.36 (0.30g, 0.8 mmol) as starting materials. Brown oil (0.13g, 32 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.26 (d, J = 8.6 Hz, 2H, CHAr), 7.09 (tt, J = 7.5, 1.9 Hz, 1H, 
CHAr), 6.97 – 6.80 (m, 4H, CHAr), 6.61 (dtd, J = 13.4, 7.5, 1.4 Hz, 1H, NH), 5.29 (s, 2H, CHAl), 
4.24 (dtt, J = 28.9, 7.3, 3.7 Hz, 1H, CHAl), 4.00 – 3.90 (m, 3H, CHAl), 3.90 – 3.72 (m, 2H, 
CHAl), 2.36 (dt, J = 13.0, 6.0 Hz, 2H, CHAl), 2.18 (d, J = 2.7 Hz, 6H, C35,36H), 0.76 (d, J = 12.3 
Hz, 9H, C29-31H), 0.01(dd, J = 18.08, 3.2 Hz, 6H, C26-27H). 
13C NMR (101 MHz, DMSO) δ 
158.3, 156.6, 141.1, 135.9, 129.7, 123.9, 122.4, 120.6, 118.7, 116.8, 115.2, 109.3, 70.6, 69.2, 
56.8, 51.0, 48.5, 45.8, 26.1, 22.0, 18.1, -4.1. LCMS m/z calc for C28H40ClN5O2Si [M+H]
+ : 






2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(1-methyl piperidin-4-yl)-1H-
benzo[d] imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.83) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-(1-methylpiperidin-4-yl) benzene-1, 2-diamine 3.65  
(0.26g, 1mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.40g, 1mmol) as starting materials. Brown oil (0.22g, 36 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.26 (dd, J = 8.5, 5.4 Hz, 2H, CHAr), 7.14 – 6.99 (m, 2H, CHAr), 6.96 – 
6.88 (m, 2H, CHAr), 6.70 (d, J = 8.0 Hz, 1H, CHAr), 6.58 (t, J = 7.6, 1.2 Hz, 1H, NH), 4.58 (d, 
J = 7.6 Hz, 1H, C12H), 4.30 (ddt, J = 12.8, 8.8, 5.6 Hz, 1H, CHAl), 4.06 (ddd, J = 20.4, 10.3, 
2.8 Hz, 1H, CHAl), 3.94 (d, J = 5.9 Hz, 2H, CHAl), 3.89 – 3.80 (m, 1H, CHAl), 3.69 (dt, J = 
12.1, 5.7 Hz, 1H, CHAl), 3.58 (dt, J = 12.8, 5.8 Hz, 2H, CHAl), 2.90 (s, 2H, CHAl), 2.32 (s, 3H, 
C38H), 2.09 (s, 1H, CHAl), 1.91 (dd, J = 11.9, 5.8 Hz, 2H, CHAl), 1.63 – 1.47 (m, 2H, CHAl), 
0.86 (d, J = 16.1 Hz, 9H, C29-31H), 0.15 – 0.04 (m, 6H, C26,27H).
13C NMR (101 MHz, DMSO-
d6) δ 158.3, 155.1, 143.1, 134.3, 129.8, 123.7, 122.8, 120.5, 119.6, 116.3, 115.2, 112.2, 71.2, 
69.8, 54.2, 53.2, 47.5, 45.5, 29.3, 26.2, 22.0, 18.3, -4.1. LCMS m/z calc for C30H42ClN5O2Si
+ 






2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(oxetan-3-yl)-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.87) 
The title compound was prepared in the manner similar to the 
general procedure (3.G) by utilizing 5-chloro-N1-(oxetan-3-yl) benzene-1,2-diamine 3.69 
(0.25g, 1mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.50g, 1mmol) as starting materials. Brown oil (0.20g, 28 %). 1H NMR (400 
MHz, DMSO-d6) δ 7.68 (d, J = 2.1 Hz, 1H, C6H), 7.26 (dd, J = 8.5, 5.8 Hz, 3H, C3H, CHAr), 
7.06 (dd, J = 8.4, 2.1 Hz, 1H, C2H), 6.96 – 6.92 (m, 2H, CHAr), 6.90 (d, J = 5.8 Hz, 1H, NH), 
5.08 – 4.94 (m, 4H, C26,28H), 4.38 (qd, J = 6.5, 3.0 Hz, 1H, C24H), 4.12 – 4.00 (m, 2H, CHAl), 
3.97 – 3.87 (m, 3H, C22H, CHAl), 3.46 (ddt, J = 26.1, 13.2, 7.1 Hz, 2H, CHAl), 0.82 (s, 9H, C33-
35H), 0.01 (d, J = 12.4 Hz, 6H, C30,31H). 
13C NMR (101 MHz, DMSO-d6) δ 158.4, 155.3, 142.5, 
133.7, 129.8, 123.5, 123.4, 121.3, 119.9, 117.0, 115.2, 109.1, 75.1, 71.2, 69.7, 48.3, 46.2, 26.1, 
21.9, 18.3, -4.3. LCMS m/z calc for C27H35ClN4O3Si
+ [M+H]+ : 527.2, found 526.8 with tR 2.64 
min. 
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(2-methoxyethyl)-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.88) 
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The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing 5-chloro-N1-(2-methoxyethyl) benzene-1, 2-diamine 3.70 (0.07g, 
0.3 mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (0.13g, 0.3 mmol) as starting materials. Brown oil (0.08g, 40 %).1H NMR 
(400 MHz, DMSO-d6) δ 7.31 – 7.19 (m, 3H, CHAr), 7.16 (d, J = 8.3 Hz, 1H, CHAr), 7.00 – 6.87 
(m, 3H, CHAr), 6.83 (s, 1H, NH), 4.39 (qd, J = 6.3, 2.7 Hz, 1H, CHAl), 4.20 – 4.14 (m, 1H, 
CHAl), 4.10 (dd, J = 10.3, 2.9 Hz, 1H, CHAl), 3.97 – 3.89 (m, 3H, CHAl), 3.53 (dt, J = 32.8, 5.6 
Hz, 4H, CHAl), 3.20 (s, 4H, CHAl), 0.86 (s, 9H, C29-31H), 0.07 (d, J = 1.1 Hz, 6H, C26,27H).
13C 
NMR (101 MHz, DMSO-d6) δ 158.4, 155.7, 141.6, 136.2, 129.8, 123.5, 123.1, 120.7, 119.9, 
116.1, 115.1, 108.5, 71.1, 70.7, 70.0, 58.8, 46.2, 42.1, 26.2, 21.9, 18.3, -4.1. LCMS m/z calc 
for C27H37ClN4O3Si
+ [M+H]+ : 529.2, found 529.0 with tR 2.74 min.  
2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((1-(2-((tert-butyl dimethyl silyl) oxy) ethyl)-6-
chloro-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.111) 
The title compound was prepared in the manner similar to the general 
procedure (3.G) by utilizing N1-(2-((tert-butyl dimethyl silyl) oxy) ethyl)-5-chlorobenzene-1,2-
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diamine 3.110 (0.15g, 0.5 mmol) and 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-
isothiocyanatopropoxy) phenyl) acetonitrile 3.36 (0.30g, 0.8 mmol) as starting materials. 1H 
NMR (400 MHz, DMSO-d6) δ 7.26 (dd, J = 8.7, 3.0 Hz, 3H, CHAr), 7.15 (d, J = 8.2 Hz, 1H, 
CHAr), 6.98 – 6.88 (m, 3H, CHAr), 6.81 (t, J = 5.7 Hz, 1H, NH), 4.11 (q, J = 5.7 Hz, 1H, CHAl), 
4.03 (dt, J = 14.2, 4.9 Hz, 3H, CHAl), 3.95 (d, J = 9.7 Hz, 3H, C23H, CHAl), 3.66 (q, J = 5.2 Hz, 
2H, CHAl), 3.60 – 3.41 (m, 2H, CHAl), 0.86 (d, J = 1.5 Hz, 9H, C29-31H), 0.70 (s, 6H, C26,27H), 
0.13 – 0.03 (m, 9H, C39-41H), -0.24 (s, 6H, C36,37H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 
156.4, 141.5, 136.6, 129.8, 123.5, 123.4, 120.5, 119.9, 116.0, 115.1, 109.0, 71.6, 70.1, 69.7, 
61.8, 48.5, 26.26, 26.23, 21.9, 18.3, 18.2, -4.0, -4.1. Brown oil (0.2g, 42 %). LCMS m/z calc 
for C32H49ClN4O3Si2
+ [M+H]+ : 628.3, found 628.1 with tR  2.82 min.  
(S)-2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-isopropyl-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile (3.113) 
The title compound was prepared in the manner similar to 
the general procedure (3.G) by utilizing 5-Chloro-N1-isopropylbenzene-1,2-diamine 3.12 
(0.13g, 0.7 mmol) and (S)-2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) 
phenyl) acetonitrile 3.112 (0.26g, 0.7 mmol) as starting materials. Brown oil (0.1g, 27 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.38 (d, J = 2.0 Hz, 1H, C6H), 7.26 (d, J = 8.6 Hz, 2H, C2H, 
CHAr), 7.17 (d, J = 8.6 Hz, 1H, C3H), 7.01 – 6.89 (m, 3H, CHAr), 6.83 (t, J = 5.7 Hz, 1H, NH), 
4.62 (p, J = 6.9 Hz, 1H, C32H), 4.41 (qd, J = 6.5, 2.9 Hz, 1H, CHAl), 4.09 (dd, J = 10.3, 2.9 Hz, 
1H, CHAl), 3.96 – 3.88 (m, 3H, CHAl), 3.46 (ddt, J = 25.9, 12.9, 7.0 Hz, 2H, CHAl), 1.48 (dd, J 
= 7.0, 1.7 Hz, 6H, C33,34H), 0.85 (s, 9H, C29-31H) 0.04 (s, 6H, C26,27H). 
13C NMR (101 MHz, 
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DMSO-d6) δ 158.4, 155.0, 142.4, 134.1, 129.8, 123.5, 122.6, 120.4, 119.9, 116.4, 115.2, 109.7, 
71.3, 69.9, 46.4, 45.7, 26.2, 21.9, 20.7, 18.3, -4.1. LCMS m/z calc for C27H37ClN4O2Si
+ [M+H]+ 
:512.7, found 512.8 with tR 2.64 min. 
General procedure (3.H) for preparation of 3.86-3.100, 3.103, 3.114.  
To a solution of (3.72-3.88, 3.111) in MeOH (50 mL) was added 20 % TFA and stirred for 48h 
at rt. The reaction was neutralized using Et3N and concentrated to the dryness. The residue was 
washed by H2O and the desired compound was extracted using ethyl acetate. The organic layer 
was concentrated and purified using column chromatography eluting the desired compound 
with 20:80 Petroleum Ether: Ethyl Acetate for most of the compounds. 
2-(4-(3-((5-Chloro-1-methyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.86) 
The title compound was prepared in the manner similar to the general 
procedure (3.H) by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy) – 3 - ((5-chloro-1-methyl-
1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.72 as a starting material. 
White solid (0.5, 70 %). 1H NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 2.0 Hz, 1H, C3H), 7.33 
– 7.23 (m, 4H, CHAr), 7.07 (dd, J = 8.4, 2.0 Hz, 1H, C1H), 7.01 – 6.93 (m, 2H, CHAr, NH), 4.13 
(m, 1H, CHAl), 4.08 – 3.96 (m, 2H, CHAl), 3.94 (s, 2H, C22H), 3.64 – 3.56 (m, 2H, CHAl), 3.55 
(s, 3H, C24H). 
13C NMR (101 MHz, DMSO-d6) δ 158.5, 155.0, 133.3, 129.7, 128.5, 126.8, 
126.0, 123.5, 120.0, 115.4, 113.7, 109.7, 70.6, 68.1, 46.4, 29.2, 21.9. LCMS m/z calc for 
C19H19ClN4O2
+ [M+H]+ : 371.1, found 371.1 with tR 2.12 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
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2-(4-(3-((5, 6-Dichloro-1-methyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.87) 
The title compound was prepared in the manner similar to the 
general procedure (3.H) by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy) -3 - ((5, 6-
dichloro-1-methyl-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.73 
(0.1g, 0.2 mmol) as a starting material. White solid (0.06g, 80 %) 1H NMR (400 MHz, DMSO-
d6) δ 7.47 (s, 1H, CHAr), 7.36 (s, 1H, CHAr), 7.26 (d, J = 8.7 Hz, 2H, CHAr), 7.10 (t, J = 5.7 Hz, 
1H, CHAr), 6.97 (d, J = 8.7 Hz, 2H, CHAr, NH), 5.44 (d, J = 5.5 Hz, 1H, OH), 4.13 (h, J = 5.5 
Hz, 1H, C12H), 4.02 (dd, J = 10.0, 4.3 Hz, 1H, CHAl), 3.95 (d, J = 10.2 Hz, 3H, C22H, CHAl), 
3.59 – 3.40 (m, 5H, CHAl).
13C NMR (101 MHz, DMSO-d6) δ 158.5, 157.4, 142.9, 135.7, 129.7, 
123.5, 122.7, 120.4, 120.0, 115.9, 115.4, 109.2, 70.8, 68.1, 46.3, 29.1, 21.9. LCMS m/z calc 
for C19H18Cl2N4O2
+ [M+H]+ : 405.0, found 404.7 with tR 2.25min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.20). 
 The title compound was prepared in the manner similar to 
the general procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-
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isopropyl-1H-benzo[d]imidazol -2-yl) amino) propoxy) phenyl) acetonitrile 3.74 (0.3g, 0.5 
mmol) as a starting material. White solid (0.17g, 77 %). 1H NMR (400 MHz, DMSO-d6) δ 7.38 
(d, J = 2.0 Hz, 1H, C6H), 7.30 – 7.22 (m, 2H, CHAr), 7.17 (d, J = 8.6 Hz, 1H, C3H), 6.96 (dd, 
J = 8.6, 2.0 Hz, 3H, C2H, CHAr), 6.80 (t, J = 5.6 Hz, 1H, NH), 5.56 (d, J = 4.8 Hz, 1H, OH), 
4.63 (hept, J = 7.1 Hz, 1H, C25H), 4.13 (q, J = 5.6 Hz, 1H, CHAl), 4.01 (dd, J = 10.0, 4.4 Hz, 
1H, CHAl), 3.94 (d, J = 6.8 Hz, 3H, CHAl), 3.60 – 3.40 (m, 2H, CHAl), 1.47 (d, J = 7.1 Hz, 6H, 
C26,27H). 
13C NMR (101 MHz, DMSO-d6) δ 158.6, 155.5, 142.1, 134.1, 129.7, 123.4, 122.7, 
120.4, 120.0, 116.3, 115.4, 109.8, 70.9, 68.3, 46.6, 45.8, 21.9, 20.6. LCMS m/z calc for 
C21H23ClN4O2
+ [M+H]+ : 399.2, found 399.1 with tR 2.23 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((1-(tert-Butyl)-6-chloro-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.91) 
The title compound was prepared in the manner similar to the 
general procedure by utilizing 2-(4-(3-((1-(tert-butyl)-6-chloro-1H-benzo[d]imidazol-2-
yl)amino)-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) acetonitrile 3.75 (0.12g, 0.2 
mmol) as a starting material. White solid (0.8, 80 %). 1H NMR (400 MHz, DMSO-d6) δ 7.50 
(d, J = 1.9 Hz, 1H, CHAr), 7.28 – 7.23 (m, 2H, CHAr), 7.18 (d, J = 8.4 Hz, 1H, CHAr), 6.99 – 
6.94 (m, 3H, CHAr), 6.03 (t, J = 5.4 Hz, 1H, NH), 5.63 (s, 1H, OH), 4.20 – 4.12 (m, 1H, CHAl), 
4.01 (dd, J = 10.0, 4.6 Hz, 1H, CHAl), 3.95 (m, 3H, CHAl), 3.66 – 3.43 (m, 2H, CHAl), 1.75 (s, 
9H, C26-28H).
13C NMR (101 MHz, DMSO-d6) δ 158.5, 156.2, 141.7, 135.4, 129.8, 123.5, 122.7, 




+ [M+H]+ : 412.1, found 412.8 with tR 2.36 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-neopentyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.92) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-neopentyl-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.76 (0.1g, 0.2 mmol) as a 
starting material. White solid (0.070g, 90 %).1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J = 2.0 
Hz, 1H, C6H), 7.28 – 7.20 (m, 2H, CHAr), 7.16 (d, J = 8.3 Hz, 1H, C3H), 6.94 (dd, J = 8.3, 2.0 
Hz, 3H, C2H, CHAr), 6.71 (t, J = 5.7 Hz, 1H NH), 5.61 (s, 1H, OH), 4.14 (m, 1H, CHAl), 4.00 
(dd, J = 10.0, 4.4 Hz, 1H, CHAl), 3.92 (dd, J = 9.8, 6.1 Hz, 3H, CHAl), 3.84 (s, 2H, C23H), 3.51 
(m, 2H, CHAl), 0.95 (s, 9H, C27-29H).
13C NMR (101 MHz, DMSO-d6) δ 158.6, 156.8, 141.4, 
137.2, 129.7, 123.4, 122.8, 120.5, 120.0, 115.9, 115.3, 109.3, 70.9, 68.4, 52.1, 46.4, 35.3, 28.2, 
21.9. LCMS m/z calc for C23H27ClN4O2
+ [M+H]+ : 427.1, found 427.2 with tR 2.46 min. Purity 
of the compound was confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-cyclopropyl-1H-benzo[d]imidazole-2-yl)amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.90) 
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The title compound was prepared in the manner similar 
to the general procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-
cyclopropyl-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.77 (0.08g, 
0.2mmol) as a starting material. White solid (0.05g, 80 %). 1H NMR (400 MHz, DMSO-d6) δ 
7.29 – 7.23 (m, 2H, CHAr), 7.22 – 7.11 (m, 2H, CHAr), 7.00 – 6.94 (m, 3H, CHAr), 6.57 (t, J = 
5.7 Hz, 1H, NH), 5.55 (d, J = 4.9 Hz, 1H, OH), 4.15 (q, J = 5.2, 4.7 Hz, 1H, CHAl), 4.07 – 4.00 
(m, 1H, CHAl), 4.00 – 3.90 (m, 3H, C22H, CHAl), 3.63 – 3.42 (m, 2H, CHAl), 3.00 (tt, J = 7.0, 
3.7 Hz, 1H, C24H), 1.21 – 1.10 (m, 2H, C26 or 27H), 0.97 – 0.80 (m, 2H, C26 or 27H). 
13C NMR 
(101 MHz, DMSO-d6) δ 158.5, 156.9, 141.4, 136.5, 129.7, 123.5, 123.0, 120.8, 120.0, 116.3, 
115.4, 108.5, 71.0, 68.2, 46.4, 22.9, 21.9, 7.0. LCMS m/z calc for C21H21ClN4O2
+ [M+H]+ : 
397.1, found 386.8 with 2.21 tR min. Purity of the compound was confirmed to be >95 % by 
LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-cyclobutyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.91) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclobutyl-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.78 (0.1g, 0.2 mmol) as a 
starting material. White solid (0.08, 76 %). 1H NMR (400 MHz, DMSO-d6) δ 7.46 (d, J = 2.1 
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Hz, 1H, C6H), 7.30 – 7.13 (m, 3H, CHAr), 7.03 – 6.91 (m, 3H, CHAr), 6.70 (t, J = 5.6 Hz, 1H 
NH), 5.52 (d, J = 4.9 Hz, 1H OH), 4.88 (m, 1H, C25H), 4.13 (m, 1H, CHAl), 4.01 (dd, J = 10.0, 
4.4 Hz, 1H, CHAl), 3.97 – 3.90 (m, 3H, CHAl), 3.54 (dt, J = 13.4, 5.6 Hz, 1H, CHAl), 3.43 (ddd, 
J = 13.4, 6.8, 5.2 Hz, 1H, CHAl), 2.79 – 2.66 (m, 2H, C26 or 28H), 2.38 (m, 2H, C26 or 28H), 1.94 
(m, 1H, C27H), 1.76 (qt, J = 10.5, 8.2 Hz, 1H, C27H).
13C NMR (101 MHz, DMSO-d6) δ 158.6, 
155.7, 142.0, 134.8, 129.7, 123.5, 122.9, 120.7, 120.0, 116.5, 115.4, 109.6, 70.9, 68.2, 47.8, 
46.6, 28.3, 21.9, 14.9. LCMS m/z calc for C22H23ClN4O2
+ [M+H]+ : 411.1, found 410.8 with tR 
2.39 min. Purity of the compound was confirmed to be >95 % by LCMS using a long method 
run. 
2-(4-(3-((6-Chloro-1-cyclopentyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.92) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclopentyl-1H-
benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.79 (0.1g, 0.2mmol) as a starting 
material. White solid (0.054g, 54 %). 1H NMR (400 MHz, DMSO-d6) δ 7.29 –7.24 (m, 2H, 
CHAr), 7.21 – 7.17 (m, 2H, CHAr), 6.99 – 6.93 (m, 3H, CHAr), 6.84 (t, J = 5.6 Hz, 1H, NH), 
5.53 (d, J = 5.1 Hz, 1H, OH), 4.76 (p, J = 8.6 Hz, 1H, C25H), 4.12 (dd, J = 8.2, 3.5 Hz, 1H, 
CHAl), 4.08 – 3.98 (m, 1H, CHAl), 3.95 (d, J = 9.5 Hz, 3H, C23H, CHAl), 3.58 – 3.38 (m, 2H, 
CHAl), [2.06 – 1.88 (m, 6H), 1.68 (s, 2H), C26-29H]. 
13C NMR (101 MHz, DMSO-d6) δ 158.6, 
156.1, 142.2, 133.7, 129.7, 123.5, 122.7, 120.6, 120.0, 116.6, 115.3, 109.4, 70.9, 68.3, 54.5, 
46.6, 28.9, 24.7, 21.9. LCMS m/z calc for C23H25ClN4O2
+ [M+H]+ : 425.1, found 424.6 with tR 
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2.33 min. Purity of the compound was confirmed to be >95 % by LCMS using a long method 
run. 
2-(4-(3-((6-Chloro-1-cyclohexyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.93) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-cyclohexyl-1H-
benzo[d] imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.80 (0.09g, 0.2 mmol) as a 
starting material. White solid (0.05g, 75 %).  1H NMR (400 MHz, DMSO-d6) δ 7.41 (d, J = 2.0 
Hz, 1H, C6H), 7.32 (d, J = 5.0 Hz, 1H, CHAr), 7.28 – 7.22 (m, 1H, CHAr), 7.17 (d, J = 8.3 Hz, 
1H, C3H), 6.96 (dd, J = 8.6, 2.0 Hz, 3H, C2H, CHAr), 6.88 (t, J = 5.8 Hz, 1H, NH), 5.60 (s, 1H 
OH), 4.49 (d, J = 5.6 Hz, 1H, C25H), 4.27 – 4.10 (m, 2H, CHAl), 4.01 (dd, J = 10.1, 4.4 Hz, 1H, 
CHAl), 3.94 (d, J = 13.7 Hz, 3H, C23H, CHAl), 3.56 (dd, J = 9.5, 4.1 Hz, 1H, CHAl), [2.16 – 2.00 
(m, 2H, CHAl), 1.84 (d, J = 10.9 Hz, 2H, CHAl), 1.69 (dd, J = 27.8, 9.9 Hz, 3H, CHAl), 1.51 – 
1.34 (m, 3H, CHAl)] C26-30H.
13C NMR (101 MHz, DMSO-d6) δ 158.5, 155.5, 141.8, 134.3, 
129.7, 123.4, 122.8, 120.5, 120.0, 116.3, 115.4, 110.1, 70.9, 68.3, 63.3, 53.7, 46.6,  30.3, 25.9, 
21.9. LCMS m/z calc for C24H27ClN4O2
+ [M+H]+ : 439.1, found 439.7 with tR 2.40 min. Purity 
of the compound was confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((1-(2-(Benzyloxy)ethyl)-6-chloro-1H-benzo[d]imidazol-2-yl)amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.94) 
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The title compound was prepared in the manner similar to the 
general procedure by utilizing 2-(4-(3-((1-(2-(benzyloxy) ethyl)-6-chloro-1H-
benzo[d]imidazol-2-yl) amino)-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) 
acetonitrile 3.81 (0.3g, 0.5mmol) as a starting material. White solid (0.13g, 65 %).  1H NMR 
(400 MHz, DMSO-d6) δ 7.32 (d, J = 2.0 Hz, 1H, C6H), 7.26 (ddt, J = 11.2, 6.8, 2.5 Hz, 5H, 
CHAr), 7.20 – 7.14 (m, 3H, CHAr), 6.95 (td, J = 8.1, 7.4, 2.1 Hz, 3H, CHAr), 6.87 (t, J = 5.7 Hz, 
1H, NH), 5.56 (s, 1H, OH), 4.45 (s, 2H, C28H), 4.24 (t, J = 5.2 Hz, 2H, C24 or 26H), 4.11 (p, J = 
5.8 Hz, 1H, CHAl), 3.99 (dd, J = 9.9, 4.4 Hz, 1H, CHAl), 3.95 (s, 2H, C22H), 3.92 – 3.89 (m, 
1H, CHAl), 3.68 (t, J = 5.1 Hz, 2H, CHAl), 3.61 – 3.39 (m, 2H, CHAl). 
13C NMR (101 MHz, 
DMSO-d6) δ 158.5, 156.2, 141.5, 138.5, 136.4, 129.7, 128.6, 127.8, 127.5, 123.4, 123.0, 120.6, 
120.0, 116.0, 115.4, 108.7, 72.4, 70.8, 68.5, 68.3, 46.3, 42.2, 21.9.  LCMS m/z calc for 
C27H27ClN4O3
+ [M+H]+ : 491.1, found 490.6 with tR 2.37 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-hydroxypropoxy) -3-
fluorophenyl) acetonitrile (3.95) 
The title compound was prepared in the manner similar to the 
general procedure by utilizing 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-
isopropyl-1H-benzo[d]imidazol-2-yl) amino) propoxy)-3-fluorophenyl) acetonitrile 3.82  
(0.13g, 0.2 mmol) as a starting material. White solid (0.08g, 77 %).  1H NMR (400 MHz, 
DMSO-d6) δ 7.38 (d, J = 2.0 Hz, 1H, C6H), 7.25 – 7.15 (m, 3H, CHAr), 7.11 (dd, J = 8.4, 2.0 
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Hz, 1H, C2H), 6.96 (d, J = 8.4 Hz, 1H, C3H), 6.82 (t, J = 5.6 Hz, 1H, NH), 5.62 (d, J = 4.4 Hz, 
1H, OH), 4.63 (hept, J = 6.9 Hz, 1H, C24H), 4.13 – 3.99 (m, 3H, CHAl), 3.99 (s, 2H, C22H), 
3.60 – 3.41 (m, 2H, CHAl), 1.47 (d, J = 6.8 Hz, 6H, C26,27H).
13C NMR (101 MHz, DMSO-d6) 
δ 155.5, 151.9 (d, J = 244.5 Hz), 146.5 (d, J = 11.2 Hz), 142.0, 134.1, 124.9 (d, J = 3.9 Hz), 
124.4 (d, J = 6.5 Hz), 122.8, 120.4, 119.6, 116.4 (d, J = 5.8 Hz), 115.8 (d, J = 1.8 Hz), 109.8, 
71.9, 68.3, 46.5, 45.8, 21.8, 20.6. LCMS m/z calc for C21H23ClFN4O2
+ [M+H]+ : 417.15, found 
416.7 with tR 2.24 min. Purity of the compound was confirmed to be >95 % by LCMS using a 
long method run. 
2-(4-(3-((6-Chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino) -2-hydroxypropoxy) -
2-fluorophenyl) acetonitrile (3.96) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-isopropyl-1H-
benzo[d]imidazol-2-yl) amino) propoxy) -2-fluorophenyl) acetonitrile 3.83 (0.16g, 0.2 mmol) 
as a starting material. White solid (0.10g, 79 %).   1H NMR (400 MHz, DMSO-d6) δ 7.38 (d, J 
= 2.0 Hz, 1H, C6H), 7.35 (t, J = 8.8 Hz, 1H, C18H), 7.17 (d, J = 8.8 Hz, 1H, C2H), 6.99 – 6.88 
(m, 2H, C3,21H), 6.87 – 6.81 (m, 1H, C17H), 6.79 (d, J = 5.6 Hz, 1H, NH), 5.57 (s, 1H, OH), 
4.63 (m, 1H, C24H), 4.14 (t, J = 5.7 Hz, 1H, CHAl), 4.05 (dd, J = 10.1, 4.2 Hz, 1H, CHAl), 4.02 
(m, 1H, CHAl) 3.90 (s, 2H, C22H), 3.59 – 3.39 (m, 2H, CHAl), 1.47 (d, J = 6.9 Hz, 6H, 
C26,27H).
13C NMR (101 MHz, DMSO-d6) δ 160.9 (d, J = 244.8 Hz), 160.4 (d, J = 10.9 Hz), 
155.4, 142.0, 134.1, 131.3 (d, J = 5.3 Hz), 122.8, 120.4, 118.8, 116.3, 111.7 (d, J = 3.1 Hz), 
110.4 (d, J = 16.2 Hz), 109.8, 102.8 (d, J = 24.9 Hz), 71.4, 68.1, 46.5, 45.8, 20.6, 16.6. LCMS 
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m/z calc for C21H22ClFN4O2
+ [M+H]+ : 417.15, found 416.6 with tR 2.26 min. Purity of the 
compound was confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-(2-(dimethylamino) ethyl)-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.97) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(2-(dimethyl 
amino) ethyl)-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.85 (0.13g, 
0.2mmol) as a starting material. White solid (0.08 g, 80 %).   1H NMR (400 MHz, DMSO-d6) 
δ 7.26 (d, J = 8.5 Hz, 2H, CHAr), 7.14 (ddd, J = 8.5, 7.3, 1.5 Hz, 1H, CHAr), 6.98 (ddd, J = 13.9, 
7.8, 1.5 Hz, 1H, CHAr), 6.91 – 6.84 (m, 3H, CHAr), 6.64 (dtd, J = 9.1, 7.6, 1.5 Hz, 1H, CHAl), 
5.18 (t, J = 4.4 Hz, 1H, CHAl), 4.63 – 4.49 (m, 1H, CHAl), 3.94 (s, 2H C23H), 3.89 – 3.72 (m, 
2H, CHAl), 3.67 (dq, J = 13.1, 5.3 Hz, 1H, CHAl), 3.60 – 3.44 (m, 1H, CHAl), 3.27 – 3.03 (m, 
2H, CHAl), 2.76 (s, 6H, C28,29H).
13C NMR (101 MHz, DMSO-d6) δ 158.4, 156.8, 141.1, 136.2, 
129.7, 123.5, 122.0, 119.9, 118.6, 117.2, 115.4, 108.3, 70.9, 67.2, 60.2, 50.7, 48.9, 43.6, 21.9. 
LCMS m/z calc for C22H26ClN5O2
+ [M+H]+ : 428.1, found 427.9 with tR 2.05 min. Purity of the 
compound was confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1- (1-methylpiperidin-4-yl) -1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.98) 
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The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-((6-chloro-1-(1-methyl 
piperidin-4-yl)-1H-benzo[d] imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.86 (0.2g, 
0.3mmol) as a starting material. White solid (0.08 g, 80 %). 1H NMR (400 MHz, DMSO-d6) δ 
7.26 (d, J = 8.6 Hz, 2H, CHAr), 7.12 – 7.06 (m, 1H, CHAr), 7.02 (d, J = 7.7 Hz, 1H, CHAr), 6.94 
– 6.90 (m, 2H, CHAr), 6.72 (d, J = 8.1 Hz, 1H, CHAr), 6.59 (td, J = 7.5, 1.3 Hz, 1H, NH), 5.27 
(s, 1H, OH), 4.35 (d, J = 7.9 Hz, 1H, CHAl), 4.07 – 3.98 (m, 2H, CHAl), 3.93 (d, J = 9.5 Hz, 
3H, C23H, CHAl), 3.90 – 3.81 (m, 1H, CHAl), 3.71 (s, 1H, CHAl), 3.53 (dt, J = 12.7, 5.7 Hz, 1H, 
CHAl), 2.67 (d, J = 11.5 Hz, 2H, CHAl), 2.16 (s, 3H, C31H), 1.85 (d, J = 12.5 Hz, 2H, CHAl), 
1.37 (q, J = 10.1 Hz, 2H, CH). 13C NMR (101 MHz, DMSO-d6) δ 158.4, 155.2, 143.7, 134.7, 
129.8, 123.3, 122.8, 120.0, 119.6, 116.4, 115.4, 112.5, 71.0, 67.8, 54.3, 48.9, 47.9, 46.3, 31.1, 
21.9. LCMS m/z calc for C24H28ClN5O2
+ [M+H]+ : 454.2, found 454.2 with tR 2.08 min. Purity 
of the compound was confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-(oxetan-3-yl)-1H-benzo[d]imidazol-2-yl)amino)-2-hydroxypropoxy) 
phenyl) acetonitrile (3.99) 
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 The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-(oxetan-3-yl)-
1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.87 (0.2g, 0.4 mmol) as a 
starting material. White solid (0.08 g, 80 %).  1H NMR (400 MHz, DMSO-d6) δ 7.67 (d, J = 
2.0 Hz, 1H, C6H), 7.26 (dd, J = 8.6, 2.0 Hz, 3H, C2H, CHAr), 7.06 (d, J = 8.6 Hz, 1H, C3H), 
6.97 (m, 2H, CHAr), 6.86 (t, J = 5.4 Hz, 1H, NH), 5.61 (tt, J = 7.6, 5.4 Hz, 1H, OH), 5.46 (s, 
1H, CHAl), 5.11 – 4.90 (m, 4H, CHAl), 4.12 (t, J = 5.7 Hz, 1H, CHAl), 4.01 (dd, J = 10.0, 4.6 
Hz, 1H, CHAl), 3.98 – 3.90 (m, 3H, C22H, CHAl), 3.59 – 3.35 (m, 2H, CHAl). 
13C NMR (101 
MHz, DMSO-d6) δ 158.5, 155.7, 142.2, 133.8, 129.7, 123.5, 123.4, 121.3, 120.0, 116.9, 115.4, 
109.2, 75.1, 70.8, 68.0, 48.5, 46.6, 21.9. LCMS m/z calc for C21H21ClN4O3
+ [M+H]+ : 413.1, 
found 412.5 with tR 2.17 min. Purity of the compound was confirmed to be >95 % by LCMS 
using a long method run. 
2-(4-(3-((6-Chloro-1-(2-methoxyethyl)-1H-benzo[d]imidazol-2-yl)amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.100) 
The title compound was prepared in the manner similar to the general 
procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-(2-
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methoxyethyl)-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.88 (0.08g, 
0.1 mmol) as a starting material. (0.05, 85 %). 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J = 
2.1 Hz, 1H, CHAr), 7.27 (d, J = 1.9 Hz, 1H, CHAr), 7.25 (s, 1H, CHAr), 7.16 (d, J = 8.3 Hz, 1H, 
CHAr), 7.00 – 6.93 (m, 3H, CHAr), 6.81 (t, J = 5.7 Hz, 1H, NH), 5.50 (d, J = 22.6 Hz, 1H, OH), 
4.20 – 4.07 (m, 3H, CHAl), 3.95 (d, J = 8.9 Hz, 3H, CHAl), 3.68 – 3.39 (m, 5H, CHAl), 3.20 (s, 
3H, C28H). 
13C NMR (101 MHz, DMSO-d6) δ 158.6, 156.2, 141.5, 136.4, 129.7, 123.5, 123.0, 
120.6, 120.0, 116.1, 115.4, 108.4, 70.8, 68.2, 58.8, 46.3, 42.1, 23.7, 21.9. LCMS m/z calc for 
C21H23ClN4O3
+ [M+H]+ : 415.1, found 414.8 with tR 2.21 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
2-(4-(3-((6-Chloro-1-(2-hydroxyethyl)-1H-benzo[d]imidazol-2-yl)amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.103) 
The title compound was prepared in the manner similar to the 
general procedure by utilizing 2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((1-(2-((tert-butyl 
dimethyl silyl) oxy) ethyl)-6-chloro-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) 
acetonitrile 3.111 (0.2g, 0.3mmol) as a starting material. (0.09g, 72 %). 1H NMR (400 MHz, 
DMSO-d6) δ 7.31 – 7.22 (m, 3H, CHAr), 7.17 (d, J = 8.3 Hz, 1H, CHAr), 7.00 – 6.93 (m, 3H, 
CHAr), 6.81 (t, J = 5.6 Hz, 1H, NH), 5.55 (s, 1H, O14H), 5.01 (t, J = 5.1 Hz, 1H, O27H), 4.11 
(q, J = 5.6 Hz, 1H, CHAl), 4.03 (dt, J = 14.2, 4.9 Hz, 3H, CHAl), 3.95 (d, J = 9.7 Hz, 3H, C22H, 
CHAl), 3.66 (q, J = 5.1 Hz, 2H, C26H), 3.59 – 3.41 (m, 2H, C24H). 
13C NMR (101 MHz, DMSO-
d6) δ 158.5, 156.4, 141.5, 136.6, 129.7, 123.4, 123.0, 120.4, 120.0, 116.0, 115.4, 108.52, 70.8, 
68.3, 60.1, 46.3, 44.8, 21.9. LCMS m/z calc for C20H21ClN4O3
+ [M+H]+ : 401.1, found 401.8 





phenyl) acetonitrile (3.114) 
The title compound was prepared in the manner similar to the 
general procedure by utilizing (S)-2-(4-(2-((tert-butyl dimethyl silyl) oxy)-3-((6-chloro-1-
isopropyl-1H-benzo[d]imidazol-2-yl) amino) propoxy) phenyl) acetonitrile 3.113 (0.1g, 
0.2mmol) as a starting material. (0.05g, 71 %). 1H NMR (400 MHz, DMSO-d6) δ 7.38 (d, J = 
2.4 Hz, 1H, C6H), 7.30 – 7.22 (m, 2H, CHAr), 7.17 (d, J = 8.6 Hz, 1H, C3H), 6.96 (dd, J = 8.6, 
2.4 Hz, 3H, C2H), 6.80 (t, J = 5.6 Hz, 1H, NH), 5.56 (d, J = 4.8 Hz, 1H, OH), 4.63 (hept, J = 
6.8 Hz, 1H, C32H), 4.13 (q, J = 5.6 Hz, 1H, C14H), 4.01 (dd, J = 10.0, 4.4 Hz, 1H, CHAl), 3.94 
(d, J = 6.9 Hz, 3H, C23H, CHAl), 3.60 – 3.40 (m, 2H, CHAl), 1.47 (d, J = 7.1 Hz, 6H, C33,34H). 
13C NMR (101 MHz, DMSO-d6) δ 158.6, 155.5, 142.1, 134.1, 129.7, 123.4, 122.7, 120.4, 
120.0, 116.3, 115.4, 109.8, 70.9, 68.3, 46.6, 45.8, 21.9, 20.6. LCMS m/z calc for 
C21H23ClN4O2
+ [M+H]+ : 399.4, found 399.1 with tR 2.23 min. Purity of the compound was 
confirmed to be >95 % by LCMS using a long method run. 
Preparation of (R)-2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile (3.115) and testing the purity of both enantiomers.  
The analytical chiral high performance liquid chromatography (HPLC) technique was 
performed on Dionex ICS-3000 with an 581Ultimate-3000 detector equipped with Lux 5 μm 
Cellulose-4, LC column 250 × 4.6 mm column. This technique was used to separate the racemic 
compound 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino)-2-
hydroxypropoxy) phenyl) acetonitrile 3.20 into enantiomerically pure isomers: 3.114 (S 
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isomer) and 3.115 (R isomer). 3.20 was separated using ethanol in hexane solvent system and 
the result showed that the mixture contains 54.5% of S isomer and 44.3% of the R isomer 
(Figure 6-1).  
 
Figure 6-1: Chiral HPLC trace of 3.20. The method used was (10/90 %, ethanol/hexane) over 40 min at 2 mL/min. 
Eluent detection was monitored by UV absorbance at 254 nm. 
 
Further analysis was employed by mixing 1:1 of 3.20 and the synthesised (S) enantiomer 3.114 
which showed in (Figure 6-2). This analysis showed that the (S) enantiomer 3.114 has a lower 
affinity for the stationary phase, and therefore was eluted from the column first, followed by 
the (R) enantiomer 3.115.  
 
Figure 6-2: Chiral HPLC trace of 1:1 mixture of 3.20 and 3.114. The method used was (15/85 %, ethanol/hexane) 
over 20 min at 2 mL/min. Eluent detection was monitored by UV absorbance at 254 nm. 
 
In addition, the purity of synthesised S isomer was analysed using the same solvent system. 






Figure 6-3: Chiral HPLC trace of synthesised 3.114. The method used was (15/85 %, ethanol/hexane) over 25 
min at 2 mL/min. Eluent detection was monitored by UV absorbance at 254 nm. 
 
Further investigation after the separation to analyse the purity of each enantiomer as 
demonstrated below showed that the purity of 3.114 was 96.9 ee% while the purity of 3.115 
was 96.1 ee%.  
 
 
Figure 6-4: Chiral HPLC trace of separated isomers (3.114 above and 3.115 below). The method used was (15/85 
%, ethanol/hexane) over 20 or 25 min, respectively at 2 mL/min. Eluent detection was monitored by UV 




Preparation of 2-(4-(2-Hydroxy-3-((1-isopropyl-1H-benzo [d]imidazol -2- yl) amino) 
propoxy) phenyl) acetonitrile (3.101) 
A solution of 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) 
amino)-2-hydroxypropoxy) phenyl) acetonitrile 3.20 (0.1g, 0.3 mmol) in MeOH, and 10% Pd 
on activated carbon (20% w/w) was stirred under balloon of H2 at rt for 16 h. The mixture was 
filtered and purified eluting the desired compound with 20:80 Petroleum Ether: Ethyl Acetate. 
White solid (0.09 g, 95 %).  1H NMR (400 MHz, DMSO-d6) δ 7.34 (d, J = 7.7 Hz, 1H, CHAr), 
7.29 – 7.23 (m, 2H, CHAr), 7.20 (d, J = 7.7 Hz, 1H, CHAr), 7.00 – 6.92 (m, 3H, CHAr), 6.88 (t, 
J = 7.7, 1.3 Hz, 1H, CHAr), 6.70 (t, J = 5.6 Hz, 1H, NH), 5.78 (d, J = 5.6 Hz,  1H, OH), 4.63 
(p, J = 6.8 Hz, 1H, C24H), 4.12 (d, J = 6.3 Hz, 1H, CHAl), 4.01 (dd, J = 9.9, 4.5 Hz, 1H, CHAl), 
3.95 – 3.90 (m, 3H, C22H, CHAl), 3.59 – 3.39 (m, 2H, CHAl), 1.49 (d, J = 6.8 Hz, 6H, C25 or 
26H). 
 13C NMR (101 MHz, DMSO-d6) δ 158.6, 154.7, 142.9, 133.2, 129.7, 123.4, 120.5, 120.0, 
118.8, 115.6, 115.4, 110.1, 70.9, 68.7, 46.7, 45.6, 21.9, 20.8. LCMS m/z calc for C21H25N4O2
+ 
[M+H]+ : 365.2, found 364.6 with 2.05 tR min. Purity of the compound was confirmed to be 






6.2 Biological evaluation  
Bacterial Strains. The P. aeruginosa strains and plasmids used in this study are listed in Table 
6-1. Bacteria were grown in (LB) at 37 °C unless stated otherwise. Where required, tetracycline 
(Tc) was added to the media at 125 μg/ mL to select recombinants, and synthetic alkyl 
quinolones added at the concentrations indicated. 
Table 6-1: Bacterial strains and plasmids used in this study. 
Strain a or Plasmid b Relevant Characteristics 
PAO1-L a Wild type PAO1, Lausanne subline.207 
PAO1-L CTX::PpqsA-lux a PAO1-L with chromosomal mini-CTX::PpqsA-lux 
insertion; TcR.128 
PA14 a Wild type UCBPP-PA14.208 
PA14 CTX::PpqsA-lux a 
 
PA14 with chromosomal mini-CTX::PpqsA-lux 
insertion; TcR.128 
mini-CTX::PpqsA-lux b R6K-based mini-CTX suicide plasmid for the 
chromosomal insertion of a PpqsA-lux transcriptional 
reporter fusion; TcR. 129 
 
6.2.1 Bioluminescence reporter gene fusion assay 
The whole cell based assay was established here according to a published protocol with some 
modifications 131 by employing a constructed bacterial strains which are (PAO1-L CTX::PpqsA-
lux and PA14 CTX::PpqsA-lux). These strains produce luminescence upon PqsR activation with 
endogenous ligands and the inhibition can therefore be quantified based on light reduction 
compared to a solvent vehicle control (DMSO). The desired strain was grown in Lysogen broth 
(LB) at 37 °C overnight and the final optical density (OD600) was measured using a 
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spectrophotometer. The bacterial culture was prepared by dilute the bacterial stock in LB to a 
final concentration of 0.01 OD600. The 10 mM concentration of the compounds DMSO stocks 
were diluted to a final concentration (10 µM) using the LB solution. In 96 well-plate, 100 µl 
of each compound and 100 µl of 0.01 bacterial culture were dispensed in triplicate and 
incubated overnight at 37 °C. The automated luminometer- spectrometer was used to determine 
the luminescence and turbidity automatically at 30 minutes interval for a duration of 8 hours. 
The luminescence data were normalised to the absorbance values for each well and they were 
then related to the solvent control to determine the remaining activity. The primary screening 
was performed at 10 µM and a selection threshold of 50 % or less in relative to the untreated 
sample was set for actives. Following this, IC50 values were determined following the same 
protocol by employing a concentration-response curve with fixed decreasing concentrations to 
accommodate the logarithmic scale (10, 3.1, 1, 0.31, 0.1, 0.031, 0.01 and 0.0031 μM) and 
related the normalized values to the solvent control. 










































































































































Figure 6-5: Concentration-response curve of compounds presented in chapter three. The inhibition of PqsR 
activity measured in a) PAO1-L Ppqsa::lux. and b) PA14 Ppqsa::lux strains. Data shown based on n = 6a or 3b.   
6.2.2 Pyocyanin and alkyl quinoline quantification 
Supernatant preparation. For pyocyanin and alkyl quinolone quantification, the same 
protocol was applied to prepare the supernatant as the following: the desired wild type strain 
was cultured in fresh LB at 37 °C overnight. The targeted concentration of the bacterial culture 
in each flask is OD600 0.05. The compounds from the other hand were assayed in triplicate at 
3× IC50 concentration with negative control of DMSO at the same concentration of the tested 
compound. The flasks incubated in shaker at 37 °C overnight with 200 rpm. The culture was 
centrifuged at 10,000 RCF for 10 min and the supernatant was filtered with HSW 10 mL Soft-
Ject Syringe and a 0.22 µM Sartorius syringe-driven filter (Fisher Brand, Loughborough, UK).  
 Pyocyanin Quantification. The extraction of pyocyanin pigment was obtained by mixing 7.5 
ml of the previous prepared supernatant with 4.5 ml of chloroform which then extracted again 
with 1.5 ml of 0.2 M HCL. The layer of HCL will be turned to pink or red depending on the 
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concentration of the pyocyanin which is determined by a spectrophotometer with OD520. The 
triplicate readings for each compound are related to the corresponding negative control to 
calculate the percentage of pyocyanin production in the presence of the tested compound.  
LCMS-MS Alkyl Quinoline Quantification. 10µl of each previous prepared supernatant was 
diluted with 90µl of an internal standard solution (500nM d4-HHQ in MeOH solution). The 
samples were vortex mixed for several minutes and then centrifuged (5min at 13k rpm). 
Samples were transferred to LC vials prior to analysis. The injection volume for each sample 
was 5.0µl. Analysis was conducted with the MS operating in MRM (multiple reaction 
monitoring) mode under positive electrospray (+ES) conditions, screening the LC eluent for 
the four AQs (HHQ, HQNO, PQS and d4-HHQ). Change in performance of the MS was 
assessed by repeat injection (x3 pre-batch and x3 post-batch) of a system suitability standard 
sample (containing 500nM of each analyte in MeOH). Confirmation that detection of AQs in 
analytical samples fell within the linear response range of the MS was performed by analysis 
of a range of calibration samples (of HHQ, HQNO and PQS) up to 1µM. 
6.2.3 Ex vivo pig lung model  
Bacterial strain. The Wild type PAO1 strain of P. aeruginosa was used as an examples of 
standard laboratory strains. This strain grew in LB agar plate overnight at 37°C. 
Artificial sputum medium and culture conditions.  Artificial sputum medium was prepared 
following the method of Palmer et al. (2007) 209 mentioned in Harrison and Diggle (2016) 210, 
the latter showed slight modification by excluding the glucose from the recipe. They found that 
the glucose facilitated growth of any resident bacteria left on the lung tissue without affecting 
the growth of P. aeruginosa. In addition, they added 50 µg/mL of ampicillin in all used media 
to further minimize the growth of any resident bacteria present in the lung tissue.   
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Lung dissection and infection. The lungs were collected from a local butcher (JT Beedham 
& Sons) as soon as possible after they arrived in the shop from the abattoir and they were used 
immediately when arriving at the laboratory. The chilled cool box was used for transportation 
to The University of Nottingham and the dissection was in a room not used for microbiological 
work. The standard sterile technique was applied throughout the process by working under 
Bunsen burner, dissection tools were autoclaved and dipped in ethanol and flaming as 
necessary during the experiment. The lung surface was briefly seared using a hot pallet knife 
to kill the surface contaminants. Using razor blades to cut along the tissue to expose the 
cartilage of the bronchus and separate the bronchus from the trachea and the surrounding 
alveolar tissue. The bronchus was washed with a 1:1 mix of RPMI and DMEM (Sigma-
Aldrich). It was cut into strips and after washing again with the same solution the strips were 
cut to cubes. These cubes were washed once with the previous solution and once with the ASM. 
Under sterilizing condition, they were transferred to the wells of a 24-well tissue culture plate 
which was prepared previously with soft pad of 400 µl ASM supplemented with 0.8 % w/v 
agarose. Then, 500 µl of ASM was added to each well. By 1 mL insulin syringe, the colony of 
PAO1 strain of P. aeruginosa was touched lightly and then touch the tissue which was 
incubated at 37°C on a rocking platform for 24 hours (acute infection) or 72 hours (chronic 
infection). After building a mock infection, 0.2 µM of 3.20 was added and incubated for further 
8 hours. After incubation, the cubes were transferred to metal bead tubes with 1 mL phosphate-
buffered saline and homogenized using a Precellys24 homogenizer. The supernatant was used 
to measure the growth and count the colony of bacteria by serial dilution in 96 well plate and 
then transfer it to LB plate.  
Furthermore, after a process of extraction by ethyl acetate, the LC/MS was used to quantify the 
concentration of HHQ and PQS with and without treatment as described in Section 6.2.2.  
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6.2.4 Cytotoxicity study 
Cell viability was assessed according to O'Brien et al.199 on A549 adenocarcinomic human 
alveolar basal epithelial cell line. The viability of A549 cell line after overnight incubation with 
three concentrations (1, 50 and 100 µM) of the corresponding compound were determined 
using alamar blue (resazurin) dye. Cells were maintained in the Dulbecco's Modified Essential 
Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and 1 % Penicillin-
Streptomycin-Neomycin. After that, 100 µL of suspended cells with a final concentration (1 × 
104 cells/wall) was seeded in 96-well plates with 100 µL of (1, 50, 100 µM) concentration of 
the tested compound was dispensed in sextuplicate. In addition, the highest concentration of 
the solvent vehicle (1 % DMSO) employed as a negative control. On the other hand, 100 µM 
of K2Cr2O7 was added as a positive control (kill cells). The plate incubated at 37°C, 5 % carbon 
dioxide for 24 hours. After 24 hours of incubation, 20 µL of alamar blue dye was added to the 
corresponding walls. The plates were further incubated for 4-6 hours and the intensity of the 
fluorescence was measured by exciting the light at 510 nm and measuring the fluorescence at 




7 Appendix  
 
Figure 7-1: The 13C NMR spectra of 2-(3-Fluoro-4-hydroxyphenyl) acetonitrile 2.26 with enlarged section of the 




Figure 7-2: The 13C NMR spectra of 2-(2-Fluoro-4-hydroxyphenyl) acetonitrile 2.27 with enlarged section of the 




Figure 7-3: The 
1
H-NMR spectra of 2-(4-(3-(6-chloro-4-oxoquinazolin-3(4H)-yl)-2-hydroxypropoxy) phenyl) 





Figure 7-4: The 
1
H-NMR spectra of 6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-amine 3.25, with enlarged 







Figure 7-5: The 13C NMR spectra of 2-(4-(3-Amino-2-((tert-butyl dimethyl silyl) oxy) propoxy) phenyl) 
acetonitrile 3.33 step2 (above) and 2-(4-(2-((tert-Butyl dimethyl silyl) oxy)-3-isothiocyanatopropoxy) phenyl) 
acetonitrile 3.36 (below) with enlarged section of the aromatic region, in DMSO-d6 solvent at 100.66 MHz 
 
Figure 7-6: The 
1
H-NMR spectra of (S)-2-(4-(3-((6-Chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl)amino)-2-
hydroxypropoxy) phenyl) acetonitrile 3.114, with enlarged section of the aromatic region in DMSO-d6 solvent at 





Figure 7-7: The 13C NMR spectra of 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl) amino) -2-
hydroxypropoxy) -2-fluorophenyl) acetonitrile 3.96 in DMSO-d6 solvent at 100.66 MHz, the highlighted peaks in 




Figure 7-8: The heteronuclear single quantum correlation (HSQC) analysis of 2-(4-(3-((6-chloro-1-isopropyl-1H-
benzo[d]imidazol-2-yl) amino) -2-hydroxypropoxy) -2-fluorophenyl) acetonitrile 3.96, with enlarged section of 
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